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Abstract 
 
The Future of Next-generation Sequencing for Blood Group 
Genotyping and its Implications in Transfusion Medicine 
 
Amr Jamal Halawani 
 
Alloimmunisation becomes a problem when serological discrepancies occur in 
matching antigens between donors and patients for blood transfusion. The rate of 
alloimmunisation has been increased especially in multiply transfused patients. Blood 
group genotyping (BGG) is a DNA-based assay that aids in reducing this situation. 
Currently, many platforms of BGG have become available, in which every technique 
has its own advantages and disadvantages. All these platforms lack the ability to 
identify novel alleles that might have an unknown clinical significance. The advent of 
next-generation sequencing (NGS) offers identification of the unprecedented alleles due 
to its basis of sequence-based typing. Moreover, it provides an extreme high-throughput 
which may be able to screen many donors and patients in a single run. In this project, 
two approaches have been developed in generating sequencing libraries followed by 
sequencing on the Ion Torrent Personal Genome Machine™ platform (Ion PGM™). The 
first approach was amplicon-based target selection using Ion Ampliseq™ Custom Panel, 
designated as Human Erythrocyte Antigens and Human Platelet Antigens Panel (HEA 
and HPA Panel). This panel assay screens 11 blood group systems, as well as 16 human 
platelet antigens. The outcome was extraordinary, in particular four novel alleles had 
been identified out of 28 samples, one in the RHCE gene 208C>T (Arg70Trp) in exon 2 
and three in the KEL gene. The first SNP was 331G>A (Ala111Thr) in exon 4. The 
second SNP was 1907C>T (Ala636Val) in exon 17 and the third SNP was 2165T>C 
(Leu722Pro) in exon 19. However, some issues occurred regarding co-amplification of 
homologous genes. The second approach was a long-range polymerase chain reaction 
(LR-PCR) based approach. This method provided a high resolution assay by 
amplification of entire genes, including the non-coding area, of the Kell and Rh blood 
group systems. The Kell blood group was initially utilised as a model in order to apply 
the same approach on the Rh system. Most alleles encoding the antigens of the Kell 
blood group, especially the high prevalence ones, were identified. The Rh LR-PCR 
approach was carried out by amplification of the RHD and RHCE genes with seven 
amplicons. For five RhD-positive samples no mutations were observed within the 
coding areas. On the other hand, five serotyped weak D samples were genotyped as; 
two weak D type 1, two weak D type 2 and one DAR3.1 weak partial D 4.0 
(RHD*DAR3.01). Regarding the RHCE, the following antigens (C, c, E, c) were 
predicted properly from the sequencing data. Moreover, the RHCE*ceVS.02 was 
identified. 64 and 39 intronic SNPs were identified in RHD and RHCE genes, 
respectively. The intronic SNPs assisted the genotyping process by identifying the 
haplotype of interest. Interestingly, the novel allele identified in the RHCE gene by the 
HEA and HPA Panel was confirmed to belong to the RHCE gene by the LR-PCR 
approach, indicating the panel misaligned it to the RHD gene. In conclusion, NGS paves 
the way to be an alternative substitution to the previous molecular techniques. It would 
supplant the conventional serology for typing blood for transfusion. 
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Chapter 1 : Literature Review  
1.1 Introduction to blood groups 
The concept that led to the discovery of blood groups began in 1901 when Karl 
Landsteiner observed that the isolated plasma of some individuals clumped 
‘agglutinated’ the RBCs of others. Accordingly, three groups (A, B, and O) have been 
identified, which were found to be antigens of the first blood group system, the ABO 
blood group system. In 1901 and 1902, a fourth antigen (AB) was discovered by 
Decastello and Sturli, respectively (Landsteiner, 1961). According to the International 
Society of Blood Transfusion (ISBT), 36 blood group systems have been identified, 
which comprise more than 300 antigens (International Society of Blood Transfusion, 
2015).  
The blood group antigen can be defined as an inherited marker outside the surface of the 
red blood cells (RBCs), which can be detected via a unique alloantibody. The antigens 
can be either proteins or carbohydrates. The carbohydrate antigens are attached to 
proteins in the form of glycoprotein or to lipids to be glycolipids (Daniels, 2013a; Reid 
et al., 2012). The antigens of the blood group are encoded by a single gene, for example 
the ABO blood group or by a cluster of two or three closely linked genes, such as the 
Rh blood group system and MNS blood group system, respectively (Avent and Reid, 
2000; Reid, 2009). The next section will describe the nomenclature of the ISBT. 
1.2 Nomenclature of the blood groups  
In 1980, the ISBT set up the Working Party on Red Cell Immunogenetics and Blood 
Group Terminology to recognise the blood group antigens. Recently, the Working Party 
has become a Committee. The antigens must be identified by both computer software 
and eye. Table 1.1 lists the table of the blood group systems, including the system 
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name, the ISBT symbol, the ISBT number, the number of antigens per system, the 
gene(s) encoding the system and its chromosomal location. Every authenticated antigen 
is classified into four categories which are systems, collections, 700 series and 901 
series (Daniels et al., 2004). 
Every system contains one or more antigens and is controlled by a single gene or two or 
three homologous genes. Every antigen that belongs to a blood group system is 
distinguished with a six-digit number. For instance, the Kell blood group system 
represents the first three digits of the system (006) and the second three digits recognise 
the antigen (006003), which is the Kpa antigen in this case. Otherwise, the system symbol 
is used instead of the system number and is followed by the antigen number. For example, 
KEL003 or KEL3 without sinistral zeros. Phenotypes are observed by the ISBT symbol 
name then a colon followed by a list of all the antigens represented and commas between 
them. Alleles are denoted by the system symbol followed by an asterisk and then the 
antigen number in which everything needs to be italicised, such as (KEL*3). Genotypes are 
written as the ISBT system symbol then an asterisk followed by alleles or haplotypes with a 
slash separating them, in which everything is written in italics. An example for the 
genotyping is (KEL*2,3/2,4). Null allele ‘Amorph’ is designated by zero. For instance, 
(KEL2,3/0) (Daniels et al., 2004). 
The collections are the identified antigens either serologically, biochemically or 
genetically which do not comply with the criteria of the blood group system. This is 
normally because the gene identity was not recognised. There are six sets of antigen 
collections and Vel was one of them until recently when it became a blood group 
system due to being genetically investigated (Cvejic et al., 2013; Storry et al., 2013). 
700 series is the set of antigens with low prevalence, which occurs in less than 1% of 
the population. 901 series (previously denoted as 900 series) is a set of antigens 
 3 
expressed in more than 90% of the population. Both 700 and 901 series do not belong to 
any blood group systems.  
 
 4 
    Table 1.1 Blood group systems.  
    Adapted from (International Society of Blood Transfusion, 2015). 
 
 
 
 
 
System name ISBT symbol ISBT number Number of antigens Gene names Chromosome 
ABO ABO 001 4 ABO 9 
MNS MNS 002 46 GYPA, GYPB, GYPE 4 
P1PK P1PK 003 3 A4GALT 22 
Rh RH 004 54 RHD, RHCE 1 
Lutheran LU 005 20 BCAM 19 
Kell KEL 006 35 KEL 7 
Lewis LE 007 6 FUT3 19 
Duffy FY 008 5 DARC 1 
Kidd JK 009 3 SLC14A1 18 
Diego DI 010 22 SLC4A1 17 
Yt YT 011 2 ACHE 7 
Xg XG 012 2 XG, CD99 X/Y 
Scianna SC 013 7 ERMAP 1 
Dombrock DO 014 8 ART4 12 
Colton CO 015 4 AQP1 7 
Landsteiner-Wiener LW 016 3 ICAM4 19 
Chido/Rodgers CH/RG 017 9 C4A, C4B 6 
H H 018 1 FUT1 19 
Kx XK 019 1 XK X 
Gerbich GE 020 11 GYPC 2 
Cromer CROM 021 18 CD55 1 
Knops KN 022 9 CR1 1 
Indian IN 023 4 CD44 11 
Ok OK 024 3 BSG 19 
Raph RAPHJ 025 1 CD151 11 
John Milton Hagen JMH 026 6 SEMA7A 15 
I I 027 1 GCNT2 6 
Globoside GLOB 028 1 B3GALT3 3 
Gill GIL 029 1 AQP3 9 
Rh-associated glycoprotein RHAG 030 4 RHAG 6 
Forssman FROS 031 1 GBGT1 9 
JR JR 032 1 ABCG2 4 
LAN LAN 033 1 ABCB6 2 
Vel VEL 034 1 SMIM1 1 
CD59 CD59 035 1 CD59 11 
Augustine AUG 036 1 SLC29A1 6 
 5 
1.3 The molecular basis for blood group polymorphism 
Basically, the presence of two or more variants in the population leads to the 
polymorphisms of the blood group antigens. The cloning of the blood group genes 
paves the way for a better understanding of the molecular background of the blood 
group variants. In 1986, the first gene of the MNS blood group system, GYPA was 
cloned (Siebert and Fukuda, 1986). Consequently, more genes have started to be cloned 
such as ABO and Rh genes were cloned in 1990 and 1992, respectively (Yamamoto et 
al., 1990; Le van Kim et al., 1992; Avent et al., 1990; Cherif-Zahar et al., 1990).  
Most of the blood group variants give rise to amino acid substitutions as the 
consequence of single nucleotide polymorphisms [SNPs] (Daniels, 2005). Other genetic 
mechanisms are involved such as deletion, for example, the deletion of the entire RHD 
gene leads to RhD-negative individuals in Caucasians (Colin et al., 1991). Moreover, 
the Vel-negative antigen is a result of the deletion of 17 base pairs (bp) in the SMIM1 
gene (Cvejic et al., 2013). Furthermore, a single nucleotide deletion that leads to a 
reading frameshift occurs in phenotypes, such as O and A2 alleles of the ABO blood 
group system (Yamamoto et al., 1992; O'Keefe and Dobrovic, 1996). Other 
mechanisms are involved such as sequence duplication in association with missense and 
nonsense mutations as in RhD-negative individuals of African descent, which results in 
an inactive RHD gene, pseudogene [RHDΨ] (Singleton et al., 2000). In addition, genetic 
mechanisms include an intergenic recombination between highly homologous genes 
that appear in Rh and MNS blood group systems. An example of a hybrid gene is RH 
(D-CE-D) of the DVI antigen type I, which occurs by substituting exons 4 and 5 of the 
RHD gene, with RHcE allele encoding proline at position 226 (Avent, 1997). Null 
phenotypes can be expressed, such as Knull phenotype, in which no expression of the 
antigens of the Kell blood group system can be observed. This makes the transfusion 
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become more complicated in order to obtain a blood unit that matches this rare 
phenotype (Storry and Olsson, 2004).  
1.4 Blood group immunogenicity 
Naturally occurring antibodies to either A antigen, B antigen or both are expressed in 
adults regarding the antigen they lack. These antibodies are predominantly in the form 
of immunoglobulin M (IgM) antibodies, while the immune antibodies are 
predominantly in the form of immunoglobulin G (IgG) antibodies. Other blood group 
antibodies arise due to immunisation as a result of transfusion or transplantation. 
Moreover, they could arise from pregnancy which may lead to a condition denoted as 
haemolytic disease of the foetus and newborn [HDFN] (Daniels and Bromilow, 2013). 
The next subsections will describe these incidences briefly.  
1.4.1 Haemolytic transfusion reactions  
The transfusion of mismatched blood units will put the recipient’s life at risk as a 
consequence of haemolytic transfusion reactions (HTR). Intravascular HTR is 
characterised by rapid haemolysis, in which most of the RBCs are damaged within 10 
minutes. It is caused by IgM antibody-mediated haemolysis in the circulation, which 
activates the classical complement pathway followed by the formation of a membrane 
attack complex. Accordingly, this punctures the RBC membrane and releases the 
haemoglobin into the plasma. The antibodies of the ABO blood group system are 
predominantly involved with intravascular HTR. The clinical manifestations include 
shock, chills, hypotension, haemoglobinaemia and haemoglobinuria with further 
complications of disseminated intravascular coagulation and renal failure (Poole and 
Daniels, 2007).  
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Extravascular HTR can be immediate which occurs within a few hours following the 
transfusion or delayed which occurs within 5 to 7 days. The IgG is an antibody of this 
type, which is not associated with the complement activation and not involved in the 
ABO system. Basically, RBCs coated with IgG bind to Fc receptors on macrophages 
and trigger a process called ‘phagocytosis’ in the liver and spleen to eliminate the 
damaged cells. The symptoms of extravascular HTR are the same as intravascular HTR 
but less severe (Poole and Daniels, 2007). 
1.4.2 Haemolytic disease of the foetus and newborn  
HDFN occurs when the foetus’ red cells with positive antigens of paternal origin leak 
into the maternal circulation of a mother who is antigen-negative, which is designated 
as foetomaternal haemorrhage (Urbaniak and Greiss, 2000). Consequently, the mother’s 
immune system recognises the positive foetal antigens as ‘foreign’ and starts producing 
IgM followed by IgG antibodies (mostly IgG1 and IgG3) against foetal RBCs. In 
subsequent pregnancies, those antibodies are capable of crossing the placenta, entering 
the foetal circulation and destroying foetal RBCs by splenic macrophages (Kumpel and 
Elson, 2001; Kumpel, 2008). Anti-D is the most common antibody to cause HDFN 
(Bowman, 1998) 
The HDFN can be managed by giving the immunised mother an injection of anti-D 
prophylaxis. Hence, this allows for rapid elimination of foetal RBCs via the maternal 
spleen by macrophages (Scott, 2001). It was thought that HDFN is exclusive to anti-D. 
However, many antibodies were reported including anti-c, anti-E, anti-K and anti-Fya 
(Babinszki and Berkowitz, 1999). The HDFN by anti-K is caused by suppressing the 
erythropoiesis, rather than haemolysis (Weiner and Widness, 1996).  
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1.5 Rh blood group system 
The Rh blood group system (004) is extremely polymorphic and is considered to be the 
most complex blood group system. It contains 54 antigens numbered from RH1 to 
RH61, while seven antigens have become obsolete (International Society of Blood 
Transfusion, 2015). There are five chief antigens, which are D, C, c, E and e. Other 
antigens can be represented in composite specificities, for instance, ce or f antigen 
which is an epitope on the Rhce protein and is not observed with RhCe or RhcE. Many 
antigens are correlated to the ethnic group of a certain population. For example, V and 
VS antigens, which are an altered e antigen, are mainly found in Blacks (Chou and 
Westhoff, 2010).  
The antigens of the Rh blood group system can be involved in HTR and HDFN. Anti-D 
is the most important antibody to cause severe HDFN which might lead to foetal 
mortality (Levine et al., 1941). Anti-D IgG prophylaxis has resolved the immunisation 
by anti-D antibodies (Freda et al., 1966). However, it has been reported that other Rh 
antibodies, such as anti-c and anti-E are involved in causing HDFN as mentioned above 
(Koelewijn et al., 2008). Furthermore, they are involved in HTR in patients who require 
a blood transfusion such as patients with sickle cell disease (SCD) when incompatibility 
of the blood has occurred and caused alloimmunisation (Aygun et al., 2002).  
1.5.1 Rh proteins  
RhD and RhCE polypeptides have 12 transmembrane domains expressed with a 
cytosolic NH2 and COOH termini, forming six extracellular loops in which the immune 
responses are directed (Avent et al., 1990). The RhD/RhCE protein is associated with 
two Rh-associated glycoprotein (RhAG) proteins to form a trimer (Conroy et al., 2005). 
RhAG shares 36% identity of the RhD and RhCE proteins and is glycosylated on its 
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first loop, while the RhD and RhCE proteins are not (Eyers et al., 1994; Marini et al., 
1997). The RhD protein is different from the RhCE protein by 30–35 amino acid 
substitutions. This is according to which RHCE allele is inherited [RHce, cE, Ce, CE] 
(Mouro et al., 1993). Figure 1.1 shows the structures of the RhD, RhCE, and RhAG 
proteins.  
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Figure 1.1 The structure of the Rh proteins. 
12 transmembrane domains are expressed with cytosolic NH2 and COOH forming six 
extracellular loops. Glycosylation is taking place in the first extracellular loop of the 
RhAG. Two amino acid substitutions (Ser103Pro and Pro226Ala) are located in the 
second and fourth extracellular tubes which are mainly responsible for the antigenic 
polymorphism C/c and E/e of the RhCE protein. Arg229 has been identified as a 
crucial residue for E/e epitope existence. Although Pro226 is an essential residue; 
however, it is not adequate for the full existence of the E antigen. Adapted from (Avent 
and Reid, 2000). 
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1.5.2 RhD polymorphism 
The Rh locus is located on chromosome 1p34-1p36. It consists of two highly 
homologous genes that share 92% sequence identity, RHD and RHCE genes (Cartron, 
1994). A tandem arrangement of both genes is in an opposite orientation [RHD (5’- > 
3’)-(3’ - < 5’) RHCE]. They are separated by a third gene called transmembrane protein 
50A (TMEM50A) previously denoted as SMP1, the role of which remains vague. Two 
rhesus boxes (approximately 9000 bp in length) flank the RHD gene and exhibit 98.6% 
homology to each other (Wagner and Flegel, 2000).  
The RhD phenotype of an individual is determined by the presence or absence of the 
entire RHD gene being RhD-positive or RhD-negative [Figure 1.2-a]. Many 
polymorphisms exist in RhD-negative individuals. In Caucasians, for example, the 
entire RHD gene is deleted (Colin et al., 1991). Accordingly, this could result in an 
unequal crossover in the rhesus boxes which leads to the existence of a hybrid rhesus 
box, as shown in Figure 1.2-b (Wagner and Flegel, 2000). On the other hand, the RhD-
negative phenotype in Africans could arise from stop codons as a result of point 
mutations or gene rearrangements. 66% of the RhD-negative Africans have the RhD-
pseudogene (RHDΨ), resulting in an RHD inactive gene [Figure 1.2-c]. This is because 
the exhibition of a 37 bp nucleotide insertion in intron 3 and exon 4 causing disruption 
to the open reading frame by producing a premature stop codon (Tyr269stop). 
Moreover, there are three missense mutations in exon 5 of the RHD gene. This 
phenotype is usually associated as being in cis with RHCE*ce. In addition, 15% of 
Africans have hybrid genes (RHD-CE-Ds), which is associated with the production of c, 
VS, weak C and e antigens. 18% of RhD-negative Africans observe the deletion of the 
entire RHD gene (Singleton et al., 2000).  
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The RhD-negative phenotype is considered to be a rare phenotype in the Asian 
population. However, different mechanisms could be implicated for RhD-negative 
observation. These include the deletion of the entire RHD gene and D-elute (DEL) 
phenotypes [section 1.5.2.4] (Shao et al., 2002; Sun et al., 1998). Moreover, hybrid 
genes were determined in RhD-negative Asian individuals including RHD-CE(2-9)-D 
and RHD-CE(3-9)-D (Peng et al., 2003; Xu et al., 2005).  
It has been noticed that some RhD-positive individuals form anti-D when they face 
RhD-positive RBCs resulting from transfusion or pregnancy. Therefore, the D antigen 
was considered to be a mosaic which comprises multiple epitopes with a lack of 
variants of D categories (Scott et al., 1996). The RhesusBase website lists regularly 
updated information for all Rh-variant alleles, including partial D alleles, weak D 
alleles, RhD-negative alleles, and RhCE allelic variants (The RhesusBase, 2015).  
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Figure 1.2 The genomic structure of the human Rh locus.  
(a) The RhD-positive individuals possess the RHD gene. (b) The RhD-negative phenotype occurs in 
Caucasians as a result of the deletion of the entire RHD gene. (c) RhD-negative Africans have a 37 
bp duplication in intron 3 and exon 4, associations of missense mutations in exon 5, and nonsense 
mutation within exon 6. Adapted from (Avent et al., 2006). 
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1.5.2.2 Partial D 
RhD-positive individuals carry grossly conventional D antigen, which possesses more 
than 30 epitopes. Individuals with partial D or qualitative D variants carry modified 
RHD genes, which lack some of the D epitopes that make its identification by a 
monoclonal anti-D difficult. These individuals can produce alloanti-D if they are 
receiving a blood transfusion with intact D antigens because they have all the epitopes 
(Scott et al., 2000; Jones et al., 1995). This could arise from a gene conversion between 
RHD and RHCE genes, which results in the formation of a hybrid gene (RHD-CE-D) 
and the replacement of the RHD part by the corresponding RHCE part. Furthermore, 
partial D may occur due to the presence of missense mutations in the extracellular 
region of the RhD protein or multiple point mutations such as DAR alleles (Flegel and 
Wagner, 2002). Figure 1.3 illustrates some types of partial D. 
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Figure 1.3 The molecular background of partial D phenotypes. 
The black boxes depict the exons of RHD, while the grey boxes are 
the exons of the RHCE gene. Adapted from (Avent and Reid, 2000).  
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1.5.2.3 Weak D 
Basically, the normal RhD-positive RBCs normally possess 10,000 to 30,000 antigen 
sites per red cell. Weak D or quantitative D variants (formerly denoted as Du) express 
all the D epitopes but at a weak level. The weak D RBCs express a lower quantity of 
antigen sites per red cell, which ranges from 60 to 5200 depending on the weak D type. 
There currently are 73 types of weak D known with a further single subdivision for type 
1 and type 2 (Reid et al., 2012). 
Wagner and co-workers (1999) revealed the mystery through sequencing the RHD gene 
from weak D individuals. Nearly all weak D phenotypes are featured by missense 
mutations existing within the intracellular and transmembrane domains of the RhD 
protein. Therefore, it may be expected to restrict with the subunit assembly of the RhD 
protein complex, resulting in a decrease in the density of the D antigen site (Wagner et 
al., 1999). 
In contrast to partial D, individuals with weak D do not normally generate an alloanti-D. 
However, in rare situations weak D individuals can produce an alloantibody (Wagner et 
al., 2000; McGann and Wenk, 2010). Therefore, the current term “weak partial D” has 
been designated for such phenotypes (Reid et al., 2012; The RhesusBase, 2015). 
Daniels (2013) suggested using a collective term “D variant” for both partial D and 
weak D. This is in order to prevent ambiguous terminology (Daniels, 2013b). The 
extreme expression of the D antigen is discussed in the next section.  
1.5.2.4 Very weak D antigen D-elute (DEL) 
The extreme weakness of expression of the D antigen can occur. This phenotype is 
designated as DEL and could possibly be mistyped as RhD-negative in blood banks. 
The individuals of DEL express a very weak form of the D antigen, which is difficult to 
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detect via serological typing such as the indirect antiglobulin test (IAT) and can only be 
investigated by adsorption and elution. Different genetic mechanisms are involved to 
encode DEL phenotypes. They are most commonly reported in Asians and are often 
caused by the deletion of 1013 bp in the region between intron 8 and intron 9 in the 
RHD gene (Chang et al., 1998). Moreover, it can be caused by a silent mutation 
1227G>A which causes interference in the splicing of exon 9 (Shao et al., 2002). 
Furthermore, it was investigated that the European population shows DEL phenotypes 
(Körmöczi et al., 2005). According to many studies of high-throughput RHD 
genotyping, a significant number of DEL red cell units were identified in an RhD-
negative donation pool (Flegel et al., 2009). According to the different genetic 
backgrounds of the D variants and because some of them are located in intronic regions 
of the RHD gene, the long-range polymerase chain reaction (LR-PCR) approach was 
designed followed by next-generation sequencing (NGS) in order to assist in the 
determination of any intronic mutations (see Chapter 6).  
1.5.2.5 RHCE polymorphism  
The principal antigens (C, c, E, e) are the products encoded by the RHCE gene. The 
amino acid substitution Ser103Pro in exon 2 is the main factor for C/c antigen 
expression and it is the only one outside the RBC membrane in the second extracellular 
loop. Moreover, there are another three amino acid substitutions, which lead to C/c 
expression, Cys16Trp in exon 1 and (Ile60Leu and Ser68Asn) in exon 2 (Mouro et al., 
1993). Cys16 is not an essential amino acid in the expression of the C antigen (Westhoff 
et al., 2001). The presence of E/e antigens depends on amino acid substitution 
Pro226Ala in exon 5. This is located on the fourth extracellular loop of the RhCE 
protein (Simsek et al., 1994). Arg229 has been identified as a critical residue for E/e 
 18 
epitope existence. Pro226 is an essential residue; however, it is not sufficient for the full 
existence of the E antigen (Chen et al., 2004).  
The variants of the RHCE gene are observed as a typical RHD gene along with a 
modified RHCE gene. Point mutations within the RHCE gene give rise to modified 
phenotypes such as Cw and Cx (Mouro et al., 1995). A rare Ew antigen can be formed by 
missense mutation resulting in Met167Lys in exon 4 (Strobel et al., 2004). This antigen 
forms an antibody to the wild type of E antigen, which can be implicated in HDFN 
(Grobel and Cardy, 1971).  
Weak expression of the e antigen can be found in Black ethnicity such as V and VS 
antigens. The V antigen results from amino acid substitution Leu245Val in association 
with a hybrid gene in exon 5. The VS antigen is a modified e antigen and is encoded by 
Leu245Val in the RHCE*ce allele (Faas et al., 1997). Some cases of the VS antigen 
observed hybrid alleles (Daniels et al., 1998). The same scenario for partial D, hybrid 
CE-D-CE alleles, has been observed which leads to weakened expressions and partial 
C, E, and e antigens may be generated, where some or all C/c and/or E/e antigens are 
missed due to the insertion of D epitopes (Noizat-Pirenne et al., 2002; Wagner and 
Flegel, 2004). 
1.5.2.6 Rhnull phenotype 
Rhnull disease or Rh deficiency syndrome is extremely rare which is characterised by a 
unique abnormality of a red cell morphological shape (stomato-spherocytosis). These 
individuals suffer from chronic haemolytic anaemia. This is due to the lack of an Rh 
complex (RhD, RhCE, RhAG), as well as the lack of intracellular adhesion molecule 4 
(ICAM-4). Furthermore, expressing a reduction or lack of glycophorin B is considered 
to be the Rhnull phenotype. Furthermore, it was investigated that cells with an Rh 
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deficiency demonstrate a knockdown of CD47. Moreover, it possesses biochemical 
abnormalities including phospholipid asymmetry, abnormal water content, and cation 
co-transport. The genetic alterations to the RHAG gene are the chief cause of the Rhnull 
phenotype (Huang et al., 1998; Cherif-Zahar et al., 1998). The entire absence of the Rh 
complex in the red cell membrane is due to ablation or crucial alterations in the Rh 
multimer assembly (Avent et al., 2006).  
1.6 Kell blood group system 
The Kell blood group system is the sixth blood group system (006) according to the 
ISBT. It is considered as one of the most clinically relevant blood groups following the 
ABO and Rh systems. The first antibody of the Kell blood group system (anti-K) was 
discovered in 1946 following the introduction of the antiglobulin test. The system’s 
name was derived from the first producer of that antibody, Mrs. Kelleher (Coombs et 
al., 1946). The system is highly polymorphic which comprises 35 antigens that are all 
expressed on the surface of the Kell glycoprotein (Reid et al., 2012).  
1.6.1 Kell glycoprotein 
The Kell glycoprotein is a type II single-pass membrane with a size of 93 kilodalton 
(kDa). It is expressed on the surface of erythrocytes at a level of 3500–17000 copies per 
red cell (Masouredis et al., 1980). Furthermore, this glycoprotein consists of 732 amino 
acids which are distributed as follows: 47 amino acids forming the short N-terminal 
intracellular domain, 20 amino acids within the single transmembrane domain and 665 
amino acids forming the large extracellular domain where all the Kell antigens are 
expressed (Lee et al., 1991). Figure 1.4 illustrates the structure of the Kell glycoprotein.  
The extracellular region of the Kell glycoprotein has five N-glycosylation sites and 
contains 15 cysteine residues, which are believed to form intramolecular disulphide 
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bonds that give rise to the Kell glycoprotein’s folded structure (Westhoff and Reid, 
2004). The amino acid residues (550–732) in the extracellular domain seem to be 
conserved. The Kell glycoprotein was found to share 33–36% of the amino acid 
sequence homology with M13 or the neprilysin family of zinc endopeptidases (Russo et 
al., 1998). They appear to cleave the large inactive polypeptides into shorter proteolysis 
bioactive ones (Lee et al., 2003a). In the red cells, the Kell glycoprotein may cleave the 
big endothelin-3 into small bioactive endothelin-3, which acts as a potent 
vasoconstrictor and stanch haemorrhage (Lee et al., 1999). All of the Kell antigens, 
except for two antigens (Jsa and Jsb), are expressed prior to residue 550 of the 
extracellular domain (Westhoff and Reid, 2004).  
The Kell glycoprotein is covalently attached to another protein in the red cell 
membrane, known as the XK protein, (Figure 1.4), via a disulphide bond between 
cysteine 72 of the Kell glycoprotein to cysteine 347 of the XK protein (Khamlichi et al., 
1995). The XK protein is a 37 kDa protein with 444 amino acids spanning the red cell 
membrane 10 times and forming five extracellular loops and is encoded by an X-linked 
gene (Cartron et al., 1998). The role of this protein remains mysterious, although it has 
been suggested that it may play a role as a membrane transport protein due its structure 
(Ho et al., 1994). A homologous protein, CED-8, is involved in apoptosis in 
Caenorhabditis elegans (Stanfield and Horvitz, 2000).  
The existence of the XK protein on the red cells is highly crucial for the expression of 
the Kell glycoprotein on the red cell membrane, and its absence leads to McLeod 
syndrome, which results from a mutation in the XK gene that causes the absence of the 
Kx blood group antigen [XK1 or 019001] (Jung et al., 2007). This syndrome is 
characterised by reduced expression of the Kell antigens, in vivo reduction of RBCs 
survival, and acanthocytosis. In addition, males infected with this syndrome suffer from 
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neurological and muscular defects. On the other hand, the lack of the Kell glycoprotein 
expresses normal erythrocytes (Danek et al., 2001).  
It was thought that the expression of the Kell glycoprotein is restricted to erythrocytes, 
but the Kell glycoprotein has also been found in bone marrow, the foetal liver, the 
tonsils, the spleen, and skeletal muscles (Russo et al., 2000). Furthermore, the 
transcription factors that are needed to activate Kell gene expression have been found in 
numerous tissues, with high levels in the brain, lymphoid tissues, and testes (Camara-
Clayette et al., 2001).  
 22 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The structure of the Kell glycoprotein.  
The Kell glycoprotein is covalently linked to another glycoprotein, which is called the XK 
protein. The linkage is a disulphide bond between cysteine 72 of the Kell glycoprotein and 
cysteine 347 of the XK protein. The Kell glycoprotein is a single-pass membrane type II 
glycoprotein of 93 kDa. The XK protein is a 37 kDa protein, which contains 444 amino 
acids, spans the red cell membrane 10 times and forms five extracellular loops. Adapted 
from (Westhoff and Reid, 2004). 
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1.6.2 Molecular basis of Kell system 
A single gene (KEL), which is located on chromosome 7q33, encodes the Kell 
glycoprotein with 19 exons spanning about 21.3 Kilobases (Kb) of the human genomic 
DNA (Lee et al., 1993). All the Kell antigens are accompanied with a SNP except 
KEL20 (Lee, 1997). The KEL20 antigen requires the existence of the XK protein 
(Daniels, 2013a). Several genetic mechanisms may lead to the absence of all Kell 
antigens, which is known as Knull (K0). These mechanisms include amino acid 
substitutions, premature stop codons, and a 5’ splicing-site mutation in the coding and 
non-coding areas (Lee et al., 2001). Different missense mutations lead to the weak 
expression of Kell antigens, Kmod, which is a rarely inherited RBC phenotype that 
features weak expression of the high incidence antigens of the Kell system. However, in 
this case Kmod can be detected (Lee et al., 2003b).  
1.6.2.1 Kell antigens 
The antigens of the Kell blood group system are categorised in seven sets of allelic 
relevance which are (K, k), (Kpa, Kpb, Kpc), (Jsa, Jsb), (KEL11, KEL17), (KEL14, 
KEL24), (KEL25, KEL28), (KEL31, KEL38). In addition, there are 17 high prevalence 
and 3 low prevalence antigens. Table 1.2 lists the antigens of the Kell blood group 
system. In this thesis, the generic name is used for the common antigens including K, k, 
Kpa, Kpb, Kpc, Ku, Jsa, Jsb, Ula and Km. However, the numerical antigen annotation 
proposed by the ISBT is used for the other antigens.  
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K antigen is the first antigen to be detected among the Kell blood group system. The 
prevalence of the K antigen among the English population is 9.02% (Daniels, 2013a). It 
varies from its antithetical antigen, k antigen, by an SNP. A nucleotide substitution 
578C>T (previously reported as 698) on exon 6 gives rise to the K antigen, which 
encodes a different amino acid; Methionine rather than Threonine (Lee et al., 1995; 
Reid et al., 2012). Anti-K is implicated in HTR and severe HDFN. Disruption to the N-
glycosylation occurs due to this amino acid substitution. This leads to the suggestion 
that the possible absence of N-oligosaccharides in this location may expose the K 
antigen’s domain, which a sugar moiety normally covers. Consequently, this leads to 
the production of an antigenic site (Lee et al., 1995).  
Kpa and KEL17 antigens are mostly found in Caucasians. Jsa antigen is nearly exclusive 
in Blacks, with a frequency of 20% in African Americans. The Finns and the Japanese 
express the Ula antigen (Reid et al., 2012). 
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   Table 1.2 List of the antigens of the Kell blood group system. 
Number ISBT Symbol Generic Name Obsolete name Mutation Exon Amino acid Prevalence Antithetic 
001 KEL1 K  Kell, K1 576C>T 6 Thr193Met Low 1 
002 KEL2 k Cellano, K2 576T>C 6 Met193Thr High 1 
003 KEL3 Kpa  Penny, K3 841C>T 8 Arg281Trp Low 2 
004 KEL4 Kpb Rautenberg, K4 841T>C, G at 842  8 Trp281Arg High 2 
005 KEL5 Ku Peltz, K5 Complex, associated with Knull - - High - 
006 KEL6 Jsa Sutter, K6 1790T>C 17 Leu597Pro Low 1 
007 KEL7 Jsb Matthews, K7 1790C>T 17 Pro597Leu High 1 
010 KEL10 Ula Karhula, K10 1481A>T 13 Glu494Val Low - 
011 KEL11 K11 Côte 905C>T 8 Ala302Val High 1 
012 KEL12 K12 Boc (Bockman, Spears 1643 G>A 15 Arg548His High - 
013 KEL13 K13 SGRO 986C>T 9 Pro329Leu High - 
014 KEL14 K14 San, Santini, Dp 539C>G 6 Pro180Arg High 1 
016 KEL16 K16 Weak k, k-like Not defined Not defined Not defined High - 
017 KEL17 K17 (Wka) Weeks 905T>C 8 Val302Ala Low 1 
018 KEL18 K18 V.M., Marshall 388T>C  
389A>G 
4 Trp130Arg 
Gln130Arg 
High - 
019 KEL19 K19 Sub, Sublett 1475A>G 13 Gln492Arg High - 
020 KEL20 Km K20 Not defined Not defined Not defined High - 
021 KEL21 Kpc Levay, K21 842G>A 8 Arg281Gln Low 2 
022 KEL22 K22 N.I., Ikar 965T>C 9 Val322Ala High - 
023 KEL23 K23 Centauro 1145A>G 10 Gln382Arg Low - 
024 KEL24 K24 CL, Callais, Cls 539 >C 6 Arg180Pro Low 1  
025 KEL25 VLAN - 743G>A 8 Arg248Gln Low 1 
026 KEL26 TOU - 1217A>G 11 Gln406Arg High - 
027 KEL27 RAZ - 745A>G 8 Lys249Glu High - 
028 KEL28 VONG - 742C>T 8 Arg248Trp Low 1 
029 KEL29 KALT - 1868A>G 17 Lys632Arg High - 
030 KEL30 KTIM - 913A>G 8 Asn305Asp High - 
031 KEL31 KYO  875G>A 8 Arg292Gln Low - 
032 KEL32 KUCI - 1271T>C 11 Val424Ala High - 
033 KEL33 KANT - 1283T>G 11 Leu428Arg High - 
034 KEL34 KASH - 758G>A 8 Cys253Tyr High - 
035 KEL35 KELP - 780T>G  
2024A>G 
8  
18 
Phe260Leu 
Gln675Arg 
High - 
036 KEL36 KETI - 1391T>C 12 Ile464Thr High - 
037 KEL37 KHUL - 877C>T 8 Arg at 293 High - 
038                    KEL38  KYOR  G at 875 8 Arg at 292 High  
    The ISBT symbol, generic and obsolete names, mutation, and prevalence. Adapted from (Daniels, 2013a; International Society of Blood Transfusion, 2015). 
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1.7 Other blood groups 
The antigens of other blood group systems were genotyped in this project (Chapter 4). 
Most of the antigenic polymorphisms arise from SNPs. On the other hand, some 
antigens observe the deletion of a number of nucleotides such as the Vel blood group 
antigen. The nucleotides changing and amino acid substitutions are given in Table 1.3.  
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                         Table 1.3 Polymorphisms in other blood group systems. 
 
System Gene Polymorphism Nucleotide change Amino acid 
ABO ABO A/B 
526C>G, 703G>A, 796C>A, 803G>C 
Arg176Gly, Gly235Ser, Leu266Met, Gly268Ala 
MNS 
GYPA 
GYPB 
M/N 
S/s 
59C>T, 71G>A, 72T>G 
143C>T 
Ser1Leu, Gly5Glu 
Thr29Met 
Duffy DARC Fya/Fyb 125G>A Gly48Asp 
Kidd SLC14A1 Jka/Jkb 838G>A Asp280Asp 
Diego SLC4A1 Dia/Dib 2561C > T Pro854Leu 
Dombrock ART4 Doa/Dob 793G>A Asp265Asn 
Colton AQP1 Coa/Cob 134C>T Ala45Val 
Yt ACHE Yta/Ytb 1057C > A His353Asp 
Vel SMIM1 Vel+/Vel− Deletion of 17 nucleotides in exon 3 Frameshift deletion 
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1.8 Human platelet antigens (HPAs) 
Platelets are blood cells that help to cease bleeding and form a blood clot. In order to 
avoid confusion with the previous names given to platelet antigens, the ISBT platelet 
working party adopted a numeric nomenclature that was performed in 1990 by ISBT 
and the International Committee for Standardisation in Haematology [ICSH] (von dem 
Borne and Décary, 1990). Following that period, the number of HPAs has been 
increased to 24 with more understanding of the molecular basis. Therefore, the 
nomenclature of HPAs was revised again in 2003 (Metcalfe et al., 2003).  
To date, 33 HPAs have been defined, which are located on six functional glycoprotein 
complexes (GPIIb, GPIIIa, GPIbα, GPIbβ, GPIa and CD109). Twenty of these antigens 
are expressed on GPIIb and GPIIIa complex. Twelve antigens of which are grouped in a 
cluster of six biallelic groups. These include HPA-1, HPA-2, HPA-3, HPA-4, HPA-5 
and HPA-15 (HPA Sequence Database, 2015). The HPAs are numbered, in which the 
high frequency platelet antigen is designated as “a” and the lower frequency form of the 
antigen is nominated as “b”. All the HPAs are encoded by a SNP, apart from HPA-14, 
and these SNPs lead to amino acid substitutions (Lucas and Metcalfe, 2000). HPAs 
were marked as “w” for (workshop) when the antibody to one of the two antigens has 
been detected (Curtis and McFarland, 2014).  
The antibodies to the HPAs can be involved in alloimmune platelet disorders, mainly 
foetal and neonatal alloimmune thrombocytopaenia [FNAIT] (Mueller-Eckhardt et al., 
1989). Furthermore, it can cause multitransfusion platelet refractoriness (MPR) and 
posttransfusion purpura [PTP] (Novotny, 1999; Gonzalez and Pengetze, 2005). In the 
Caucasian population, the most common antibody to cause MPR, PTP and NAIT is 
anti-HPA-1a. This antigen is expressed in 98% of the Caucasian population (Newman et 
al., 1989). Moreover, this antibody was the reason for 85% of the incidences of FNAIT 
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cases, which was confirmed by serology (Curtis and McFarland, 2014). The second 
antibody to cause immune platelet disorders, which has more frequency next to the 
HPA-1a antibody, is the anti-HPA-5b antibody (Kiefel et al., 1989; Curtis and 
McFarland, 2014). 
1.9 Typing of blood groups 
1.9.1 Serological methods 
The RBCs are not prone to agglutinate each other because they possess a negative 
charge due to the presence of sialic acid. The adjoining RBCs can become close to each 
other, causing a direct agglutination by bridging the gap by pentamer IgM. This is 
represented in compatibility typing for ABO, while IgG cannot accomplish this 
(Pamphilon and Scott, 2007). A direct antiglobulin test (DAT) is performed to 
investigate immune haemolytic anaemia and to observe whether RBCs are sensitised by 
antibodies. Antihuman globulin is incubated with the washed RBCs of the patients, 
which leads to an observable agglutination. This is also designated as the Coombs test 
due to its discovery by Robin Coombs (Coombs and Roberts, 1959).  
Next, the IAT test is carried out in order to investigate a patient’s serum with the 
donor’s RBCs to provide a compatible blood unit. Following several washes, the 
addition of the antiglobulin reagent takes place, and the RBCs are examined to 
determine whether they have become sensitised. The antiglobulin test has been 
implemented in many applications, including haemolysis by alloimmunisation including 
HTR and HDFN as well as autoimmune haemolysis (Coombs and Roberts, 1959).  
The typing of the blood groups by serology remains the gold standard approach for the 
compatibility procedure in order to make the blood transfusion feasible. It is a simple 
and rapid procedure and possesses an appropriate sensitivity to major transfusion 
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practices. However, the disadvantages of the serotyping include that it is labour-
intensive and the high cost of the reagents, which lessen its feasibility to accomplish 
extended screening of blood groups for blood donors (Reid, 2009). Moreover, the cost 
of serotyping is higher in some cases such as multiply transfused patients. This is due to 
the extended screening of further blood groups in order to provide safer compatible 
blood units and reduce the risk of alloimmunisation (Mazonson et al., 2014). 
Furthermore, some of the serological reagents are limited, are weakly reactive or are not 
available for certain blood groups (Reid, 2009). 
In fact, the RBCs of patients who have received a recent transfusion or mothers during 
pregnancy can be coated by IgG antibodies. In addition, the presence of a donor’s RBCs 
in a patient’s blood hampers the serotyping and prevents the identification of the right 
phenotype, in particular in cases of receiving a massive transfusion. Consequently, the 
existence of rare or weak expression of the antigens can complicate the serological 
typing. It may be difficult to differentiate between alloantibodies and autoantibodies in 
antigen-positive individuals (Reid et al., 2000; Reid, 2009). All the previous issues can 
be resolved by applying the blood group genotyping (BGG).  
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1.9.2 Genotyping of blood groups 
Following the cloning of the blood group genes and the advent of the PCR, 
deoxyribonucleic acid (DNA)-based testing became more feasible (Mullis et al., 1987). 
Therefore, there are multiple approaches for BGG that are based on PCR. For example, 
the restriction fragment length polymorphism-PCR (RFLP-PCR) (Nishihara et al., 
1994; Fukumori et al., 1995), sequence specific primers-PCR (SSP-PCR) and real-time 
PCR [RT-PCR] (Polin et al., 2008) capture many DNA targets using multiplex PCR 
(Tax et al., 2002; Beiboer et al., 2005) and microarray technology (Karpasitou et al., 
2008).  
The microarray technology possesses a high multiplexing capacity using a miniaturised 
solid surface. The solid surface can be either glass-arrays or bead-arrays. These surfaces 
are coupled to probes, which have numerous specific blood group alleles attached to the 
surface. During the assay, the labelled amplified PCR products are hybridised to the 
corresponding probes followed by measuring the fluorescent intensity in order to 
determine the blood group genotype.  
There are several commercial kits of glass-arrays; human erythrocyte antigens (HEA) 
BeadChip™ array provided by Bioarray Solutions identifies 24 antigens (Hashmi et al., 
2005; Hashmi et al., 2007) and BLOODchip®, which detects 47 variants and is 
produced by Progenika Biopharma S.A. The BLOODchip® was the outcome products 
from the Bloodgen project (Avent et al., 2007). An example of the bead-array is the ID 
Core+ kit provided by Progenika Biopharma S.A., which is associated with the 
Luminex system. The ID Core+ kit was used for BGG (Chapter 3).  
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1.9.2.1 Applications of BGG 
There are numerous benefits of using BGG over conventional serology. Daniels (2013) 
stated three chief reasons for the utilisation of the molecular approach using DNA. 
These include when the source of the RBCs is no longer available, the provision of 
more or better knowledge than the serotyping and the efficiency and cost effectiveness 
of the BGG in contrast to the serology (Daniels, 2013a). 
The BGG has been applied in the determination of the foetal blood group by testing the 
isolated foetal DNA from the maternal plasma to prevent the risk of HDFN (Avent, 
1998). Furthermore, extensive genotyping of blood donors is required in alloimmunised 
patients to preclude the formation of further alloantibodies and those causing 
alloimmunisation. BGG can be used in the investigation of the blood group of a recently 
transfused patient. Moreover, rare blood phenotypes can be found by screening the 
blood donors. BGG can determine the frequency of blood group polymorphisms in a 
specific population. Furthermore, the RHD zygosity of a father to a foetus at risk of 
HDFN can be assessed. BGG can distinguish the D variants properly and classify them 
properly and can conserve the RhD-negative units in stocks. Patients with autoimmune 
haemolytic anaemia can be typed easily using BGG (Anstee, 2009; Westhoff, 2006). 
The next section will explain the importance of genotyping for HPAs.  
1.9.2.2 Applications of the genotyping of HPAs 
The requirement of serological typing to have adequate numbers of fresh platelets, the 
scarcity of the serological reagents and the labour-intensive technique itself all hamper 
the typing by serology. In addition, it is only restricted to specific antigens, thus not all 
the HPAs can be tested (Curtis, 2008).  
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PCR paves the way for genotyping the blood groups and HPAs. Ribonucleic acid 
(RNA) was isolated with difficulty from platelets and reverse transcriptase PCR 
amplification then took place in order to determine the HPA-1a/1b allele. Following that 
complex procedure, Newman and colleagues accomplished the genotyping of the HPA-
1a/1b allele using RFLP-PCR (Newman et al., 1989). After that, the SSP-PCR became 
the most widespread technique used for HPAs genotyping as it is a simple procedure 
(Curtis and McFarland, 2014). However, the drawback of this technique includes the 
post-analysis using gel documentation for genotyping (Hurd et al., 2002). Moreover, 
many alleles have been discovered and an automated system is required to facilitate the 
genotyping of different alleles of HPAs. Many assays have arisen such as melting curve 
analysis and RT-PCR (Curtis, 2008). High-throughput systems become available 
commercially in the form of array-based platforms including glass and bead arrays 
(Beiboer et al., 2005; Denomme and Van Oene, 2005).  
The benefits of these platforms include: fast procedure that is less laborious, 
interpretation of the results is better using sophisticated computer software and fewer 
clerical errors can happen in data handling and during storage. The disadvantages of the 
high-throughput systems are the requirement of costly specific instruments with special 
reagents, as well as the expertise needed for operation.  
The disadvantage of all the genotyping platforms mentioned above is that they cannot 
identify new alleles. Therefore, they require improving and updating to the current 
assay when new alleles have been discovered. Therefore, investigators of BGG move to 
use NGS to obtain the high-throughput sequencing information as well as the ability to 
identify the unprecedented alleles (Avent et al., 2015).  
Sanger sequencing has frequently been used to resolve the complexity of the blood 
group variants, in particular the new ones. Nowadays, NGS has been used recently in 
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BGG. For example, Stabentheiner et al. (2011) used NGS to genotype the 10 exons of 
the RHD gene. Moreover, a panel was designed to capture the exons of the genes for 18 
blood groups for sequencing (Fichou et al., 2014). Avent et al. (2015) utilised NGS 
through amplification of the entire genes of the blood groups by LR-PCR followed by 
NGS. Moreover, NGS was used in prenatal diagnosis and determination of the foetal 
genotyping from maternal plasma (Rieneck et al., 2013; Wienzek-Lischka et al., 2015). 
In order to explain the NGS principle, the knowledge regarding Sanger sequencing is 
discussed first and NGS is discussed in the next sections.  
1.10 Conventional sequencing ‘Sanger sequencing’  
Sanger sequencing is also called the chain-termination method. The sequencing 
template must be denatured and obtained in a single stranded form. Furthermore, the 
primer must be complementary to the 3’ strand of the template, thus the DNA 
polymerase can extend the primer and generate the sequencing by synthesising a 
nascent strand of the template.  
Equal amounts of this reaction mixture are placed into four tubes, and four 
dideoxynucleotides triphosphates (ddNTPs) are added to each tube. The replication is 
initiated by adding deoxynucleotide triphosphates (dNTPs), however, the addition of 
ddNTPs will terminate the sequence synthesis (Sanger et al., 1977).  
The contents of the reaction tubes are then subjected to four lanes of polyacrylamide 
electrophoresis gel and the oligonucleotide sequences are separated according to the 
size and type of nucleotides. The shortest sequences are moved further down to the 
bottom of the gel and the reading can be achieved from the bottom to the top. Figure 
1.5 illustrates the principle of Sanger sequencing while running on polyacrylamide 
electrophoresis gel. 
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Following that period, the method was evolved to include fluorescent labelling (Prober 
et al., 1987). Moreover, the automation of 96 or 384 independent capillaries was 
designed to increase the throughput and facilitate sequencing of more samples 
(Shendure and Ji, 2008). Furthermore, the read length of sequencing can be achieved by 
Sanger sequencing up to around 1000 bp and a high level of accuracy of 99.999% can 
be obtained. Sanger sequencing is still the gold standard of DNA sequencing although 
the cost of it has been valued at $0.50 per Kb (Shendure and Ji, 2008). Interestingly, 
Sanger sequencing was used in sequencing the entire human genome in the Human 
Genome Project [HGP] (Bentley, 2000). The sequencing of five individuals, around 
14.8 billion bp, took over nine months (Venter et al., 2001). Therefore, the requirement 
of new platforms to provide rapid sequencing at an affordable price was needed in order 
to obtain the benefits of the sequencing.  
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Figure 1.5 Sanger sequencing.  
A complementary primer anneals to a 3’ single-stranded template to start the extension of the template 
by adding dNTPs using polymerase enzyme. Equal amounts of the reaction mixture are placed into four 
tubes, and four ddNTPs are added to each tube, which terminate the sequence synthesis. The contents of 
the reaction tubes are then subjected to four lanes of polyacrylamide electrophoresis gel and the 
oligonucleotide sequences are separated according to the size and type of nucleotides. The smallest 
sequences are moved further down to the bottom of the gel, while the biggest sequences are remained at 
the top of the gel. The reading can be carried out from the bottom to the top as depicted with the blue 
arrow.  Adapted from (Mardis, 2013). 
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1.11 Next generation DNA sequencing  
Following the accomplishment of the HGP, the requirements of the rapid production of 
DNA sequencing at low cost were to provide a high-throughput which increases the 
number of assessed samples. These led to the advent of the technology of NGS, which 
can be acquired by personal investigators including small laboratories (Shendure and Ji, 
2008). NGS is also denoted as massively parallel sequencing, deep sequencing or total 
genome sequencing (Hert et al., 2008).  
In contrast to Sanger sequencing, NGS uses a different principle in its mode of action. 
In all NGS platforms, following the extraction of the genetic materials, a sequencing 
library is prepared. Initially, the sequencing library is constructed by shearing the 
targeted DNA into small fragments, either by using enzymes or physical sonication. A 
ligation process then takes place by attaching both ends of the fragmented DNA to 
adaptors, which are pairs of signal sequence oligonucleotides. The fragmented DNA 
along with the adaptors forms the sequencing library (paired end library). The 
sequencing library is then fixed to bead particles or solid surfaces, depending on the 
platform used, in order to prepare the sequencing template for clonal amplification. The 
clonal amplification either uses emulsion PCR or solid phase amplification depending 
on the platform used, which is performed in order to enrich and obtain a high number of 
sequencing templates to ascertain appropriate signal production in the sequencing 
reaction that is sufficient for a sensitive detection.  
The amplification procedure involves high consideration because a low fidelity 
polymerase may generate errors by incorporating mismatched nucleotides. Accordingly, 
high rates of sequencing reads may be excluded and successively lead to a low depth of 
coverage especially in homozygous samples. A depth of coverage can be defined as 
numbers of times that the sequencing reads are sequenced repeatedly. Moreover, allelic 
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dropouts can be occurred due to PCR primer optimisation or possibility of presence of 
any new alleles in the primer-binding site. In addition, low quality data can be obtained 
and need to be trimmed if do not meet the quality standards (Gabriel et al., 2011). See 
[section 2.5.5] for further information regarding the data analysis of NGS.  
However, some sequencers are known as third generation sequencing and they do not 
need any amplification involved in the process of constructing the sequencing library. 
These are also designated as single molecule sequencing which includes platforms such 
as Pacific Biosystems and Oxford Nanopore (Mardis, 2008).  
1.11.1 Platforms of NGS  
There are a number of platforms offered nowadays, and each one possesses a different 
capacity to generate read length, coverage, speed, and accuracy. Table 1.4 demonstrates 
different types of NGS platforms. The first commercially available platform of the NGS 
was the Roche/454 FLX. This platform is also referred to as pyrosequencing, 
specifically due its performance of using pyrophosphate-based sequencing (Margulies et 
al., 2005). The sequencing libraries are constructed by fragmenting the targeted 
template and ligating adaptors at both ends. Then the clonal amplification takes place, in 
which a single sequencing library is attached to a bead within droplets of PCR reaction 
mixture in oil emulsion. This results in each bead being covered by ten million copies of 
the targeted template. Following the clonal amplification procedure, the emulsion is 
broken and denaturation of the DNA template occurs in order to obtain a single stranded 
template. The beads that carry single stranded DNA are deposited into the wells of a 
fibre-optic slide. The sequencing is based on synthesising a new strand in which the 
pyrophosphate is released and a photon is generated (Margulies et al., 2005). Basically, 
most NGS platforms generate a nascent DNA strand during the sequencing. This is 
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actually called sequencing by synthesis. The next section will discuss the NGS platform 
used in this PhD.  
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                    Table 1.4 NGS platforms.  
 
NGS Platform Clonal amplification Sequencing chemistry Average read length 
454 Emulsion PCR Pyrosequencing (sequencing by synthesis) Up to 1000 bp 
Illumina Bridge amplification Reverse dye terminator (sequencing by synthesis) 50-300 bp 
Solid Emulsion PCR Oligonucleotide 8-mer chained ligation (sequencing by ligation) 75 bp 
Ion Torrent Emulsion PCR Proton detection (sequencing by synthesis) 100-400 bp 
PacBio N/A Phospholinked Fluorescent nucleotides (sequencing by synthesis) 8500 bp 
                 Adapted from (Hodkinson and Grice, 2015). 
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1.11.1.1 Ion Torrent Personal Genome Machine™ (Ion PGM™)  
Ion PGM™ was developed by Ion Torrent (Guildford, CT, United States), and is 
currently owned by Thermo Fisher Scientific (Carlsbad, CA, United States). It is a 
benchtop semiconductor sequencer. Ion Torrent entered the market in 2010 as a simple 
sequencer that was affordable and fast due to its running time from two hours to seven 
hours. It utilises a combination of semi-conductor chip technology and simple 
chemistry. The sequencing technology of the Ion PGM™ is based on sequencing by 
synthesis. In other words, every time the DNA polymerase incorporates a nucleotide to 
generate a new strand of DNA, a hydrogen ion (H+) is released. Therefore, it does not 
depend on intermediary light in comparison with other platforms. This hydrogen ion 
alters the pH of the surrounding solution (0.02 pH units) for every single base that has 
been incorporated. The detection then takes place using a sensor underneath each well, 
working as a solid-state pH meter. Off-chip electronics finally digitise the voltage to 
digital information and the base calling. The detection procedure takes around 4 seconds 
per base. Following a flow of every nucleotide, a wash step is utilised to ensure the well 
is free from any nucleotides (Rothberg et al., 2011). Figure 1.6 demonstrates the 
sequencing reaction of the Ion Torrent™ platforms.  
Three sizes of chip are provided for Ion PGM™, (Ion 314™ Chip, Ion 316™ and Ion 
318™ Chip) in order to give each laboratory the scalability according to the assay they 
are performing. Four read lengths are provided for the Ion PGM™ platform (100 bp, 200 
bp, 300 bp and 400 bp). The output of this sequencer ranges from 30 Mb to 2 Gb 
depending on the type of chip used as well as the reading length considered for the 
sequencing (Thermo Fisher Scientific, 2015a). The total reads can be produced by the 
Ion PGM™ which ranges from 400 thousand to 5.5 million reads. Ion PGM™ is ideal for 
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small projects and small laboratories in which it is able to sequence genes, panels of 
genes, small genomes, and profile gene expressions. 
In January 2012, a new platform (the Ion Proton™) was launched which is even more 
powerful in producing sequencing data than the Ion PGM™. It has the capability to carry 
out whole genome sequencing (WGS) and whole exome sequencing [WES] (exons of 
the human genome) within a range of two to four hours. The read length available to 
this platform is only 100 bp and 200 bp. The Ion Proton™ platform provides an 
extremely high output which reaches up to 10 Gb and 60 to 80 million reads can be 
generated by such a platform (Thermo Fisher Scientific, 2014a). 
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Figure 1.6 The sequencing reaction on the Ion PGM™.  
(a) A schematic structure of the Ion Chip demonstrates the addition of nucleotide causing release of the 
hydrogen ion H+. This leads to changing of pH of the surrounding solution and the detection then occurs 
using a sensor underneath each well, working as a solid-state pH meter. Off-chip electronics finally 
digitise the voltage to digital information and the base calling. (b) The sequencing by synthesis is based on 
pH sensing, in which as every nucleotide is incorporated, a hydrogen ion is released and the base is called. 
Adapted from (Mardis, 2013). 
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1.12 Thesis aims and objectives  
BGG provides more comprehensive blood typing in comparison to the conventional 
serology. Indeed, it shows a high impact in reducing the risk of alloimmunisation to 
multiply transfused patients, such as patients with SCD. Microarray technology (bead-
arrays) was utilised in order to genotype blood group alleles (Chapter 3). This was as 
training for different approaches of genotyping assays.  
NGS has been utilised in many research aspects for genotyping. The aim of this PhD 
project was to assess the genotyping by sequencing based on NGS using the Ion PGM™ 
platform. In this study, two approaches were designed using NGS for BGG.  
The first approach targeted and selected amplicons of interest using the Ion Ampliseq™ 
Custom Panel, which is designated as the Human Erythrocyte Antigens and Human 
Platelet Antigens Panel (HEA and HPA Panel). The panel assay includes 11 blood 
group systems and 16 human HPAs (Chapter 4). This project comprises the following 
objectives:  
 To develop a comprehensive assay in order to genotype both the alleles 
encoding the blood group antigens and HPAs in a single sequencing run.  
 To establish a rapid protocol for genotyping with a lower cost in contrast to the 
previous BGG platforms. 
 To identify novel alleles which have not been reported previously.  
The second approach was a LR-PCR followed by the NGS for the Kell (Chapter 5) and 
Rh blood group systems (Chapter 6). This type of sequencing develops a better 
understanding about the various genetic mechanisms that may be involved in the blood 
group genes because of sequencing the entire gene of interest including the coding and 
non-coding areas.  
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This project contains the following objectives: 
      Kell blood group 
 To develop a high resolution assay for genotyping the KEL gene.  
 To predict the main antigens of the Kell blood group system, in particular the 
high prevalence ones.   
 To identify the KEL alleles encoding the Kell antigens that cannot be identified 
by the standard serology.  
 To utilise the Kell blood group system as a model to establish the same protocol 
for the Rh blood group system.   
Rh blood group  
 To develop a high resolution assay for genotyping the RHD and RHCE genes. 
 To distinguish between RhD-positive, weak D, and partial D samples. 
 To investigate all the SNPs which are related to a particular allele.  
 To determine the specific allele from the intronic SNPs and predict its associated 
phenotype.  
 To identify rare alleles that may be common in different ethnicity.  
 To differentiate if an allele is wrongly genotyped to a different gene, by other 
BGG platforms, in case of non-specific primers due to the high homology 
between RHD and RHCE genes.  
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Chapter 2 : Materials and Methods 
2.1 Sourcing of blood samples  
Blood samples were provided by the National Health Service Blood and Transplant 
(NHSBT) Filton from anonymous volunteer blood donors with informed ethical donor 
consent. The random blood samples were received in ethylenediaminetetraacetate 
(EDTA) anti-coagulated tubes and serological testing was accomplished for all samples 
by the same institute. The phenotyping was for the following blood groups: ABO, Rh, 
MNS, P1, Lutheren, Kell, Lewis, Duffy, Kidd and Sickle cell status.  
Twenty-eight samples were chosen randomly and genotyped by microarray using the ID 
Core+ assay [Cohort A, Chapter 3]. Another 28 samples, Cohort B, were analysed for 
red cell antigens and HPAs using HEA and HPA Panel based on NGS [Chapter 4]. 
Regarding Cohort C, 20 samples were chosen known serology and used for Kell LR-
PCR followed by NGS, 18 kk and 2 Kk [Chapter 5]. Regarding cohort D, 10 samples 
were chosen with known serology for Rh LR-PCR followed by NGS, in which five 
RhD-positive and five weak D samples. A further investigation was carried out for a 
single sample of the HEA and HPA Panel samples by Rh LR-PCR followed by NGS. 
This sample observed a novel allele in the RHCE gene detected by the HEA and HPA 
Panel [Chapter 4]. Figure 2.1 shows a diagram for the numbers of blood samples were 
used for different projects. 
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                                   Figure 2.1 The different blood samples were used in this PhD project.  
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2.2 Genomic DNA extraction  
2.2.1 Routine genomic DNA extraction  
To extract the genomic DNA, buffy coats need to be obtained from the sample of the 
whole blood. In order to obtain buffy coats, the blood samples were spun at 2500 × g 
for 10 minutes in order to separate the components of the whole blood into three parts, 
which are plasma, a layer of buffy coat, and concentrated red cells. The buffy coat layer 
was collected and the other two components were discarded. Genomic DNA was 
purified using the QIAamp DNA Blood Mini Kit (Qiagen Ltd, West Sussex, United 
Kingdom). A volume of 20 µl of Qiagen Proteinase K was added to 200 µl of the 
extracted buffy coat in a clean 1.5 mL Eppendorf tube. Then, a volume of 200 µl of AL 
buffer was added to the mixture. The mixture was mixed vigorously and incubated at 56 
°C for 10 minutes. Next, a volume of 200 µl of absolute ethanol (Fisher Scientific UK, 
Leicestershire, United Kingdom) was added to the mixture and was mixed for 15 
seconds. After that, the mixture was applied to the QIAamp mini spin column, which 
had a collection tube, and the tube was spun at 6000 × g for 1 minute. The QIAamp 
mini spin column tube was placed into a new clean collection tube and the previous 
collection tube was discarded which contained the filtrate. Next, a volume of 500 µl of 
AW2 was added to the QIAamp mini spin column tube and was spun at 20,000 × g for 
3 minutes. Then, the QIAamp mini spin column was placed in a new 1.5 mL Eppendorf 
tube and the tube which contained the filtrate was discarded. A volume of 200 µl of AE 
buffer was added to the QIAamp mini spin column and the tube was incubated at room 
temperature for 1 minute. Finally, the tube was spun at 6000 × g for 1 minute and the 
purified DNA was obtained and stored at −20°C for long-term use.  
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2.2.2 Genomic DNA extraction for long amplicons  
Genomic DNA was extracted from blood samples and purified for very long genomic 
DNA in order to amplify a PCR product bigger than 20,000 bp. Gentra® Puregene® 
Blood kit from Qiagen Ltd (West Sussex, United Kingdom) was utilised in this 
experiment. The buffy coat layer was obtained as described above [section 2.2.1]. 
Because the buffy coat contained red cells, 3 volumes of RBCs Lysis Solution (750 µl) 
were added to a 15 mL centrifuge tube with 250 µl of buffy coat. The tube was inverted 
in order to mix it properly and was incubated at room temperature for 10 minutes. After 
the incubation period, the tube was spun at 2000 × g for 5 minutes. Then, the 
supernatant was discarded by pouring and leaving around 200 µl of the solution with the 
pellet. After that, the tube was mixed vigorously in order to resuspend the pellet in the 
remaining solution. A volume of 3 mL of Cell Lysis Solution was added to the tube and 
was mixed thoroughly to lyse the cells. Next, a volume of 15 µl of RNase A Solution 
was added to the tube and the solution was mixed by inverting the tubes 25 times. 
Following the proper mixing, the tube was incubated at 37°C for 15 minutes. After that, 
the tube was incubated on ice for 3 minutes for fast cooling of the sample. Then, a 
volume of 1 mL Protein Precipitation Solution was added to the solution and was mixed 
at high speed for 20 seconds followed by spinning at  2000 × g for 5 minutes. A volume 
of 3 mL of isopropanol was dispersed into a new 15 mL centrifuge tube and the 
supernatant was poured cautiously from the previous step. The tube was mixed 
thoroughly by inverting the tube 50 times followed by spinning at 2000 × g for 3 
minutes. The supernatant was then discarded and the tube was drained by inverting it on 
absorbent paper. It must be ensured that the pellet is still in the tube. After that, a 
volume of 3 mL of 70% ethanol was added and was mixed properly by inverting the 
tube many times in order to wash the DNA pellet. Then the tube was spun at 2000 × g 
for 1 minute. After washing the pellet with ethanol, the tube was drained again by 
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inverting the tube on absorbent paper for up to 10 minutes. After that, a volume of 300 
µl of DNA Hydration Solution was added to the tube and mixed vigorously for 5 
seconds followed by incubation at 65°C for 1 hour in order to dissolve the DNA. Next, 
the tube was incubated at room temperature overnight with gentle shaking in order to 
mix the genomic DNA with the DNA hydration Solution. Finally, the pure genomic 
DNA was transferred into a new 1.5 mL Eppendorf tube and kept at −20°C for long-
term storage.   
2.2 Assessment of DNA quality and quantity  
DNA concentration was obtained using Qubit® dsDNA BR Assay kit (Thermo Fisher 
Scientific, Paisley, United Kingdom). A Qubit™ Working solution was prepared by 
diluting the Qubit™ reagent in a ratio of 1:200 with Qubit™ buffer. Two different 
standards (standard 1 and standard 2) were prepared by adding 190 µl of the Qubit™ 
Working solution with 10 µl of standard 1 and standard 2, respectively. For each 
sample, a volume of 199 µl of Qubit™ Working solution was mixed with 1 µl of the 
DNA sample to obtain a total volume of 200 µl. Next, the assay tubes were mixed 
vigorously for 2 seconds followed by incubation at room temperature for 2 minutes. 
Finally, the samples were read on the Qubit™ Fluorometer instrument and readings of 
ng/µl were obtained. Samples ranged in concentrations between 90-250 ng/µl (Thermo 
Fisher Scientific, Paisley, United Kingdom).   
DNA purity was assessed by utilising a NanoVue Plus Spectrophotometer (GE 
Healthcare, Little Chalfont, United Kingdom). The optical density (OD) A260/A280 
ratio was used to assess DNA purity, which was in the range of 1.7 to 1.95. The DNA 
samples were stored at −20°C for long-term storage. The results of the DNA 
concentrations and purity are demonstrated in Appendix B.   
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2.3 Genotyping using microarray beads 
2.3.1 Multiplex PCR  
The ID Core+ kit was utilised which is based on microarray suspension beads. All the 
reagents of the ID Core+ kit were provided by Progenika Biopharma S.A. (Derio, 
Spain; distributed by Grifols). Two reactions of multiplex PCR were prepared. The first 
reaction (A) could identify the antigens for RhCE, Kell, Kidd, Duffy, and MNS blood 
group systems. The second reaction (B) was used for the antigens of Diego, Dombrock, 
Colton, and Yt blood group systems. The two tubes comprised IDCore A/IDCore B 
PCR mixes with Master ID PCR Mix, Biotin deoxycytidine triphosphate (dCTP), 
IDCore Primer Set A, and IDCore Primer Set B, respectively. Both mixes (IDCore A 
PCR Mix and IDCore B PCR Mix) were gently mixed and spun down. A volume of 10 
µl of these mixtures was added into each well of a 96-well PCR plate for column A and 
column B. A volume of 2.5 µl of genomic DNA was added with 50 ng/µl, and the plate 
was then sealed with a sealing film. Next, the plate was placed in a centrifuge plate to 
be spun until it reached 900 rpm. After that, the 96-well PCR plate was covered by a 
MicroAmp compression pad before starting the run on a Veriti thermocycler. The 
following programme was conducted: the polymerase was activated at 95°C for 15 
minutes, followed by 40 cycles at 95°C for 30 seconds for denaturation, 60°C for 30 
seconds for annealing, and 72°C for 80 seconds for extension. Finally, the final 
extension was 72°C for 7 minutes, and was held at 4°C.  
2.3.2 Hybridisation  
Hybridisation mixtures were prepared according to the hybridisation step for both 
column A and column B, respectively. The mixtures were made by using IDCore Beads 
A/B, a hybridisation ID buffer, and a control ID buffer. The mixtures were spun for 30 
seconds prior to use. A volume of 95 µl of the IDCore+A/B hybridisation mix was 
added to a 96-Thermowell Polycarbonate PCR Microplate (Corning, Flintshire, United 
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Kingdom). Then, a volume of 5 µl of the PCR product was added to the hybridisation 
mixture. The mixture then needed to be mixed thoroughly 20 times by pipetting up and 
down. After that, the plate was then sealed with the appropriate film (Microseal ‘A’ 
Film, BioRad, United Kingdom). After placing the plate on the thermocycler, the plate 
was covered by two silicone pads. The hybridisation programme was set to 95°C for 5 
minutes for denaturation and to 52°C for 15 minutes for hybridisation, and was finally 
held at 52°C.  
2.3.3 Labelling  
A Millipore filter plate (MultiScreenHTS Filter Plates Millipore, Merck Millipore, United 
Kingdom) was pre-moistened with 50 µl of a conjugate of a streptavidin and 
phycoerythrin (SAPE) dilution buffer. Vacuum pressure was applied at −10 kPa 3 times 
at 30 second intervals. A labelling mix was prepared with SAPE and SAPE dilution 
buffer and kept in the dark. A volume of 95 µl of the hybridisation mix was transferred 
to the Millipore filter plate. The dispensing occurred against the wall to prevent any 
contact that may happen between the pipette tips and the membrane filter. After that, 
vacuum pressure was applied again to the Millipore filter plate with the same conditions 
as previously described. A volume of 75 µl of the labelling mix was added to each well. 
Finally, the Millipore filter plate was wrapped with aluminium foil to protect the 
reaction from the light and placed into a plate shaker at 1000 rpm for 15 minutes.  
2.3.4 Quantification  
The Millipore plate was instantly analysed with the Luminex® 100/200™ platform for 
quantification. The results were analysed using Luminex xPonent® LX100/LX200 
Version 3.1. This software worked in association with BLOODchip® ID Software 
(BIDS) [Workstation Progenika Version 2.0 Beat 6] to produce a genotyping report of 
every sample and to predict the phenotypes. 
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2.5 NGS libraries construction 
2.5.1 NGS libraries construction using a panel of short amplicons  
The HEA and HPA Panel were designed using Ion Ampliseq™ Designer (Ion Ampliseq 
Designer, 2014). The design included 11 blood group systems (ABO, Rh, Kell, Kidd, 
Duffy, MNS, Diego, Dombrock, Yt, Colton and Vel) and targeted HPAs 1-16. Two 
pools of ultra-high multiplex primers were provided for all the targets. The starting 
material of DNA was diluted to 10 ng per pool and was assessed using a Qubit® 2.0 
Fluorometer using the Qubit® dsDNA BR Assay kit. Therefore, 20 ng of each DNA 
sample was used to amplify all the targets. The total number of amplicons was 167, and 
the first pool comprised 85 amplicons, while the second one contained 82 amplicons. 
The panel size was 31.18 Kb and the coverage was 99.33%. Table 2.1 demonstrates the 
coverage summary of the design including the target name, chromosome location, start 
position, end position, number of amplicons used to amplify the required target, total 
bases, covered bases by the design and the missed bases. 
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Table 2.1 Coverage summary of the HEA and HPA Panel.  
The panel was designed by Ion Ampliseq™ Designer (Ion Ampliseq Designer, 2014). The table shows the 
target name, chromosome location, start and end position, number of amplicons used to amplify the 
whole target, total bases, covered bases and missed bases in the design. The fields regarding the starting 
and end positions for the genes are blank due to the design covers all the exons within these genes.  
 
Target 
name 
Chromosome 
Starting 
position 
End 
position 
Number of 
amplicons 
Total 
bases 
Covered 
bases 
Missed 
bases 
ABO chr9 . . 11 1064 1034 30 
GYPA chr4 . . 7 453 453 0 
GYPB chr4 . . 5 276 276 0 
GYPE chr4 . . 3 237 237 0 
RHD chr1 . . 11 1254 1254 0 
RHCE chr1 . . 11 1300 1300 0 
KEL chr7 . . 21 2199 2136 63 
DARC chr1 . . 6 2028 2028 0 
SLC14A1 chr18 . . 9 1489 1489 0 
SLC4A1 chr17 . . 24 2736 2691 45 
ART4 chr12 . . 6 945 945 0 
ACHE chr7 . . 15 1976 1976 0 
AQP1 chr7 . . 10 1215 1215 0 
SMIM1 exon 1 chr1 3689340 3689430 1 90 86 4 
SMIM1 exon 2 chr1 3689610 3689770 1 160 160 0 
SMIM1 exon 3 chr1 3691880 3692100 2 220 220 0 
SMIM1 exon 4 chr1 3692330 3692570 2 240 240 0 
HPA-1 chr17 45360589 45360773 1 184 184 0 
HPA-2 chr17 4836321 4836433 1 112 112 0 
HPA-3 chr17 42452988 42453128 0 140 140 0 
HPA-4 chr17 45361875 45361995 0 120 120 0 
HPA-5 chr5 52358655 52358844 2 189 189 0 
HPA-6 chr17 45369669 45369851 0 182 182 0 
HPA-7 chr17 45369500 45369700 2 200 200 0 
HPA-8 chr17 45377730 45377950 2 220 220 0 
HPA-9 chr17 42452930 42453120 2 190 190 0 
HPA-10 chr17 45360780 45361020 2 240 240 0 
HPA-11 chr17 45376680 45376950 2 270 270 0 
HPA-12 chr22 19711170 19711530 2 360 360 0 
HPA-13 chr5 52368960 52369240 2 280 280 0 
HPA-14 chr17 45376680 45376950 2 270 270 0 
HPA-15 chr6 74493400 74493600 2 200 200 0 
HPA-16 chr17 45361700 45361990 2 290 290 0 
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2.5.1.1 Amplification of the HEA and HPA Panel  
Each sample was amplified in two different pools using ultra-high multiplex PCR using 
the Ion Ampliseq™ Library Kit (Thermo Fisher Scientific, Paisley, United Kingdom). 
The reaction mix contained 5X Ion AmpliSeq™ HiFi Mix, 2X Ion AmpliSeq™ Primer 
Pool, genomic DNA and nuclease-free water. The thermocycler was set as follows: 
99°C for 2 minutes to activate the enzyme, 19 cycles of denaturation at 99°C for 15 
seconds, annealing and extension at 60°C for 4 minutes and the reaction was then held 
at 10°C. The primers were then partially digested by adding 2 μL of FuPa reagent and 
the thermocycler was set to the following programme: 50°C for 10 min, 55°C for 10 
min, 60°C for 20 min and then held at 10°C for up to 1 hour.  
2.5.1.2 Adapters ligation of HEA and HPA Panel 
For every barcoded adapter, a final dilution of (1:4) was prepared by mixing Ion P1 
adapters and Ion Xpress™ barcode (X). Then, 4 μL of Switch solution was mixed with 2 
μL of the diluted adapters to obtain a total volume of 28 μL. After that, the thermocycler 
was set to the following programme: 22°C for 30 minutes followed by 72°C for 10 
minutes and held at 10°C for up to 1 hour.   
2.5.1.3 Purification of HEA and HPA Panel 
A purification step then took place using the Agencourt® AMPure® XP reagent by 
adding 45 μL of the beads to each sample (1.5X of the original sample). The mixture 
was incubated for 5 minutes at room temperature and then placed in a magnetic rack for 
2 minutes. The required sequencing libraries were in the pellet, therefore the 
supernatant was discarded without touching the pellet. Two ethanol washes were 
performed by adding 150 μL of 70% ethanol and then the pellet was left to air-dry for 
up to 5 minutes and finally the sample was eluted using 50 μL of low Tris-EDTA. 
Following this procedure, quantitation of the Ampliseq™ sequencing libraries were 
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quantified by Agilent® 2100 Bioanalyzer (Agilent Technologies LDA UK Limited, 
Stockport, United Kingdom) as explained in the next section.  
2.5.1.4 Quantification of the sequencing libraries using qPCR 
This experiment was performed by Dr. Michele Kiernan at the Systems Biology Centre 
at Plymouth University. By using the Ion Library Quantitation Kit, a 100-fold dilution 
was carried out by mixing 5 μL of the sample with 495 μL of nuclease-free water. Each 
standard, negative control and the samples were analysed in duplicate of 20 μL reaction. 
Typically, the unamplified libraries have yields between 100 and 500 pM. 10-fold serial 
dilutions of the E. coli DH10B Ion Control Library were prepared, which is around ~68 
pM from the Ion Library Quantitation Kit, at 6.8 pM, 0.68 pM and 0.068 pM.   
Three 10-fold serial dilutions were prepared of the E. coli DH10B Ion Control Library 
(~68 pM; from the Ion Library Quantitation Kit) at 6.8 pM, 0.68 pM, and 0.068 pM. 
Reaction mixtures were prepared for each sample, control, and standard by combining 
20 μL of 2X TaqMan® MasterMix with 2 μL of 20X Ion TaqMan® Assay and we then 
dispensed 11‐μL aliquots into the wells of a PCR plate. 9 μL of the diluted (1:100) Ion 
AmpliSeq™ library or 9 μL of each control was diluted in each well as duplicates, for a 
total reaction volume of 20 μL.  
The PCR condition was set up at 50 °C for 2 minutes, 95 °C for 20 seconds followed by 
40 cycles of 95 °C for one second and 60 °C for 20 seconds. Following the PCR, the 
average concentration of the diluted libraries was multiplied by the dilution factor (100). 
Following quantitation the sequencing libraries were diluted to 100 pM as 
recommended in the protocol to ensure they were suitable for template preparation.  
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2.5.2 Next-generation sequencing for long amplicons  
2.5.2.1 Long-range PCR for Kell blood group system  
Two long PCR products, each approximately 12 Kb in size, were both amplified to 
cover the entire KEL gene. Table 2.2 lists the primer sequences, which were designed 
by Dr. Narendra Kaushik using National Centre for Biotechnology Information (NCBI) 
Primer Blast (National Centre for Biotechnology Information Primer Blast, 2015) and 
received in a high performance liquid chromatography (HPLC) form from Eurofins 
MWG Operon (London, United Kingdom). The reaction contained a 1X master mix 
(LongAmp Hot Start Taq 2X Master Mix, New England Biolabs, United Kingdom), 
with 200 ng of DNA template and 0.4 µM for the forward and reverse primers. The 
temperature profile was started with 94°C for 3 minutes for the initial denaturation, 
followed by 30 cycles of denaturation at 94°C for 20 seconds, annealing at 62°C for 30 
seconds and extension at 65°C for 11 minutes. The final extension was 65°C for 10 
minutes, and it was held at 4°C.  
2.5.2.2 Agarose gel electrophoresis for the KEL gene 
The PCR samples were loaded on 0.7% agarose gel, 1X TAE [40 mM Tris-acetate and 
1 mM EDTA pH 8.0] (Sigma-Aldrich Company Ltd, Dorset, United Kingdom), which 
was mixed with fluorescent nucleic acid dye with a 1:10000 dilution of GelRed 
(Biotium Inc, Hayward, United States). A volume of 10 µl PCR sample was mixed with 
2 µl of the DNA loading buffer [10 mM Tris-hydrochloric acid (pH 7.6), 0.03% 
bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, and 60 mM EDTA]. The 
Quick-Load® 1 Kb Extend DNA Ladder (New England Biolabs, United Kingdom) was 
used to assess the amplicon size. The samples were subjected to electrophoresis 
(Powerpac Basic Biorad, Hercules, United States) by applying 80V constant voltage. 
The samples were run until they reached the bottom of the gel, typically around 1 hour 
and 40 minutes. Then, the gel was placed into an EC3 imaging system (Ultra Violet 
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Products Ltd, Cambridge, United Kingdom). The software Launch Vision WorksLS 
was utilised to conduct the analysis of the PCR amplicons.  
 
 
        
 
 
                  Table 2.2 Primer sequences used in LR-PCR to amplify the entire KEL gene. 
Primer Sequence 5’-3’ Exons GC (%) Tm(°C) Size (bp) 
Kel-121 
Kel-122 
agcagcatgttcatacccacgacct 
ggaggctgtaagagtgctaatgttg 
1-9 
 
48 
48 
67 
62.6 
12,243 
Kel-123 
Kel-124 
gggaactccaagaatatctgctgtc 
ccagccaatgataagcagccaacta 
10-19 
48 
48 
63.5 
67.2 
12,226 
                Tm = melting temperature.  
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2.5.2.3 Long-range PCR for Rh blood group system 
A total of seven LR-PCR products were designed to cover the entire genes of RHD and 
RHCE; three products for RHD and four products for the RHCE gene. The primer 
sequences for RHD and RHCE are shown in Table 2.3 and Table 2.4, respectively. The 
primers that exceed 75°C in their melting temperature were used in the Bloodgen 
project (Avent et al., 2007)  and other primers were designed using NCBI Primer Blast 
(National Centre for Biotechnology Information Primer Blast, 2015). This primer 
sequence (Ds2-s) was adapted from (Legler et al., 2001). The primers were ordered in 
HPLC form from Eurofins MWG Operon (London, United Kingdom).  
The reaction contained a 1X final concentration of 5X PrimeSTAR GXL Buffer, 
Takara, Japan), 200 µM of dNTP mixture, 0.2 µM of each primer and 1.25 unit of 
PrimeSTAR GXL Polymerase per 50 µl and the DNA concentration was 500 ng per 
reaction. A two-step protocol was performed as 25 cycles of 98°C for 10 seconds and 
68°C for 24 minutes and finally it was held at 4°C. The amplicons were purified on 
0.5% agarose gel with 80V applied for 1 hour and 40 minutes.  
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                       Table 2.3 Primer sequences used in LR-PCR to amplify the whole RHD gene. 
Primer set Primer name Sequence 5’-3’ Tm (°C) Size (bp) Exons covered 
RHD 1st amplicon 
RHD F1 S 
397R* 
gattgggtccgtgattggcatt 
ggccgcgggaattcgattgttgtctttatttttcaaaaccct 
60.3 
>75 
22,829 1, 2 and 3 
RHD 2nd amplicon 
Ds2-s§ 
798R* 
gccgcgaattcactagtgtgacgagtgaaactctatctcgat 
ggccgcgggaattcgattgaggctgagaaaggttaagcca 
>75 
>75 
23,610 
 
2 to 7 
RHD 3rd amplicon 
701F* 
1097R* 
gccgcgaattcactagtgacaaactccccgatgatgtgagtg 
ggccgcgggaattcgattgtggtacatggctgtattttattg 
>75 
>75 
22,731 7 to 10 
          §= This primer sequence was adapted from (Legler et al., 2001). 
          *= These primer sequences were used in the Bloodgen project (Avent and Madgett, unpublished data).  
 
 
 
                      Table 2.4 Primer sequences used in LR-PCR to amplify the whole RHCE gene. 
Primer set Primer name Sequence 5’-3’ Tm (°C) Size (bp) Exons covered 
RHCE 1st amplicon 
RHCE R1 X 
ce ex3 right* 
agtatccactttccaccttccactt 
ggccgcgggaattcgatttttttcaaaaccccggaag 
61.3 
>75 
19,426 1 to 3 
RHCE 2nd amplicon 
RHCE SUB 2 
RHCE R2 
ctactatcaagctcactgcccgattt 
atcctggctctccttctca 
63.2 
56.7 
11,215 3 & 4 
RHCE 3rd amplicon 
RHCE F2 
RHCE_NR3 
caagtccatgtgcagtgac 
acagccagcatcttctttcagtcag 
56.7 
58.9 
17,856 
 
4 to 7 
RHCE 4th amplicon 
RHCEex7-left* 
RHCE F3 
ggccgcgggaattcgattcacatctccgtcatgcactc 
gggcagagacttgacactcc 
>75 
61.4 
24,387 7 to 10 
          *= These primer sequences were used the in Bloodgen project (Bloodgen Consortium, unpublished data).  
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2.5.2.4 Purification of LR-PCR Products 
1.8X of Agencourt® AMPure® XP reagent (~63 µl) was added to the sample (~35 µl). 
The mixture needed to be mixed thoroughly and incubated at room temperature for 5 
minutes. The tubes were placed in a magnet for 3 minutes in order to separate the small 
fragments, which contain the primer-dimer and polymerase. The supernatant was 
discarded and the bead pellet was washed twice with 300 µl freshly prepared 70% 
ethanol (Fisher Scientific UK, Leicestershire, United Kingdom). The samples were air 
dried for up to 4 minutes and ultimately the samples were eluted with 50 µl of nuclease-
free water.  
2.5.2.5 Equimolar of PCR products  
The starting concentration of the sequencing libraries for the long amplicons is 100 ng. 
Therefore, a 100 ng concentration was divided by the number of amplicons and the 
outcome was divided by each amplicon to obtain the volume for each one to pool the 
amplicons in equimolar of 100 ng. For instance, there were two products of each sample 
for the KEL gene, therefore, 50 ng of each amplicon was pooled together to obtain a 
final concentration of 100 ng. Regarding the products of both genes, RHD and RHCE, 
each gene product was pooled separately from the other gene. 
Finally, the equimolar products were measured using the Qubit® 2.0 Fluorometer using 
the Qubit® dsDNA BR Assay kit [see section 2.2]. The products were pooled together 
equally in 1.5 mL Eppendorf tubes.  
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2.5.2.6 Fragmentation  
The procedure of NGS library construction has four consecutive steps which include 
fragmentation, ligation to barcoded adaptors, size selection and quantification of the 
library using the Agilent® 2100 Bioanalyzer assay [section 2.5.2.7] prior to preparing 
the template for sequencing. The following protocol was used except for the size 
selection: ‘Preparing Long Amplicon (>400 bp) Libraries Using the Ion Xpress™ Plus 
Fragment Library Kit (Thermo Fisher Scientific, 2012). The equimolar amplicons of 
100 ng were mixed with 5 µl of Ion Shear™ Plus 10X Reaction Buffer and nuclease-free 
water to bring the volume to 40 µl in a 1.5 mL Eppendorf tube. Then, 10 µl of Ion 
Shear™ Enzyme Mix II was added to the mixture for a total volume of 50 µl. The 
mixture was mixed thoroughly without generating any bubbles. The tube was then 
incubated at 37°C for 15 minutes to obtain a 200 base-read library. 5 µl of Ion Shear™ 
Stop buffer was added to the mixture, which was mixed vigorously for at least 5 
seconds to terminate the fragmentation reaction. The fragmented DNA was purified by 
Agencourt® AMPure® XP reagent by adding 1.8X of the total volume of the fragmented 
sample as shown in section 2.3 except the elution, which was 25 µl of low Tris-EDTA 
pH 8.0. The size of the fragmented DNA was assessed using the high sensitivity DNA 
Kit which was run on the Agilent® 2100 Bioanalyzer as discussed in the next section.  
2.5.2.7 NGS libraries quantification by Agilent® 2100 Bioanalyzer system  
A gel-dye mix needed to be prepared to begin the experiment. A volume of 15 µl of 
High Sensitivity DNA dye concentrate (blue dye) was added to a High Sensitivity DNA 
gel matrix with a red vial. The mixture was then mixed vigorously and transferred to the 
spin filter. Next, the tube was spun at 2240 × g for 10 minutes. Finally, the filter was 
discarded and the solution was kept in the dark at 4°C.  
Prior to starting the assay, the gel-dye mix needed to be equilibrated at room 
temperature for 30 minutes. A new High Sensitivity DNA chip was placed in the chip 
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priming station. A volume of 9 µl was added to the first indicated well as shown in 
Figure 2.2 (a). The plunger was positioned in 1 mL in the chip priming station and was 
then closed. Then, the plunger was pressed and held by the chip for 60 seconds. Next, 
the plunger was slowly pulled back to the 1 mL position. The chip priming station was 
opened and a volume of 9 µl of gel-dye mixture was added to the three indicated wells 
as shown in Figure 2.2 (b). Then, a volume of 5 µl of marker was added to the twelve 
indicated wells as demonstrated in Figure 2.2 (c). After that, a volume of 1 µl of High 
Sensitivity DNA ladder was added to the indicated well as shown in Figure 2.2 (d). 
Finally, the samples were loaded in each well separately with 1 µl as indicated in Figure 
2.2 (e).  
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Figure 2.2 An illustration of the indicated wells of the High Sensitivity DNA chip regarding the 
loading positions for the quantification assay.  
The assay was carried out using the Agilent® 2100 Bioanalyzer system. Adapted from (Agilent 
Technologies, 2013). The method is discussed in [section 2.5.2.7].  
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2.5.2.8 Ligation  
The purified DNA fragments were then ligated to adaptors and nick-repaired by mixing 
25 µl of the purified DNA with 10 µl of 10X ligase buffer, 2 µl of Ion P1 adaptor, 2 µl 
of Ion Xpress™ Barcode X (because multiple samples were used), 2 µl dNTP mix, 49 µl 
of nuclease-free water, 2 µl DNA ligase, and 8 µl nick repair polymerase in a 0.2 mL 
PCR tube. Then, the tube was placed in a thermocycler at 25°C for 15 minutes, then at 
72°C for 5 minutes and the samples were finally held at 4°C. Following the run on the 
thermocycler, the ligation reactions were purified with 1.4X of Agencourt® AMPure® 
XP reagent for 200 base-read sequencing. The reactions were purified as discussed 
above in section 2.5.2.4.  
2.5.2.8 Size selection of DNA Library  
Initially, the purified ligated libraries were brought up to a total volume of 100 µl. The 
ratio used for the size selection was (0.8X-0.7X). Various optimisation ratios were 
performed are demonstrated in Appendix C.  For such a starting material of 100 µl of 
the sequencing library, 0.8X of SPRIselect® (80 µl) was added and then incubated at 
room temperature for 5 minutes. The reaction was then placed on a magnet in order to 
remove the large DNA fragments, which were larger than 200 bp. Then, the supernatant 
was transferred, which was around 180 µl (i.e. 100 μl of DNA + 80 μl of SPRIselect® 
beads) into a new 1.5 mL tube. After that, 0.7X of SPRIselect® (70 µl) was added and 
then incubated at room temperature for 5 minutes and placed on a magnet. The desired 
fragments were bound to the beads, while the small fragments lower than 100 bp were 
not. The supernatant was discarded and the beads were then washed twice using 300 µl 
of 80% freshly prepared ethanol. The pellet was left to air-dry for up to 4 minutes. 
Finally, the beads were eluted using 50 µl of nuclease-free water and transferred to a 
new tube. Prior to preparing the sequencing template, the size-selected sequencing 
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libraries were quantified using the Agilent® 2100 Bioanalyzer instrument as discussed 
in section 2.5.2.7.  
2.5.3 Preparation of sequencing template  
2.5.3.1 Assessment of the sequencing libraries and preparation of sequencing 
template   
In order to prepare the template for sequencing on the Ion PGM™, the sequencing 
libraries needed to be quantified in order to determine the template dilution factor. The 
size distribution and the concentrations of the sequencing libraries were assessed using 
the Agilent® 2100 Bioanalyzer with the High Sensitivity DNA Kit as described in 
[section 2.5.2.7] and Ion Library Quantitation Kit [section 2.5.1.4]. The dilution factor 
for the sequencing libraries was determined using the following formula:  
 
 
For instance, the library concentration was 363 pM. Therefore, the dilution factor would 
be as follows:  
Dilution factor = 363 pM/100 pM= 3.63 
Thus, 1 µl of DNA library was mixed with 2.63 µl of nuclease-free water to obtain a 
yield of approximately 100 pM.  
The sequencing template was then immobilised to ion sphere particles (ISPs) that were 
clonally amplified using emulsion PCR, followed by emulsion breaking and enrichment 
for positive sphere particles using the Ion OneTouch™ system. The following sections 
will discuss this procedure in detail.  
2.5.3.2 Monoclonal Amplification by Ion OneTouch™ 2 
The template preparation and the sequencing protocol were performed by Dr. Michele 
Kiernan at the Systems Biology Centre at Plymouth University. This was according to 
Dilution Factor  = (Library concentration in pM/100 pM) 
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the following: protocol Ion PGM™ Template OT2 200 Kit for use with the Ion 
OneTouch™ 2 (Thermo Fisher Scientific, 2014b). The sequencing libraries of all the 
samples were diluted with nuclease-free water to give a total volume of 25 µl. The 
samples were then mixed vigorously for 5 seconds, spun down for 2 seconds and placed 
on ice. After that, an amplification solution was prepared by mixing a volume of 25 µl 
of the diluted sequencing libraries with the following reagent: 500 µl of Ion PGM™ 
Template OT2 200 Reagent Mix, 300 µl of Ion PGM™
 
Template OT2 200 PCR Reagent 
B, 50 µl of Ion PGM™ Template OT2 200 Enzyme Mix and 25 µl of nuclease-free 
water. The mixture was then mixed vigorously for 5 seconds and spun down for 2 
seconds.  
100 µl of ISP was mixed vigorously and then added to the mixture. The amplification 
mixture was mixed vigorously for 5 seconds. The prepared amplification solution was 
added to the sample port of the Ion PGM™
 
OneTouch Plus Reaction Filter Assembly 
[Figure 2.3]. Then, 1000 μl of Ion OneTouch™ Reaction Oil was added through the 
sample port. After that, a further 500 μl was added to the sample port. Then the filled 
Ion PGM™ OneTouch Plus Reaction Filter Assembly was inverted and installed into the 
three holes on the top stage of the Ion OneTouch™ 2 Instrument. Finally, the clonal 
amplification was performed by running the emulsion mixture on the Ion OneTouch™ 2 
Instrument.
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Figure 2.3 The sample port that was used to prepare the sequencing template for the clonal 
amplification.  
The clonal amplification was performed using the Ion OneTouch™
 
2 System. 
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2.5.3.3 Recovery of the positive ISPs 
At the end of the run, which took about 4 hours, the reaction was spun in the centrifuge 
of the same instrument, i.e. the Ion OneTouch™ 2 Instrument. The Recovery Router was 
discarded immediately following the centrifugation step. All but 50 μL of the Ion 
PGM™ OT2 Recovery Solution was removed from each Recovery Tube. The ISPs were 
resuspended in the remaining Ion PGM™ OT2 Recovery Solution. The pellet was mixed 
properly until it dissolved in the solution. After that, the suspensions from both tubes 
were transferred to a new 1.5 mL Eppendorf tube for a total volume of 100 µL followed 
by adding 1 mL of Ion OneTouch™ Wash Solution. The ISPs were mixed by pipetting 
up and down and were then transferred into Well 1 of an 8-well strip [Figure 2.4] for a 
total volume of 100 μL of suspended ISPs. The quality of the unenriched template and 
positive ISPs was assessed using the Qubit
® 2.0 Fluorometer. Ultimately, enrichment 
was accomplished to obtain many copies of the positive ISPs.  
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Figure 2.4 The eight wells for the enrichment of the template using the Ion OneTouch Enrichment System.  
 71 
2.5.3.4 Enrichment the template positive ISPs  
Dynabeads® MyOne™ Streptavidin C1 Beads were created by mixing the tube for 30 
seconds to resuspend the beads followed by spinning for 2 seconds. The beads were 
then dispersed and mixed properly using a new pipettor tip and immediately 13 μL of 
Dynabeads® MyOne™ Streptavidin C1 Beads was transferred to a new 1.5-mL 
Eppendorf LoBind® Tube. After that, the tube was placed on a magnet for 2 minutes 
and the supernatant was carefully removed and discarded without disturbing the pellet. 
130 μL of MyOne™ Beads Wash Solution was added to the beads. The tube was taken 
off the magnet and mixed for 30 seconds and spun for 2 seconds. The total amount of 
130 μL was added to Well 2 of the 8-well strip [Figure 2.3]. Then Wells 3, 4 and 5 were 
filled with 300 μL of Ion OneTouch™ Wash Solution (W). Wells 6 and 8 were empty 
[Figure 2.3]. Well 7 was filled with freshly prepared melt-off solution that was prepared 
by mixing 280 μL of Tween solution with 40 μL of 1 M NaOH.  
2.5.3.5 The Run of the Enrichment System 
The Enrichment System was prepared by loading a new tip in the Tip Arm as shown in 
[Figure 2.3]. An opened 0.2 mL tube was inserted into the hole in the base of the Tip 
Loader and was filled with 10 μL of neutralisation solution. Prior to starting the run, the 
mixture in well 2 was mixed properly to resuspend the beads. The run time was up to 35 
minutes. After finishing the run, the 0.2 mL tube was closed and removed from the 
Enrichment System, which possessed the positive ISPs. The mixture of the 0.2 mL tube 
was mixed by gently inverting the tube 5 times. Then, the templates were ready to be 
sequenced on the Ion PGM™. The quality of the enrichment efficiency for positive ISPs 
was assessed using the Qubit® 2.0 Fluorometer. 
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2.5.4 Sequencing on the Ion Torrent PGM™  
The Ion PGM™ must be cleaned and initialised prior to use for sequencing according to 
the manufacturer’s instructions. In a 0.2 mL PCR tube, the enriched template positive 
ISPs were prepared by adding 5 μL of Control Ion Sphere™ Particles to the enriched 
template-positive ISPs. The solution was mixed thoroughly and was spun at 15,500 × g 
for 2 minutes. The supernatant was then removed but 15 μL was left in the tube without 
disturbing the pellet. A total volume of 12 μL of sequencing primer was added to obtain 
a total volume of 27 μL. The whole solution was mixed carefully without disturbing the 
pellet. The reaction was run on a thermocycler on the following programme: 95°C for 2 
minutes followed by 37°C for 2 minutes with utilising the heated lid option. This step 
was performed to anneal the sequencing primer to the ISPs. After the run was finished, 
3 μL of Ion PGM™ Sequencing 200 v2 Polymerase was added to the ISPs to obtain a 
total volume of 30 μL. The sequencing reaction was then mixed properly and incubated 
at room temperature for 5 minutes.  
The Ion 316™ chip was assessed for sequencing using the Ion PGM™ according to the 
manufacturer’s instructions. In order to load the sequencing reaction to the chip, the 
liquid inside the chip needed to be removed. The chip was tilted to 45 degrees and the 
liquid was removed by inserting the pipette tip firmly into the loading port, which is the 
lower port on the chip. The chip was then placed in an upside-down position in the 
centrifuge adapter bucket and the bucket was transferred to the MiniFuge with the chip 
tab pointing in, i.e. toward the centre of the centrifuge. Then the chip was spun for 5 
seconds to entirely empty the chip. Next, The chip was placed in the bucket on a flat 
and steady surface and the loading was performed slowly in the loading port at a rate of 
1 to 2 μL per second. The chip and bucket were spun in the MiniFuge for 30 seconds 
with the chip tab pointing in. After setting the pipette to 30 μL, the sequencing reaction 
was mixed by tilting the chip to 45 degrees by pipetting the sample in and out of the 
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chip three times. The chip was spun again for 30 seconds in the MiniFuge but with the 
chip pointing out. The sample was mixed again thoroughly by pipetting the solution in 
and out three times. The liquid on the chip’s port was removed from the loading port by 
tilting the chip to 45 degrees. The chip was finally positioned in the Ion PGM™ 
sequencer and the sequencing reaction was starting by running the sequencing 
programme as described by the manufacturer’s instructions. The sequencing on the Ion 
PGM™ is based on sequencing by synthesis in which a polymerase incorporates a 
nucleotide. Accordingly, a hydrogen ion is released and the base is called.  
2.5.5 Data analysis for NGS  
Ion PGM™ sequencer transferred the raw sequencing data, which were the digital 
representation of the voltage results from pH change in the wells, to the Torrent Server. 
Consequently, the Torrent Server converted the raw sequencing data to base calls. 
Figure 2.5 illustrates the workflow data analysis of NGS. Torrent Suite™ Software 
Version 4.4 was used in order to generate a summary sequencing report indicating the 
number of reads generated by the sequencer and the percentage of chip loading. The 
Torrent Suite™ was used different filters to remove duplicate reads, low quality reads, 
polyclonal templates and primer dimer. Furthermore, it generated different files for the 
analysis including Fastq files, Binary Alignment Map (BAM) in a conjunction with 
Binary Alignment Index (BAI) and Variant Call Format (VCF) files.  
The FastQC software was run to assess the quality control across the reads generated 
(Andrews, 2010). The sequencing samples were then aligned to reference the human 
genome (hg19) using the BAM/BAI files and were visualised using Integrative Genome 
Viewer (IGV) Version 2.3.46. Moreover, the IGV software was used to assess the depth 
of coverage of the sequencing reads, zygosity, quality of the sequencing reads and the 
mapping quality.  
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The samples were then annotated using the VCF files to obtain the SNPs and indels to 
analyse the genotype and predict the phenotype. The Ion Reporter™ Version 4.6 and 
SeattleSeq Annotation tool 141 site were performed to annotate the sequencing data of 
the HEA and HPA Panel and LR-PCR approach, respectively (SeattleSeq Annotation 
Tool 141, 2014). Antigens were determined by choosing the right transcript according 
to the Blood Group Antigen Factsbook (Reid et al., 2012). Each antigen was determined 
by its chromosomal location, the type of variant whether it was an SNP or indel, gene, 
the reference nucleotide, the changing nucleotide, depth of coverage, the zygosity, the 
transcript used in analysis based on the NCBI database, the location of the variant 
whether it was intronic, synonymous or exonic SNPs, codon, an exon number of that 
variant, an amino acid substitution and the position of the nucleotide change. According 
to Bentley et al. (2008), the depth of coverage was determined to 15X and 33X for 
homozygous and heterozygous SNPs, respectively.  
2.5.5.1 Masking the Rh genes  
Due to the high homology between the RHD and RHCE genes, when analysing the gene 
of interest masking the other gene was required. The unrequired gene was annotated by 
‘Ns’ on their sequencing nucleotides. Figure 2.6 demonstrates the masking procedure 
for the Rh sequencing data. By using Browser Extensible Data (BED) files, the 
maskfasta utility from the bedtools website was used to mask the RHCE gene in order 
to analyse the RHD gene and vice versa (Bedtools, 2015). This type of analysis was 
performed by Dr. Xinzhong Li.  
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Figure 2.5 A brief summary of NGS data analysis workflow. 
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Figure 2.6 Masking the Rh genes.  
(a) When the analysis carried out for the RHD gene, the RHCE gene was masked by ‘Ns’ to prevent any 
misalignement occurred.  
(b) The RHD gene was masked by ‘Ns’ when the analysis was performed to the RHCE gene.  
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2.5.6 Validation of the NGS data by Sanger sequencing 
Sanger sequencing was performed in order to validate some of the KEL results that were 
obtained by the LR-PCR approach. The purified amplicon was mixed with one of the 
primers and nuclease-free water and was then sent to the Eurofins service for 
sequencing. The files were received in (.ab1) format for the DNA sequence 
chromatogram and this was visualised and analysed using MacVector Software Version 
12.7.0. Table 2.5 lists the primers used to validate SNPs found in the RHCE and KEL 
genes.  
The forward primer for exon 2 of the RHCE was adopted from (Legler et al., 2001), 
while the reverse primer was adopted from the Bloodgen project (Avent et al., 2007).  
The primers of exon 6 of the KEL gene were adopted from (Beiboer et al., 2005). The 
primers for exon 4, 17 and 19 of the KEL gene was designed using NCBI Primer Blast 
(National Centre for Biotechnology Information Primer Blast, 2015) and received in 
HPLC form from Eurofins MWG Operon (London, United Kingdom). 
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                                               Table 2.5 Primer sequences used to validate the SNP encoding the K antigen from NGS data. 
            
Primer Gene Sequence 5’-3’ Exon GC (%) Tm (°C) Product size (bp) 
Kell exon 4 F 
Kell exon 4 R 
KEL 
acttgcacagagcatcttcc 
atgttctttgcctagcccc 
4 
50% 
52.6% 
57.3 
56.7 
290 
Kell exon 6 F 
Kell exon 6 R 
KEL 
gccgcgaattcactagtgagctgtgtaagagccgatcc 
ggccgcgggaattcgattaagggaaatggccatactga 
6 
55.3% 
52.6% 
>75 
>75 
207 
Kell exon 17 F  
Kell exon 17 R 
KEL 
gccatgcaactgtacttg 
agaccacaagggaggcc 
  
17 
50% 
64.7% 
53.7 
57.6 
455 
Kell exon 19 F 
Kell exon 19 R 
KEL 
ccagggaggtgttggtcg 
gtcaccgggtcagctttg 
 
19 
66.6% 
61.1% 
60.5 
58.2 
275 
Ds2-s 
296R 
RHCE 
gccgcgaattcactagtgtgacgagtgaaactctatctcgat 
ggccgcgggaattcgattagaagtgatccagccaccat 
 
2 
47.6% 
55.2% 
>75 
>75 
1315 
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Chapter 3 : Blood Group Genotyping by Microarrays  
3.1 Introduction  
By the 1990s all the major blood group systems had been identified at the molecular 
level. Most of the polymorphisms of these blood groups are caused by SNP, which 
change the conformation on the protein structures (Avent, 1997). The previous 
genotyping techniques such as RFLP-PCR and SSP-PCR were carried out to genotype 
some blood groups such as Lewis blood groups system and the Kell blood group 
system, respectively (Avent and Martin, 1996; Kudo et al., 1996). These techniques 
have disadvantages, including time consuming, labour intensive and analysis of the 
post-PCR gel. Furthermore, incomplete digestion of the PCR products can be occurred 
for the RFLP-PCR (Veldhuisen et al., 2009). In addition, they are not suitable for high-
throughput genotyping of the blood groups. Consequently, a high-throughput platform, 
to genotype the blood group antigens, are required as well as the ease of the automation 
of the process to be utilised in the blood banks [see section 1.9.2] (Veldhuisen et al., 
2009). 
The Bloodgen project (2003-2006) was conducted by a consortium of universities, 
blood centres and Progenika Biopharma SA. The aims of Bloodgen project were to 
design a DNA array-based assay in order to obtain extended genotyping of the blood 
group antigens for routine blood donors and for the patients. This was aim to help 
patients especially those suffering from alloimmunisation due to receiving multiple 
blood units. Moreover, another aim was to have long-term health benefits by extensive 
genotyping at the birth of each individual (Avent et al., 2009). The assay is more 
accurate in comparison to the standard typing by serology and might replace it in the 
future.  
There are currently many platforms using microarray for BGG. Two approaches of have 
been manufactured by Progenika Biopharma SA. These were: glass array and 
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suspension beads array. BLOODchip® is a product depends on glass array to genotype 
genomic polymorphisms that give rise to the blood group antigens and HPAs.   
3.2 Aims 
In this chapter, the ID Core+ kit is used to genotype the blood group alleles. The 
method of this test is discussed in [section 2.3]. The ID Core+ kit is a test targeting 31 
SNPs from the following blood group system (RhCE, Kell, Kidd, Duffy, MNS, Diego, 
Dombrock, Colton and Yt). The first step in this procedure was an amplification of the 
targeted region of genomic DNA using multiplex PCR with biotinylated dCTP. 
Denaturation then took place to hybridise the amplified products to oligonucleotide 
probes, which are attached to the beads. After that, the hybridised DNA was labelled 
with a fluorescence SAPE conjugate. The existence of specific SNP in the sample can 
be determined by the correlation of the fluorescence signal, which is intrinsic to each 
microsphere with the existence or absence of a corresponding phycoerthrin signal. The 
detected signals were then quantified by a Luminex® 100/200™ flow cytometer. Finally, 
Progenika’s Work Station Software was used to analyse the data and produce a report 
with the predicted phenotypes. The aim of this method was to provide training on blood 
group genotyping using the microarray technology as well as assessment of the 
accuracy of the ID Core+ kit in comparison to the standard typing by serology. 
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3.3 Results 
Twenty-eight samples (Cohort A) were chosen randomly and examined in total, of 
which 24 samples obtained full results, while four samples had an issue of non-valid 
results. Table 3.1 lists the serological results provided by NHSBT Filton. Table 3.2 
illustrates the predicted phenotypes of the 24 samples that resulted when using the ID 
Core+ kit. All of the 24 sample results from the ID Core+ test were similar to those 
previously typed by serology, which were done at the NHSBT Filton, Bristol. Table 3.2 
demonstrates the results of the predicted phenotypes of four samples that had an issue of 
a non-valid assay test using the ID Core+ kit. In another sample all the first pool (RhCE, 
Kell, Kidd, Duffy and MNS) was non-valid and in two samples the second pool (Diego, 
Dombrock, Colton and Yt) was non-valid. Sample 227P shows two non-valid results for 
KEL*02.06 and KEL*02.07 alleles encoding the Jsa and Jsb antigens, respectively.   
Four samples were genotyped as heterozygous RHCE*C/c and three as homozygous 
RHCE*C/C, while 17 samples were found to be homozygous for the RHCE*c allele. 
Regarding the E antigen, three samples were found to be homozygous RHCE*E/E and 
four were heterozygous RHCE*E/e. Seventeen samples were found to be homozygous 
for the RHCE*e allele.  
The K antigen was observed as heterozygous KEL*01/02 in a single sample out of total 
24 samples. The KEL*02.03 allele encoding the Kpa antigen was found in two samples 
to be heterozygous with the KEL*02.04 allele encoding the Kpb antigen. The 
KEL*02.07 allele, encoding the Jsb antigen, was found to be homozygous in all the 
samples. For the Kidd blood group system, nine samples were found to be homozygous 
for the JK*A allele, four homozygous for JK*B allele and 11 heterozygous for both 
alleles, JK*A and JK*B. There were nine samples homozygous for the FY*A allele, six 
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homozygous samples for the FY*B allele and nine heterozygous samples for both 
alleles.  
For the MNS blood group system, 12 samples were found to be heterozygous for both 
GYPA*M and GYPA*N alleles, nine homozygous for the GYPA*M allele and three 
homozygous for the GYPA*N allele. Three samples of GYPB*S allele, 10 samples of 
homozygous GYPB*s allele and 11 samples of heterozygous GYPB*S and GYPB*s 
alleles were observed. The U antigen was predicted in all the samples. Regarding the 
Diego blood group system, all the samples observed the DI*B allele.  
12 samples were found to be heterozygous for the DO*A and DO*B alleles of the 
Dombrock blood group. The DO*A allele was found to be homozygous in five cases, 
while DO*B allele was found to be homozygous in seven cases. The DO*02.04 and 
DO*02.05 alleles, which encode the Hy and Joa antigens, respectively were observed in 
all the samples. Regarding the Colton blood group system, the CO*A allele was found 
to be heterozygous with CO*B in two samples. However, the remaining 22 samples 
were found to be homozygous for the CO*A allele. YT*B allele was found to be 
heterozygous in one sample, while the remaining 23 samples were found to be 
homozygous for the YT*A allele.  
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 ABO Rh D C E c e Cw M N S s P1 Lua Lub K k Kpa Kpb Lea Leb Fya Fyb Jka Jkb A1 
057D O+ R0r + − − + +  +  + +  − + −  − +   − + + +  
103E A- rr − − − + + − +  + −  − + −  − +   + − − +  
105U B− rr − − − + + − + − + + +   −    − + + + + −  
303N A+ R2r + − + + +         −           
310P A− rr − − − + +  +  + +  −  −  −    − + + +  
311N A+ R2r + − + + +         −          + 
314B A+ R2R2 + − + + − − +  − +  − + −  − +   + − + −  
352* O− rr − − − + + −        −           
363* O− rr − − − + +         −           
427H A− rr − − − + + − − + − +  − + −   + − + − + + −  
524J O− rr − − − + + − + + + +    −    + − + − + −  
526K O+ R1r + + − + +         −           
552G A+ R1R1 + + − − +  +  + −  −  −  −    + + + + + 
631E A+ R1R1 + + − − + − +   +  −  −  −    + − + −  
728Q AB− rr − − − + + − + − − + + − + − + − + + − + − − +  
729V B+ R1R2 + + + + + −        −           
731H B+ R1R1 + + − − +         −           
739K O− rr − − − + + − + − − +    −  −    − + + +  
744Q O+ R2r + − + + +  +  − +  −  −  −    + + − +  
753T B+ R2R2 + − + + − − + − − +  +  −  −    + − + −  
846D O+ R1r + + − + + − + + + +  − + −  − + − + + + + +  
910H O− rr − − − + +         +           
967L B+ R1r + + − + + − +  − +    −      + + + +  
0657 A+ R2R2 + − + + − −        −           
227P B+ R1R2 + + + + +         +           
140Y O+ R2r + − + + + − +   + +   −    −  −  + +  
5015 A− rr − − − + + − +  −     −      −  + +  
389A A+ R1r + + − + +  +       −    −    + +  
Table 3.1 The serological results provided by NHSBT Filton for 28 samples that were used for microarray.  
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 RhCE Kell Kidd Duffy MNS Diego Dombrock Colton Yt 
Sample  ID C c E e Cx Cw VS K k Kpa Kpb Jsa Jsb Jka Jkb Fya Fyb M N S s U Dia Dib Doa Dob Hy Joa Coa Cob Yta Ytb 
057D  +  +     +  +  + + +  + + + + + +  + + + + + + + +  
103E  +  +     +  +  +  + +  +  +  +  + + + + + +  +  
105U  +  +     +  +  + +  + + +  + + +  + + + + + +  +  
303N  + + +     +  +  + + + +  + + + + +  +  + + + +  + + 
310P  +  +     +  +  + + +  + + + + + +  + + + + + +  +  
311N  + + +     +  +  + + + +   + + + +  + +  + + +  +  
314B  + +      +  +  + +  +  +   + +  +  + + + +  +  
352*  +  +     +  +  + + + +   +  + +  + + + + + +  +  
363*  +  +     +  +  + + +  + + +  + +  + + + + + +  +  
427H  +  +     +  +  + +   +  +  + +  + + + + + +  +  
524J  +  +     +  +  + +  +  + + + + +  +  + + + + + +  
526K + +  +     +  +  + + +  + + + + + +  +  + + + +  +  
552G +   +     +  +  + + + + + +  +  +  + + + + + +  +  
631E +   +     +  +  + +  +  + +  + +  + + + + + +  +  
728Q  +  +     +  +  +  + +  +   + +  + +  + + +  +  
729V + + + +     +  +  +  + + + + + +  +  + + + + + +  +  
731H +   +     +  +  + +  + + +  + + +  + + + + + +  +  
739K  +  +     +  +  + + +  + +   + +  + +  + + +  +  
744Q  + + +     +  +  +  + + + + +  + +  +  + + + +  +  
753T  + +      +  +  + +  +  +   + +  + +  + + +  +  
846D + +  +     +  +  + + + + + + + + + +  + + + + + +  +  
910H  +  +    + +  +  + +  + + +  + + +  +  + + + +  +  
967L + +  +     + + +  + + + + + + +  + +  +  + + + +  +  
0657  + +      + + +  + +  + + + + + + +  + +  + + +  +  
Table 3.2 The results of the predicted phenotypes of 24 samples using the ID Core + kit. 
The kit investigates the alleles of the following blood group systems: RHCE gene from Rh system, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, 
and Cartwright. DNA samples were extracted from the blood donors, amplified using multiplex PCR, hybridised to allele-specific oligonucleotide 
probes containing the SNP, labelled to fluorescent dyes, and finally quantified using the Luminex® system. The genotypes and phenotypes of the blood 
groups were detected via software analysis using BIDS (Workstation Progenika Version 2.0 Beat 6, which worked in combination with Luminex 
xPonent® LX100/LX200 Version 3.1). The blank fields are considered as negative results for clarity. 
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 RhCE Kell Kidd Duffy MNS Diego Dombrock Colton Yt 
Sample  ID C c E e Cx Cw VS K k Kpa Kpb Jsa Jsb Jka Jkb Fya Fyb M N S s U Dia Dib Doa Dob Hy Joa Coa Cob Yta Ytb 
227P + + + +    + +  + NV NV +  + +  + + + +  + + + + + +  +  
140Y NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV NV  +  + + + +  +  
5015  +  +     +  +  + + +  + + +  + + NV NV NV NV NV NV NV NV NV NV 
389A + +  +     +    + + + +  +  +  + NV NV NV NV NV NV NV NV NV NV 
Table 3.3 The predicted phenotypes of four samples that had some non-valid results using the ID Core+ kit. 
One of the samples (227P) only had two non-valid (NV) SNPs, in another sample all the first pool (RhCE, Kell, Kidd, Duffy and MNS) was non-valid 
and in two samples the second pool (Diego, Dombrock, Colton and Yt) was non-valid. Sample 227P shows two non-valid results for the SNPs encoding 
Jsa and Jsb antigens. The blank fields are considered as negative results for clarity. 
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3.4 Discussion 
The importance of BGG has become extremely obvious, especially in multiply 
transfused patients. Consequently, the requirement of a high-throughput platform for 
both donors and patients is needed (Avent et al., 2007). The ID Core+ test is a 
genotyping blood test for most clinically significant blood groups (RhCE, Kell, Duffy, 
Kidd, MNS, Colton, Dombrock, Diego and Yt). This kit depends on the microsphere-
based suspension array using the (xMAP technology) Luminex® system for the 
detection of SNPs in blood samples. Up to 48 samples can be examined in a single run 
to increase the high-throughput screening of the donors. 
The results obtained from this experiment were matched to the serology testing 
provided and gave 100% accuracy. Some issues were reported in which the samples 
were not valid for all the SNPs in one of the two pools [Table 3.3]. Although the reason 
one pool works and the other does not may be related to the hybridisation that has not 
taken place and not related to the purity of the DNA samples, as some results were 
obtained. There may be a technical problem in the hybridisation, which requires mixing 
the beads properly with the PCR products 20 times by pipetting up and down. 
Therefore, this might be the actual reason for the non-valid results. In one sample, there 
were two non-valid SNPs that were associated with the alleles KEL*02.06 and 
KEL*02.07 encoding the Jsa and Jsb antigens although the remaining SNPs in both pools 
were working properly and results were obtained. It could be that the amplification of 
the responsible PCR amplicons did not take place in the first instance. This may be due 
to a mutation in primer-binding sites or a novel allele, often this is referred to as allelic 
dropout.   
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It should be noted that the genotyping of blood groups with such a kit gives an 
extensive prediction of the phenotypes of the blood group systems such as Diego, 
Dombrock, Colton and Yt. For example, the low prevalence alleles can be examined 
easily by the ID Core+ test. The predicted antigens include Ytb and Cob, the first of 
which is found as 8% in Europeans and the latter as 10% in all populations (Reid et al., 
2012). 
The drawback of ID Core+ kit is that it could not detect the ABO and RhD antigens, 
which are the most clinically significant systems. This is according to the fact that the D 
antigen is encoded by the RHD gene, which has many polymorphisms due to various 
genetic events. These include the deletion of the entire RHD gene, as appeared in RhD-
negative individuals, and gene rearrangement in some of the partial D phenotypes 
(Avent et al., 2006). On the other hand, BLOODchip® depends on a glass microarray 
that allows the genotyping of extended blood group antigens, which are detected by ID 
Core+, as well as the D antigen with its variants (D+, D−, Del, partial D, and weak D), 
the ABO blood group system (A, B, AB, O, and weak A), and HPAs. The 
BLOODchip® genotyping takes longer to run, which is about 9 hours in comparison to 
the ID Core+ test, but it is a more comprehensive test. It might be used as a front-line 
method, due to its higher resolution compared to serological typing, as well as due to its 
discrimination between partial D and weak D (Avent et al., 2007; Avent et al., 2009).  
BLOODchip® v 1.0 is the product of the Bloodgen project that includes five steps: 
DNA isolation, multiplex PCR amplification, fragmentation, labelling, hybridisation 
and data analysis. The test can detect 116 SNPs of the blood groups alleles, of which 73 
SNPs were designed for the RHD. 3000 samples were investigated by BLOODchip® at 
eight centres across Europe to obtain CE marking. There was a discrepancy caused by 
serology but BLOODchip® correctly genotyped the samples. Some of these samples 
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were typed by serology as RhD-positive, whilst they were genotyped as partial D and 
weak D by BLOODchip®. Moreover, three samples were typed as weak D but they 
were in fact partial D. Furthermore, BLOODchip® was able to predict the weak Fy(b+w) 
phenotype. In addition to the higher resolution of the BLOODchip® in comparison to 
the standard serology, BLOODchip® provides extensive genotyping for the blood group 
alleles that do not have serological reagents such as the Dombrock blood group (López 
Marínez et al., 2009). Interestingly, all the previous reasons suggest that genotyping is 
more accurate when using BLOODchip® and that it provides a higher resolution for 
predicting the phenotypes in comparison to the serology. It should be noted that any 
new alleles would not be determined by BLOODchip® as the SNPs need to be added to 
the test panel beforehand.  
Denomme and Van Oene (2005) designed a microarray platform to examine 12 SNPs 
defining the following alleles that include exons 4 and 9 of the RHD gene, RHCE*C/c, 
RHCE*E/e, GYPB*S/s, KEL*01/02, KEL*02.03/02.04, FY*A/B, FY*02N.01, JK*A/B, 
DI*A/B and HPA*1a/1b. Among the 372 samples tested, 345 were successfully 
genotyped. The undetermined genotypes include two samples of RHD exon 9, three 
samples of RHCE*E, one sample of KEL*02.03, two samples of JK*A/B and two 
samples of FY*B. It should be noted that four samples failed to detect all the SNPs 
(Denomme and Van Oene, 2005). Although this system is capable of detecting those 
alleles, it still needs to be improved to overcome the error rate of detection. This can be 
overcome by using a technology such as NGS.  
Hashmi and co-workers (2005) designed a microarray platform, which is known as 
BLOOD-1 BeadChip™. The assay contains nine SNPs defining the following alleles 
that include FY*A/B, FY*02N.01 DO*A/B, CO*A/B, LW*A/B, DI*A/B and SC*1/2. 
Then the panel was extended to analyse 18 targeted SNPs including the following: 
GYPA*M/N, GYPB*S/s, LU*A/B, KEL*01/02, FY*265, JK*A/B, DO*02.04 encoding 
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Hy antigen, DO*01.05 encoding Joa antigen and Haemoglobin S. The platform was 
designated as HEA BeadChip™.  
The HEA BeadChip™ procedure starts by amplifying these targets using multiplex PCR. 
The amplicons need to be purified to remove residual primers and dNTPs prior to 
carrying out the downstream analysis of the microarray. This gives an advantage to the 
ID Core+ kit and BLOODchip® over HEA BeadChip™ that does not require any 
purification following the amplification. Regarding the HEA BeadChip™ kit, a 
denaturation step takes place to generate a single stranded DNA. After that, the PCR 
amplicons are annealed and elongated to beads that are coupled to oligonucleotide 
probes and immobilised on synthetic microparticles. The fluorescence of each bead is 
finally analysed using the array imaging system to determine the allelic presence or 
absence. Special software calculates the adjusted intensity in every reaction to assign 
genotypes and report the predicted phenotypes. The duration of the assay is 5 hours 
which includes the hands-on time but not the DNA extraction process (Hashmi, 2007).  
An analysis was performed of more than 400 blood donors and showed concordant 
results with serology, as well as the molecular techniques including SSP-PCR and 
RFLP-PCR. In addition, two alleles of the Dombrock blood group were identified 
(Hashmi et al., 2005). However, one sample Fy(a−b−) was collected on two occasions 
and typed as FY*B/B and GATA heterozygous A/B by both BeadChip™ and RFLP-PCR, 
as well as FY*265 homozygous A by only the RFLP-PCR. It should be noted that the 
sequencing of all the exons and introns, including the regulatory regions, revealed that 
there was no reason for silencing the FY*B alleles (Hashmi et al., 2005). In 2007, HEA 
BeadChip™ was used to examine 2355 donors to genotype minor blood group antigens. 
24 discrepancies were found, of which 16 were a consequence of clerical errors in data 
entry or when recording the serological results. Eight of these were discordant due to 
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the silent allele of GYPB*S (Hashmi et al., 2007). Sequence-based typing using NGS 
may resolve the issues of silencing alleles.  
Karpasitou and co-workers (2008) designed an in-house panel that is based on 
microarray beads using the Luminex® system. The designed panel examined the 
following alleles using a single pool; JK*A/B, FY*A/B, GYPB*S/s, KEL*01/02, 
KEL*02.03/02.04, KEL*02.06/02.07, CO*A/B and LU*A/B (Karpasitou et al., 2008). A 
further test on 2020 samples was performed to genotype the same targeted SNPs. The 
consistency was 100% with the predefined serology apart from one Co(a−b−), 74 
Fy(b+w) and 56 Fy(a−b−) samples, which were identified only by serology (Drago et 
al., 2009; Drago et al., 2010). The outcome of this study stressed that the microarray 
beads may not be a suitable platform for detecting the weak or null alleles. Genotyping 
by NGS is able to overcome such an issue in the detection of these variants (Avent et 
al., 2015). 
Paris and co-workers (2014) designed a 96-well flexible microarray platform that used 
two robotic workstations in order to facilitate the automation of the blood group 
genotyping process from the DNA extraction to data analysis. Eight SNPs were 
examined for the following alleles: KEL*01/02, KEL*02.03/02.04, JK*A/ B, FY*A/B, 
FY*02M.01, FY*01N.01, GYPA*M/N and GYPB*S/s. The advantages of this test were 
in the automation of the genotyping procedure and that the duration of the whole 
procedure was less than 8 hours. On the other hand, out of the 960 samples examined, 
three were discordant between serology and genotyping in the detection of a SNP in 
each of the Kell, Kidd and MNS blood group systems. The undetermined alleles include 
KEL*02.03 encoding Kpa antigen, FY*02M.01 encoding Fyx phenotype and GYPB*s. 
Furthermore, very limited SNPs were examined and the number of investigated SNPs 
needs to increase (Paris et al., 2014). It might be an issue to increase the number of 
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examined SNPs when increasing the number of pools for the multiplex PCR, as it may 
affect the number of samples and reduce the throughput and the price will be higher.  
3.4.1 Cost of the microarray platforms 
The cost of the ID Core+ test is around £50 per sample and around £1.51 per SNP. The 
price per SNP of the test provided by Karpasitou and co-workers is more expensive than 
the ID Core+, which was ~£2 per SNP (Karpasitou et al., 2008). Paris et al. (2014) 
designed a microarray platform using the 96-well format system for the test the price 
was £1.67 per SNP, including the genomic DNA extraction, genotyping, labour and 
equipment. This price per SNP might be a slightly higher than the ID Core+ test but this 
included the genomic DNA extraction and the rest of the procedure (Paris et al., 2014). 
Denomme and Van Oene (2005) stated that the price for the assay they designed is 
lower by 20-fold than the standard typing by serology. This may give the microarray 
system the ability to perform a high-throughput screening of the donor samples 
(Denomme and Van Oene, 2005). 
Nevertheless, the approach that was provided by Jungbauer and co-workers (2012) is 
still more affordable in contrast to microarray platforms, which costs around £10.73 per 
sample and £0.31 per SNP. The authors stated that the genotyping cost could be reduced 
to 25% of the assay cost for every SNP that has been tested in comparison to the 
standard serology (Jungbauer et al., 2012).  
The test includes the same phenotypes tested by the ID Core+ kit as well as 
KEL*02.11/02.17, KEL*02.21, FY*02M.01, LU*A/B, LU*02.08/02.14 and IN*A/B 
alleles. Similarly to the ID Core+ kit, this test does not type the ABO and the Rh blood 
group antigens. The experiment used six pools of multiplex primers, followed by 
purification of the results using gel electrophoresis. The results of the genotyping of 
6000 samples gave 99.83% accuracy, of which 350 SNPs were not detected in the first 
experiment and required the test to be repeated to overcome the situation. In addition to 
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that, ten cases of FY*02M.01 allele could not be investigated (Jungbauer et al., 2012). 
However, the post analysis of such a technique which involves the running of agarose 
gel electrophoresis cannot be automated. Moreover, this technique may be prone to 
obtaining transcription errors (Jungbauer et al., 2012). This in fact gives the advantage 
in accuracy of detection to the microarray technology over the approach proposed by 
Jungbauer et al. (2012) in detecting the SNPs. 
Generally, the suspension beads array provides fast reaction kinetics, rapid 
interpretation of the data analysis and report production. Furthermore, no purification of 
the PCR amplicons is required after the multiplex PCR amplification in most platforms. 
In addition, it has a high sensitivity in allele detection apart from in antigens with weak 
or null expression as mentioned above. Drago et al. (2009) stated that the suspension 
beads array is flexible, in which the beads can be formulated depending on the 
laboratory’s needs. However, the disadvantages of this technique include the lack of 
automation, particularly in the washing steps and sample loading. Moreover, large 
numbers need to be tested to ensure the test is cost effective, therefore, the laboratories 
with a low workload will not obtain the benefits of such a procedure (Drago et al., 
2009).  
All of the microarray platforms require previous knowledge of the allele to be 
incorporated into the platforms. This issue can be overcome using NGS technology. 
Microarray platforms have an obstacle in identifying the weak and null alleles as 
discussed above. McBean et al. (2014) stated that the BLOODchip® platform was 
designed to test the European population and BeadChip™ was designed to detect the 
alleles of the American population, in particular the Africa-American population. 
However, in Australia, a large population from multi-ethnic backgrounds and a large 
population with Asian ancestry need a special test. These two platforms will not be a 
suitable choice for such populations (McBean et al., 2014). In fact, NGS could be a 
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suitable platform for all populations because it can define and discover new alleles 
because it depends on genotyping by sequencing. Moreover, it can detect weak and null 
alleles easily. Such a technique can obtain genotyping by sequencing at an affordable 
price and can provide automation as well as barcoding for the samples to facilitate 
dealing with the data analysis and their storage. In the next chapters, NGS will be 
discussed in further detail with two different approaches: amplicon-based target 
selection using the Ampliseq™ Custom Panel and LR-PCR approach to sequence the 
entire genes of the blood group systems.  
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Chapter 4 : Human Erythrocyte Antigens and Human 
Platelet Antigens Panel (HEA and HPA Panel) 
4.1 Introduction  
Haemagglutination still remains the gold standard method that makes blood transfusion 
feasible (Reid, 2009). It is extremely difficult to interpret the serological data in some 
cases, such as in patients who suffer from SCD, aplastic anaemia, autoimmune 
haemolytic anaemia and thalassemia. This is because of the presence of donor cells in 
the blood stream of the patients or they might be coated with immunoglobulin in a 
positive DAT (Reid et al., 2000).  
Serological testing of a large cohort is highly expensive, time consuming and labour-
intensive and some blood groups do not have a special reagent to type them. These 
issues have increased the demand of BGG to overcome the limited typing by 
conventional serology (Veldhuisen et al., 2009). Foetal genotyping has been used for 
routine services when the foetus is at risk of alloimmunisation to red cell antigens or 
platelets (Reid, 2003). It is highly recommended to genotype the patients who receive 
multiple units of blood through transfusion such as patients with SCD (Avent et al., 
2007). Moreover, BGG can be performed for blood donors and patients to build a 
database for rare phenotypes. These include low prevalence antigens or any silencing or 
null mutations that cannot be identified by the standard serological typing or other BGG 
platforms, such as microarray platforms [see Chapter 3]. In addition, BGG can be 
feasible with high throughput, through which a large number of blood donors can be 
tested. NGS has provided high-throughput test in which the screening of a large cohort 
can take place (Avent et al., 2015).  
Platelet transfusions are required in patients who suffer from thrombocytopenia. With 
the same scenario as blood group antigens, the HPAs need to be matched between the 
donors and patients. The antibodies to HPAs can be involved in alloimmune platelet 
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disorders [see section 1.8]. The detection of platelet antibodies by serology in 
association with genotyping the HPAs establishes a comprehensive diagnosis of 
alloimmune platelet disorders. Furthermore, the genotyping test makes the typing of the 
low prevalence platelet antigens feasible due to the scarcity of serologic reagents for 
these rare antigens (Curtis, 2008). Therefore, genotyping of the HPAs rather than the 
conventional serology is considered to be the gold standard for platelet typing (Curtis, 
2008). Accordingly, NGS can be used to target the HPAs as well as the red cell antigens 
in a single assay due to its high capacity and throughput.  
4.2 Aims   
The aim of this project was to design a panel that is based on NGS and capable of 
genotyping the blood group systems and HPAs to establish it for a high-throughput 
assay to be used in routine work. The design was for 11 blood group systems including 
ABO, Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Yt, Colton and Vel and HPAs 
(1-16). The size of the panel was 31.18 Kb with two pools of primer pairs and the 
coverage was 99.33%.  
The method was based on Ion Ampliseq™ Custom Panel provided by Thermo Fisher 
Scientific, Paisley, United Kingdom. Most of the blood group antigens arise through 
SNPs, although other genetic events such as gene deletion and gene rearrangement that 
give hybrid genes are present (Daniels, 2009). Therefore, the panel targeted the exons, 
the coding regions, of the blood group genes. Regarding HPAs, PCR products of each 
antigen were designed by setting the primers within upstream and downstream regions 
of the SNP of interest.  
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4.3 Results 
Twenty-eight blood samples (Cohort B) were chosen according to the serology. The 
extracted DNA was initially amplified using two different pools of primers with ultra-
high multiplex PCR. Then, the sequencing libraries were made by partial digestion of 
the primer sequences of each amplicon and ligated to barcoded adaptors [section 2.5.1]. 
Unlike other protocols of NGS, there was no fragmentation step or multiple purification 
steps which gives an advantage to the rapid method of BGG by using such a panel. 
Figure 4.1 illustrates a schematic diagram for the library construction using Ion 
Ampliseq™ Custom Panel.  
In order to proceed with the template preparation and sequencing the samples on Ion 
PGM™, the sequencing libraries need to be quantified to 100 pM. The Ion Library 
Quantitation Kit was used for concentration normalisation. After that, the sequencing 
libraries were immobilised to beads in order to prepare the template for sequencing. 
These beads had a complementary strand to one of the adaptors and the monoclonal 
amplification took place followed by enrichment of the positive sequencing templates 
[section 2.5.3.2]. Finally, the sequencing templates were loaded onto Ion 316™ chip and 
sequenced on Ion PGM™ [section 2.5.4].   
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Figure 4.1 Schematic diagram for constructing a sequencing library using Ion Ampliseq™ Custom Panel.  
The amplification process of genomic DNA, using two different pools of primer sets (Pool A and Pool B), takes place 
by extending the annealing primers using a polymerase enzyme. A partial digestion is then carried out and finally the 
adaptors are ligated to both ends.  
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4.3.1 Sequencing report  
Twenty-eight samples in total were sequenced using the HEA and HPA Panel on the 
Ion PGM™. A summary of the sequencing report run is demonstrated in Figure 4.2. The 
loading density of the chip for the sequencing run was 91%, in which this was the 
percentage that the ISPs addressed by the chip wells. The total reads were 3,478,290 
and the read length mean was 171 bp [Figure 4.2]. 
The enrichment of the clonal amplified templates successfully achieved a high 
percentage of 100%. The clonal amplification was 64%, whereas the polyclonal 
amplification was 36%. The percentage of the clonal templates shows the template that 
has a single sequencing library attached to the ISP after performing the emulsion PCR. 
This is in contrast to the polyclonal templates, where more than a single sequencing 
library is attached to the ISP [Figure 4.2]. The percentage of the usable reads was 61% 
and the final library was 95% in which 5% was removed due to poor quality.  
Two sets of software were used as parts of the Ion PGM™ sequencing report run; the 
first was well classification and the other was responsible for filtering and trimming. 
The well classification considered the addressable wells in comparison to the empty 
wells and was reported as bead loading density. Regarding the filtering and trimming 
software, the filter removed the polyclonal reads with more than one template that was 
attached to the beads, reads with low quality or less than 4 bp and a primer dimer with 
less than 8 bp.   
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 Figure 4.2 An overview of a report on the sequencing run of the HEA and HPA Panel. 
(a) Loading density of ISP that was addressed by the chip wells, which was 91%.  
(b) Total of 3,478,290 reads after filtering and trimming. 
(c) A histogram of the read length of the sequencing libraries with a mean of 171 bp, on which the y-axis demonstrates the read count, while the  
x-axis shows the read length in the bp. 
 
(a) (b) (c) 
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4.3.2 Quality Control 
4.3.2.1 Per base sequence quality 
FastQC software was utilised to assess the quality control of the generated sequences by 
HEA and HPA Panel. Phred score is software used to calculate the quality of 
sequencing reads with a special algorithm and it was developed for the HGP (Ewing et 
al., 1998). A Phred score of 20 gives an accuracy of sequencing reads of 99%, in which 
the probability of the base being called incorrect is 1 in 100. Generally, any high-
throughput sequencing platforms start the run with the best quality reads and then the 
quality starts to drop when the run progresses. 
Figure 4.3 displays the quality score across the position reads. The x-axis represents the 
position of the reads in the bp, while the y-axis represents the Phred score of quality. 
The background of the y-axis is divided into three colour areas: green for the best reads, 
orange for the reasonable reads and red for the low quality reads.  
Box and Whisker plots were drawn on every position per bp. The inter-quartile range 
(25-75%) was represented by yellow boxes, which obviously stopped just following the 
highest position in bp. The upper and lower whiskers demonstrate 10% and 90% points. 
The blue line shows the mean of the Phred quality score across the sequencing reads in 
bp and the central red line demonstrates the median of the quality score.  
Regarding the sequencing run of the HEA and HPA Panel, the mean of the quality score 
started with a high quality score around 32 and then dropped and remained steady at 
around 27 and at the end of the sequences it dropped again after position in reads 239 bp 
and remained steady at a score of 20. Accordingly, this quality score represented a high 
quality and achieved accuracy of higher than 99%.  
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Figure 4.3 Phred quality scores across all the bases for a single sample of the HEA 
and HPA Panel. 
The background of the y-axis demonstrates the Phred score, while the x-axis shows the 
position in reads in bp. The background of the graph divides the y-axis into three different 
areas with three different colours; green for the best quality sequencing reads, orange for 
the reasonable sequencing reads and red for the low quality ones. Box and Whisker plots 
were drawn on every position per bp. The inter-quartile range (25-75%) was represented 
by yellow boxes, which stops after the highest position of the reads. The upper and lower 
whiskers demonstrate 10% and 90% of points. The blue line demonstrates the mean of the 
quality according to the Phred score across the reads in position, while the central red line 
shows the median of the quality score. The mean started at a Phred score of 32 and then 
dropped to 20 at the end of the sequencing run. All the analysed samples had the same 
Phred score. 
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4.3.2.2 Per Sequence Quality Scores  
FastQC software was also used to evaluate if a subset of one of the sequencing reads 
represented poor quality reads. Figure 4.4 demonstrates the mean of the quality 
sequence per reads across the count of the reads according to the Phred score. The x-
axis shows the mean of sequencing quality, while the y-axis demonstrates the 
sequencing counts. The mean quality across the samples was around 27 which means 
the sequencing reads were of high quality and provided accuracy of over 99%. 
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Figure 4.4 Quality scores per sequencing count for a single sample of the HEA and 
HPA Panel. 
The mean sequence quality according to the Phred score is demonstrated across the read 
counts. FastQC software was used to assess if a subset of the sequencing reads are of poor 
quality. The results show the quality of most reads was 27 according to the Phred score, 
which indicates high quality reads with an accuracy of 99%. All the analysed samples had 
the same Phred score. 
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4.3.3 Sequencing visualisation 
The sequencing data of HEA and HPA Panel were visualised using IGV software 
Version 2.3.46. The IGV software mapped the generated sequences by Ion PGM™ to 
the whole human genome (hg19) and then the navigation was performed by looking at 
the targets of interest in order to assess the genotyping analysis. This software assisted 
to evaluate the depth of coverage of each target as well as to determine the zygosity. 
Figure 4.5 shows a homozygous SNP, hemizygous SNP in this case for weak D, 809 
T>G (Val270Gly) for a weak D type 1 in exon 6 of the RHD gene. The depth of 
coverage represented for that SNP was 346 reads, as the number of repeated sequences 
at specific targets. This can appear as multiple grey lines above the reference sequence. 
Figure 4.6 shows a heterozygous SNP 2108A>C (Tyr703Ser) for the HPA-15 a/15b 
genotype in CD109 gene.  
4.3.3.1 Alignment obstacles 
Mapping quality in IGV software can be seen in colours. In other words, for the good 
quality reads, the mapping quality score was represented in grey colour as shown in 
Figure 4.7. On the other hand, the poor quality mapping reads appeared in white colour, 
as seen in Figure 4.8.  
Some areas in the ABO and RHD genes were observed as a very low depth of coverage. 
Figure 4.9 shows a poor mapping quality score in exon 8 of the RHD gene, as observed 
in white colour, as well as a very low depth of coverage. In addition to that, there were 
only two sequencing reads in amino acid positions (377-379), which were missed in 
some samples within exon 8. Two missed regions in exon 7 of the ABO gene were 
observed in amino acid positions (202-225) and (347-354). Figure 4.10 shows the 
missed regions in exon 7 of the ABO gene.  
An interesting finding was observed regarding to the exon 1 of the RHCE gene. There 
was an allelic imbalance with a ratio of 77% to the reference nucleotide in comparison 
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of 23% to the changing nucleotide. Figure 4.11 shows the allelic imbalance found in 
RHCE gene.  
Furthermore, in the MNS blood group system, some samples observed a low depth of 
coverage and missed regions. Figure 4.12 illustrates a comparison between two samples 
in the GYPA gene of the MNS blood group system. There was no difference in the 
nucleotides between GYPA*N allele, which matches the reference gene, and the 
antithetical GYPA*M allele regarding the amino acid position 24. Figure 4.12 a and 
Figure 4.12 b show the amino acid position 24 for GYPA*N allele and GYPA*M allele, 
respectively. Issues related to this sample include low coverage depth, low quality 
mapping and a missed region.  Figure 4.13 illustrates an output from the IGV software 
demonstrating two samples with A and B phenotypes observed a nucleotide insertion. 
The purple sign indicates the insertion of a single nucleotide (G) at amino acid number 
88. This is because the reference allele used was O allele. In this allele, a deletion of G 
nucleotide at position 261 causes a frameshift in the reading frame leading to 118 stop 
codon (88fs118stop). 
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Figure 4.5 A homozygous SNP (hemizygous in this case for weak D sample). 
The SNP is 809 T>G (Val270Gly) in exon 6 of the RHD gene. The depth of coverage of this SNP was 346 and it 
appeared as multiple grey lines above the reference gene (in blue) of RHD. The zygosity shows very clearly that 
T was replaced by G in all rows as indicated by a full box with a brown colour at the top. Output from IGV 
software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and 
the reference gene in blue at the bottom.  
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Figure 4.6 A heterozygous SNP for HPA-15a/15b genotype in the CD109 gene. 
Two colours (green for the reference nucleotide “A” and blue for the mutated nucleotide ”C”) are shown to indicate the 
heterozygous SNP. The percentage of this heterozygous SNP was 50% for the reference nucleotide and 50% for the 
other nucleotide. Further to that change in the nucleotide, the amino acid was substituted from tyrosine to serine at a 
position of 703. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal 
locations are shown on the top and the reference gene in blue at the bottom. 
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Figure 4.7 Good mapping quality for the sequencing reads 
The screenshot shows a grey colour for the good quality mapping of the repeated sequencing reads. This screenshot demonstrates exon 7 of the 
RHD gene. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and 
the reference gene in blue at the bottom. 
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Figure 4.8 Poor mapping quality in exon 10 of the RHD gene.  
The poor mapping reads can be seen in white colour. Output from IGV software demonstrates the visualisation of the sequencing data. 
Chromosomal locations are shown on the top and the reference gene in blue at the bottom. 
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Figure 4.9 Poor mapping quality for the sequencing reads for exon 8 of the RHD gene. 
The poor mapping reads can be seen in white colour. Furthermore, a low depth of coverage in exon 8 of the RHD gene in which there 
were less than 16 reads and only around two reads (in grey, indicated by a black arrow) at amino acid 379 which makes genotyping for 
the RHD*DAU allele impossible. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal 
locations are shown on the top and the reference gene in blue at the bottom. 
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Figure 4.10 Missed regions within the exon 7 of the ABO gene. 
These regions include amino acid positions (202-225) indicated by the red arrow and (347-354) indicated by the black arrow. Output 
from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and the 
reference gene in blue at the bottom. 
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Figure 4.11 Allelic imbalance in exon 1 of the RHCE gene. 
The reference nucleotide (C) represents 77% while the other nucleotide (G) represents 23%. Some reads with poor mapping quality can be 
shown in white colour. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown 
on the top and the reference gene in blue at the bottom.  
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Figure 4.12 A comparison between two samples of the GYPA gene in the MNS blood group system. 
There was no difference in the nucleotides between GYPA*N allele (a), which matches the reference gene, and the antithetical GYPA*M 
allele regarding the amino acid position 24 (b). The amino acid position 24 is indicated with a black arrow. Issues related to this sample 
include low coverage depth, low quality mapping and a missed region. This may be because non-specific primers were used for the 
amplification of both homologous genes, GYPA and GYPB. Output from IGV software demonstrates the visualisation of the sequencing 
data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom.  
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Figure 4.13 A nucleotide insertion with ABO gene in two samples with A and B phenotypes.  
The purple sign indicates the insertion of a single nucleotide (G) at amino acid number 88. This is because the reference allele used is O 
allele. In this allele, a deletion of G nucleotide at position 261 causes a frameshift in the reading frame leading to 118 stop codon 
(88fs118stop). Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on 
the top and the reference gene in blue at the bottom. 
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4.3.4 Variant analysis using Ion Reporter ™ software 
In order to start the genotyping analysis, the VCF files were analysed using the Ion 
Reporter™ software. This software was used to annotate the sequencing data in order to 
genotype the blood group antigens and HPAs resulting from the HEA and HPA Panel. 
The data of the Ion Reporter™ can be exported in different formats including .pdf file 
format and in Excel sheets.  
Figure 4.12 shows a screenshot of the report analysis for one sample of the HEA and 
HPA Panel that was exported as an Excel sheet. The Ion Reporter™ facilitated the 
analysis by giving the annotated information including chromosomal location, type of 
variant and whether it was a single nucleotide variant (SNV) or indels, gene, the 
reference nucleotide, the changing nucleotide, depth of coverage, the transcript used in 
the analysis based on the NCBI database, the location of the variant and whether it was 
(intronic, synonymous, exonic) SNPs, codon, exon number of that variant, amino acid 
substitution and position of the nucleotide change. The genotyping results are presented 
in the next section. 
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Figure 4.14 An Excel sheet for the genotyping analysis report using the Ion Reporter™ software. 
Each variant was given by its locus at the chromosomal location, the type of variant including SNV or indels, the reference nucleotide (ref), the length of the variant, 
the genotype result, the depth of the coverage to that variant (coverage), allele coverage, gene, transcript which was based on the NCBI database, the location of the 
variant and whether it was intronic or within the exons, codon, exon number where the variant was located, protein changed or synonymous and the position of the 
coding nucleotide. This analysis represents a single sample, which was sequenced by the HEA and HPA Panel on the Ion PGM™.  
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4.3.5 Genotyping results of HEA and HPA Panel  
Twenty-eight samples were examined for 11 blood group systems and 16 HPAs. The 
blood samples underwent serology testing at NHSBT Filton for the following blood 
groups ABO, Rh, MNS, P1, Lutheran, Kell, Lewis, Duffy, Kidd and Sickle cell status. 
Table 4.1 shows that the serological testing was performed for all 28 samples.  
4.3.5.1 Genotyping of ABO Blood group system 
Out of the 28 samples, 10 samples were serotyped as A phenotype, four samples as B 
phenotype and 14 samples as O phenotype. Table 4.2 lists the genotyping results for the 
ABO blood group system. Samples from all three phenotypes observed the following 
SNPs 106G>T (Val36Phe) in exon 3, 188G>A (Arg63His) in exon 4, 220C>T 
(Pro74Ser) in exon 5 and 261delG 88fs118stop in exon 6. These SNPs are related to O 
phenotype, which means the samples were A/O, B/O and O/O alleles.  
Regarding the O phenotype, two homozygous samples and five heterozygous samples 
observed 829G>A (Val227Met) in exon 7, which is a SNP found to be associated with 
other SNPs in rare Japanese allele (Reid et al., 2012). In addition, a single sample 
observed a heterozygous SNP of 594C>T (Arg198Cys) in exon 7.  
Regarding the A phenotype, in A1 phenotype there was no association of any mutation 
in the exons, apart from a single sample which observed a heterozygous SNP 467C>T 
(Pro156Leu) and that SNP is found mainly in Asians (Reid et al., 2012).  
Regarding the B phenotype, all four samples observed the four main SNPs that are 
associated with the B phenotype in exon 7. These included one homozygous and three 
heterozygous for 526C>G (Arg176Gly), one homozygous and three heterozygous for 
703G>A (Gly235Ser), one homozygous and three heterozygous for 796C>A 
(Leu266Met) and one homozygous and three heterozygous for 803G>C (Gly268Ala). A 
SNP 296G>A (His99Arg) was found in B phenotype (two homozygous and two 
heterozygous) and in O phenotype (two homozygous and seven heterozygous).  
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4.3.5.2 Genotyping of RHD gene 
Eighteen samples were RhD-negative samples, while 10 samples were serologically 
typed as weak D. Table 4.3 demonstrates the NGS genotyping for the weak D samples 
within the RHD gene including nucleotide changes and amino acid substitutions. 
Regarding the weak D samples, which were typed by serology, four samples were 
observed to be weak D type 1 (RHD*01W.01) 809T>G (Val270Gly), four samples of 
weak D type 2 (RHD*01W.02) 1154G>C in exon 9 (Gly385Ala) and one sample of 
DAR3.1 weak partial D 4.0 (RHD*DAR3.01). The latter had three nucleotides 602C>G 
(Thr201Arg) in exon 4, 667T>G (Phe223Val) in exon 5 and 819G>A (silent) in exon 6. 
Interestingly, one of the weak D samples, which was typed as weak D by conventional 
serology appeared to be an RhD-positive sample. In other words, no mutations were 
detected in any of the exons of the RHD gene.  
4.3.5.3 Genotyping of other blood group systems 
The antigens of the other blood group systems (RhCE, Kell, Kidd, Duffy, MNS, Diego, 
Dombrock, Colton. Yt and Vel) were genotyped and the predicted phenotypes are listed 
in Table 4.4. Regarding RHCE gene, four samples were genotyped as RHCE*C and 
were found to be heterozygous 48G>C (Trp16Cys) in exon 1. There was no difference 
observed between RHCE*C and RHCE*c alleles regarding exon 2. In other words, there 
were no SNPs related to the RHCE*C allele and it was only shown Pro103 in exon 2.  
Five samples were genotyped as RHCE*E, in which they were heterozygous in exon 5 
of the RHCE gene for 676C>G (Ala226Pro). The genotyping data by NGS for the 
RHCE*C and RHCE*E alleles confirmed the phenotypes provided by the serology. The 
following allele (RHCE*ceVS.04 allele) was found in a single sample as 48G>C 
(Trp16Cys) in exon 1, 733C>G (Leu245Val) in exon 5 and 1025C>T (Thr342Ile) in 
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exon 7.  This allele predicts partial e phenotype, V and VS antigens, which is found 
mainly in Africans (Reid et al., 2012). 
Kell and Kidd blood groups 
For the Kell blood group system, KEL*02 (k), KEL*02.04 (Kpb) and KEL*02.07 (Jsb) 
were found in all samples and confirmed the information obtained by serology. 
Regarding the Kidd blood group system, 10 samples were found to be heterozygous for 
JK*A/B, eight samples were homozygous for JK*B and five samples were homozygous 
for JK*A. Jk(a+w) were predicted in four samples and were found to be heterozygous 
with JK*B. The associated mutation with the JK*01W.01 allele, encoding the Jk(a+w) 
phenotype, was 130G>A (Glu44Lys). The rest of the samples that performed by NGS 
were the same as the serology.  
Duffy blood group  
Ten samples were found to be homozygous for FY*B allele in which they observed 
125G>A (Gly42Asp) in exon 2, while a single sample was homozygous for FY*A 
125A>G (Asp42Gly). Seventeen samples were heterozygous for both FY*A/B. A SNP 
298G>A (Ala100Thr) was found in seven samples which is associated with the 
FY*02M.01 allele, in which six of them were in association with heterozygous FY*A/B 
and one with FY*B allele.   
MNS blood group 
Regarding the MNS blood group system, eight samples were found as GYPA*N allele 
by NGS which contradicted with the serology data, where they were typed as M 
antigen. Only four samples were genotyped with GYPA*M allele by NGS although they 
were observed in a low depth of coverage of five sequencing reads and some of them 
missed bp around amino acids (positions 23-31). Two non-valid samples were found in 
which no alleles could be identified. The rest of the samples matched the serology 
although most of them did not have the serological information. Twelve samples were 
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genotyped by NGS as GYPB*s/s with the SNP 143T>C (Met48Thr), two samples were 
found to be GYPB*S/S with the SNP 143C>T (Thr48Met) and 14 samples were 
heterozygous for both alleles GYPB*S/s. Out of the total of the 28 samples, two samples 
were typed by serology as S+ and they were revealed by NGS to be heterozygous 
GYPB*S/s. Interestingly, there was one sample found by NGS as GYPB*S/S, which 
confirmed the serotyping as S+.  
Diego blood group  
Regarding the Diego blood group system, 27 samples were homozygous for 2561T>C 
(Leu854Pro) in exon 19 of the SLC4A1 gene which observes DI*B allele. On the other 
hand, only one sample was heterozygous DI*A/B. 
Dombrock blood group  
For the Dombrock blood group system, DO*A was found in a single sample as 793G>A 
(Asp265Asn) in exon 2 of the ART4 gene. Eleven samples were homozygous for the 
DO*B allele observing 793A>G (Asn265Asp). One sample was heterozygous which 
had both alleles DO*A/B. All the samples were found the DO*02.04 allele 323G<T 
(Val108Gly) in exon 2 and DO*02.05 allele as 350T>C (Ile117Thr) in exon 2. These 
two alleles predict Hy and Joa antigens, respectively.  
Colton blood group  
For the Colton blood group system, 25 samples observed the CO*A allele and were 
found to be homozygous for the SNP 134T>C (Val45Ala). Only a single sample was 
found to be CO*B, which observed a homozygous SNP 134C>T (Ala45Val). In 
addition, two samples were heterozygous for both alleles CO*A/B.  
Yt and Vel blood groups  
Regarding the Yt blood group system, 26 samples were typed by NGS as YT*A which 
was observed as 1057A>C (Asn353His) in exon 2 of the ACHE gene. Furthermore, two 
 121 
samples were heterozygous YT*A/B, observing the SNP 1057C>A, (His353Asn). For 
the Vel blood group system, all samples observed the Vel allele.  
4.3.5.4 Genotyping of human platelet antigens 
The HPAs were also tested using the HEA and HPA Panel. Table 4.5 demonstrates the 
phenotypes of HPAs 1 to 16 as well as the common form of the antigen (a) and the less 
common form of the platelet antigen (b). HPA-1 observed nine heterozygous for HPA-
1a/1b and 19 homozygous for HPA-1a/1a. In HPA-2, five samples were heterozygous 
HPA-2a/2b and 23 were homozygous HPA-2a/2a. Regarding HPA-3, 14 individuals 
were homozygous for HPA-3a/3a, 10 homozygous for HPA-3b/3b and four samples 
were heterozygous HPA-3a/3b. In HPA-5, 25 samples were homozygous for HPA-
5a/5a and three samples were heterozygous for HPA-5a/b. Regarding HPA-6, 22 
samples were homozygous for HPA-6a/6a, one sample was homozygous for HPA-6b/6b 
and five samples were heterozygous for HPA-6a/6b. In HPA-15, six individuals were 
homozygous for HPA-15a/15a, 13 were homozygous for HPA-15b/15b and nine 
samples found to be HPA-15a/15b. All the samples were homozygous for HPA-4a/4a, 
HPA-7a/7a, HPA-8a/8a, HPA-9a/9a, HPA-10a/10a, HPA-11a/11a, HPA-12a/12a, HPA-
13a/13a, HPA-14a/14a and HPA-16a/16a. 
4.3.5.5 Novel alleles detected by the HEA and HPA Panel  
Four novel alleles were identified by the HEA and HPA Panel. One was in the RHCE 
gene and three were in the KEL gene. Table 4.6 lists the four new SNPs investigated by 
the panel. The first SNP was detected in the RHCE in exon 2 heterozygous 208C>T 
(Arg70Trp). Initially, this SNP was assigned incorrectly to the RHD gene with an allelic 
imbalance ratio of (60:40) as demonstrated in Figure 4.15. This issue was resolved by 
amplification of both RHD and RHCE genes using LR-PCR approach following by 
sequencing on Ion PGM™ [see Chapter 6].  
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Regarding the KEL gene, the first SNP was found in sample 8 and was heterozygous 
331G>A (Ala111Thr) in exon 4. The result of this SNP is shown in Figure 4.16. Sample 
26 had another two novel SNPs. The first SNP was heterozygous 1907C>T 
(Ala636Val) in exon 17 as shown in Figure 4.17. The second SNP was in exon 19 and 
was found to be heterozygous 2165T>C (Leu722Pro) as demonstrated in Figure 4.18. 
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 ABO Rh D C E c e Cw M N S s P1 Lua Lub K k Kpa Kpb Lea Leb Fya Fyb Jka Jkb A1 
1 O+ R0r + − − + + − + + + + + − + −  − +  − − + + +  
2 A+ R1r + + − + + − +  +     −        + +  
3 A+ R2r + − + + + − +               + +  
4 O+ R1r + + − + + −                   
5 O− rr − − − + + −   + +   +  +  +   + + + −  
6 A− rr − − − + + − − + +  −  + − +   − +   + + + 
7 A− rr − − − + + − +  + +    −      + + + +  
8 A− rr − − − + + −        −      +  + +  
9 O− rr − − − + + − +  − + −  + −   + −  +  + +  
10 A− rr − − − + + − +  − +          + + + +  
11 O− rr − − − + +  +      + −   +     + +  
12 O− rr − − − + +        + −   +        
13 B− rr − − − + + − +  +     −        + +  
14 O− rr − − − + + − − + − + + − + − + −  − + − + + −  
15 B− rr − − − + + − +  +     −        + +  
16 O− rr − − − + + − +  +    + −   +     +   
17 O− rr − − − + +         −           
18 O− rr − − − + +        + −   +        
19 O− rr − − − + +        + −   +        
20 B− rr − − − + + − +  −     −           
21 O− rr − − − + + − −  − +  − + −  − + −  + + + −  
22 O− rr − − − + + − +  +    + −   +   + + + +  
23 O+ R2r + − + + + − +  + − +   −      − + − +  
24 A+ R1r + + − + + − −  −  +       −    − +  
25 A+ R1r + + − + +         −        + −  
26 B+ R2r + − + + +         −           
27 A+ R2r’’ + − + + +         −           
28 A+ R2r + − + + + − +  −     −        − +  
Table 4.1 The serological results provided by NHSBT Filton for the 28 samples. 
These samples were tested by NGS using the HEA and HPA Panel. The samples indicated in blue were typed as weak D by 
serology, while the rest of the samples were RhD-negative. 
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Table 4.2 The genotyping results of the ABO blood group system obtained by the HEA and HPA Panel. 
 
§Hom and het refer to homozygous and heterozygous, respectively. fs= frameshift.  
  
 
 
 
 
 
 
Phenotype 
No. of 
samples 
Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 
Possible 
Genotype 
A 10 
106G>T 
Val36Phe 
(9 hom§) 
188G>A 
Arg63His 
(10 hom) 
220C>T 
Pro74Ser 
(10 hom) 
261delG 
88fs118stop 
(2 hom & 
6 het§) 
467C>T 
Pro156Leu 
(1 het) 
A/O 
B 4 
106G>T 
Val36Phe 
(2 hom & 
2 het) 
188G>A 
Arg63His 
(2 hom & 
1 het) 
 
 
220C>T 
Pro74Ser 
(2 hom & 
2 het) 
296G>A 
His99Arg 
(2 hom & 
2 het) 
 
261delG 
88fs118stop 
(1 hom & 
2 het) 
829G>A 
Val227Met 
(2 het) 
526C>G 
Arg176Gly 
(1 hom &  
3 het) 
703G>A 
Gly235Ser 
(1 hom & 
 3 het) 
796C>A 
Leu266Met 
(1 hom &  
3 het) 
803G>C 
Gly268Ala 
(1 hom & 
 3 het) 
3 samples 
of B/O 
1 sample 
of B/B 
O 14 
106G>T 
Val36Phe 
(7 hom & 
7 het) 
188G>A 
Arg63His 
(8 hom & 
6 het) 
 
 
220C>T 
Pro74Ser 
(8 hom & 
5 het) 
296G>A 
His99Arg 
(2 hom & 7 
het) 
 
261delG 
88fs118stop 
(1 het) 
829G>A 
Val227Met 
(2 hom &  
5 het) 
 
594C>T 
Arg198Cys 
(1 het) 
526C>G 
Arg176Gly 
(1 het) 
O/O 
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                                                             Table 4.3 Genotyping results using NGS of weak D samples obtained by the HEA and HPA Panel. 
No. of 
Samples 
Exon Nucleotides Amino acid NGS Genotyping 
1 4 
5 
6 
602C>G 
667T>G 
819G>A 
Thr201Arg 
Phe223Val 
Silent 
DAR3.1 weak partial D 4.0 
(RHD*DAR3.01) 
 
4 6 809T>G Val270Gly Weak D type 1 (RHD*01W.01) 
4 9 1154G>C Gly385Ala Weak D type 2 (RHD*01W.02) 
                                                             A single sample observed no related mutations within all the exons. 
 
 
 
 
 
 126 
 
 
 
 
   Table 4.4 The predicted phenotypes of NGS genotyping results for other blood groups by the HEA and HPA Panel.   
   The blood groups include RhCE, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Yt and Vel blood group systems by the HEA and HPA Panel.  
   § = low coverage depth, +w = weak form of the antigen, NV = non-valid. The blank fields are considered as negative results for clarity. 
 
 
 
 
 
 
  RhCE Kell Kidd Duffy MNS Diego Dombrock Colton Yt Vel 
# Serology C c E e Cx Cw VS K k Kpa Kpb Jsa Jsb Jka Jkb Fya Fyb Fyx M N S s U Dia Dib Doa Dob Hy Joa Coa Cob Yta Ytb Vel 
1 R0r  +  +   +  +  +  + + +  +   + + + +  + + + + + +  +  + 
2 R1r NV +  +     +  +  + +w + + +   + +  +  + + + + + +  +  + 
3 R2r  + + +     +  +  + + + + +  +  + + +  + + + + + +  +  + 
4 R1r NV +  +     +  +  + + + + +   +  + +  +  + + + +  +  + 
5 rr  +  +     +  +  + +  + +   + + + +  + + + + +  + + + + 
6 rr  +  +     +  +  + + + + +   + + + +  + + + + + +  + + + 
7 rr  +  +     +  +  + +w + + +   + + + +  +  + + + + + +  + 
8 rr  +  +     +  +  + + + + +   + + + +  +  + + + +  +  + 
9 rr  +  +     +  +  + + +  +   +  + +  +  + + + +  +  + 
10 rr  +  +     +  +  + +w + + +   +  + +  + +  + + +  +  + 
11 rr  +  +     +  +  + + + + +   + + + +  + + + + + +  +  + 
12 rr  +  +     +  +  + +w +  +  NV NV + + +  +  + + + +  +  + 
13 rr  +  +     +  +  + + +  +  +§ + + + +  +  + + + +  +  + 
14 rr  +  +     +  +  +  + + +   +  + + + + + + + + +  +  + 
15 rr  +  +     +  +  + +  + +  +§  + + +  + + + + + + + +  + 
16 rr  +  +     +  +  +  +  +   + + + +  +  + + + +  +  + 
17 rr  +  +     +  +  + +   +   +  + +  + + + + + +  +  + 
18 rr  +  +     +  +  +  +  +   + + + +  +  + + + +  +  + 
19 rr  +  +     +  +  +  + + +   + + + +  + + + + + +  +  + 
20 rr  +  +     +  +  + + + + +   +  + +  + + + + + +  +  + 
21 rr  +  +     +  +  + +   +   +  + +  +  + + + +  +  + 
22 rr  +  +     +  +  + + + + +  NV NV + + +  + + + + + +  +  + 
23 R2r  + + +     +  +  +  +  +   + +  +  + + + + + +  +  + 
24 R1r NV +  +     +  +  +  + + +   +  + +  +  + + + +  +  + 
25 R1r NV +  +     +  +  + +  + +  +§   + +  +  + + + +  +  + 
26 R2r  + + +     +  +  + + + + +  +§   + +  + + + + + +  +  + 
27 R2r''  + + +     +  +  +  +  +   +  + +  + + + + + +  +  + 
28 R2r  + + +     +  +  +  + +    +  + +  + + + + + +  +  + 
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        Table 4.5 The predicted phenotypes of the HPAs from the genotyping results using HEA and HPA Panel. 
HPA 
Sample   HPA-1 HPA-2 HPA-3 HPA-4 HPA-5 HPA-6 HPA-7 HPA-8 HPA-9 HPA-10 HPA-11 HPA-12 HPA-13 HPA-14 HPA-15 HPA-16 
 a b a b a b a b a b a b a b a b a b a b a b a b a b a b a b a b 
1 +  +  + + +  +   + +  +  +  +  +  +  +  +  +  +  
2 + + +   + +  +   + +  +  +  +  +  +  +  +  + + +  
3 +  +  +  +  + +  + +  +  +  +  +  +  +  +   + +  
4 +  +  + + +  +   + +  +  +  +  +  +  +  +  + + +  
5 +  +  + + +  +   + +  +  +  +  +  +  +  +   + +  
6 +  +   + +  +   + +  +  +  +  +  +  +  +  +  +  
7 +  +  +  +  + +  + +  +  +  +  +  +  +  +   + +  
8 +  +  +  +  +   + +  +  +  +  +  +  +  +  + + +  
9 +  +  +  +  +   + +  +  +  +  +  +  +  +  + + +  
10 + + +  + + +  + +  + +  +  +  +  +  +  +  +  + + +  
11 + + +  +  +  +   + +  +  +  +  +  +  +  +   + +  
12 +  + + +  +  +   + +  +  +  +  +  +  +  +  + + +  
13 +  +  + + +  +   + +  +  +  +  +  +  +  +   + +  
14 +  +  +  +  +   + +  +  +  +  +  +  +  +  +  +  
15 +  + + + + +  +   + +  +  +  +  +  +  +  +  +  +  
16 + + +  + + +  +   + +  +  +  +  +  +  +  +  + + +  
17 + + +  +  +  +   + +  +  +  +  +  +  +  +   + +  
18 +  + + +  +  +   + +  +  +  +  +  +  +  +   + +  
19 + + +  + + +  +   + +  +  +  +  +  +  +  +  + + +  
20 +  + + +  +  +   + +  +  +  +  +  +  +  +   + +  
21 +  +  +  +  +   + +  +  +  +  +  +  +  +  +  +  
22 +  +  +  +  +   + +  +  +  +  +  +  +  +   + +  
23 + + +   + +  +  + + +  +  +  +  +  +  +  +   + +  
24 + + +  +  +  +  + + +  +  +  +  +  +  +  +   + +  
25 + + +  + + +  +  +  +  +  +  +  +  +  +  +   + +  
26 +  +   + +  +  + + +  +  +  +  +  +  +  +  + + +  
27 +  + + +  +  +  + + +  +  +  +  +  +  +  +  +  +  
28 +  +  + + +  +  + + +  +  +  +  +  +  +  +   + +  
        The blank fields are considered as negative results for clarity.  
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                                                                      Table 4.6 The novel alleles detected by the HEA and HPA Panel. 
Sample 
number 
Gene Exon Nucleotides Zygosity Amino acid 
4 RHCE 2 208C>T Heterozygous Arg70Trp 
8 KEL 4 331G>A Heterozygous Ala111Thr 
26 KEL 17 1907C>T Heterozygous Ala636Val 
26 KEL 19 2165T>C Heterozygous Leu722Pro 
                                                                      Two novel SNPs in the KEL gene were found in a single sample, which was sample 26.  
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Figure 4.15 A novel SNP that was misaligned to the RHD gene instead of the RHCE gene with an allelic imbalance ratio of (60:40). 
The SNP is 208C>T (Arg70Trp) in exon 2 of the RHCE gene [see Chapter 6]. Output from IGV software demonstrates the visualisation of 
the sequencing data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom.     
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Figure 4.16 A novel SNP found in exon 4 of the KEL gene. 
The SNP was heterozygous SNP 331G>A (Ala111Thr). The KEL gene is an anti-sense strand, therefore the SNP was shown as C>T on the 
reference gene instead of G>A. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations 
are shown on the top and the reference gene in blue at the bottom.     
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Figure 4.17 A novel SNP found in exon 17 of the KEL gene. 
The SNP was heterozygous 1907C>T (Ala636Val). The KEL gene is an anti-sense strand, therefore the SNP was shown as G>A on the 
reference gene instead of C>T. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are 
shown on the top and the reference gene in blue at the bottom.     
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Figure 4.18 A novel SNP found in exon 19 of the KEL gene. 
The SNP was heterozygous SNP 2165T>C (Leu722Pro). The KEL gene is an anti-sense strand, therefore the SNP was shown as A>G on the 
reference gene instead of T>C. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are 
shown on the top and the reference gene in blue at the bottom.     
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4.4 Discussion 
The HEA and HPA Panel is a customised panel that was based on the Ion Ampliseq™ 
Custom Panel. The panel can be used to test 11 blood group systems (ABO, Rh, Kell, 
Kidd, Duffy, MNS, Diego, Dombrock, Colton, Yt, Vel) and HPAs 1-16 in a single 
assay (Halawani et al., 2014). In this study, 167 amplicons were amplified using two 
primer pools with ultra-high multiplex amplification. Primer digestion then took place 
and was followed by ligation of the barcoded adaptors. Unlike the other protocol of 
NGS, the advantages of this panel include the non-requirement for fragmentation step as 
well as the multiple purification steps. Therefore, this will make the panel the method of 
choice in the future for typing the blood group and HPAs.  
Moreover, this panel was based on NGS and it is a sequence-based typing which is able 
to detect the nucleotide sequence, in particular for the novel SNPs. Four novel SNPs 
were identified, one in the RHCE gene 208C>T (Arg70Trp) and three in the KEL gene. 
The first SNP was 331G>A (Ala111Thr) in exon 4. The second SNP was 1907C>T 
(Ala636Val) in exon 17 and the third SNP was 2165T>C (Leu722Pro) in exon 19. 
Unfortunately, due to poor electropherogram results the data of Sanger sequencing were 
non-conclusive.  
4.4.1 Genotyping by the HEA and HPA Panel  
The sequencing data obtained by the HEA and HPA Panel led to successful genotyping 
and the phenotypes were extrapolated easily. The Ion Reporter™ software facilitated the 
annotation of the sequencing data and accordingly the genotyping data were produced 
by the software. The prediction of the phenotypes was performed according to the 
Blood Group Antigen Factsbook (Reid et al., 2012). In this study, the ABO genotyping 
data successfully confirmed the serology information provided [Table 4.2] in 
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comparison to previous work by Fichou group where it was not possible to genotype for 
the ABO blood group system (Fichou et al., 2014).  
10 weak D samples were assessed by the HEA and HPA Panel. Nine samples were 
successfully genotyped [Table 4.3]. These were four samples of weak D Type 1 
(RHD*01W.01), four samples of weak D Type 2 (RHD*01W02) and one sample of 
DAR3.1 weak partial D 4.0 (RHD*DAR3.01). Interestingly, in the last sample no 
mutations were observed within any of the 10 exons of the RHD gene. This could be 
mistyped by serology as a weak D, while it is indeed an RhD-positive sample. On the 
other hand, it could be mistyped by NGS and due to the issue of unspecific primers no 
mutations were detected. However, the 10 exons need to be sequenced using Sanger 
sequencing to identify whether the sample is weak D or RhD-positive. Because of the 
time factor this sequencing was not performed.  
The alleles of the RHCE gene were successfully genotyped, especially the weak form 
that could not be identified by serology. The predicted antigens included partial e, V 
and VS antigens. The RHCE*C and RHCE*c alleles could not be identified correctly by 
the HEA and HPA Panel, apart from the SNP of 48C>G (Cys16Trp) in exon 1. The 
same outcome was obtained by Fichou and co-workers, in which they could not 
distinguish between the RHCE*C and RHCE*c alleles (Fichou et al., 2014).  
However, in our data a novel heterozygous SNP 208C>T (Arg70Trp) was detected in 
the RHCE gene. However, this SNP was misaligned to the RHD gene in an allelic 
imbalance ratio of 60:40 [Figure 4.13]. This issue was revealed using specific primers 
along with the LR-PCR approach followed by sequencing on the Ion PGM™ [see 
Chapter 6]. It was very obvious that the primer design for the HEA and HPA Panel did 
not take the gene homology into consideration. The same issue was found by Fichou et 
al. (2014) in which the primer design did not predict the typing of C, c, M and N 
antigens due to non-specific primers of their design.  
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The genotyping of the other blood group systems was properly achieved by the panel. 
The JK*01W.01 allele encoding the weak form (Jka+w) was easily identified in four 
samples. The low prevalence form of the alleles can possibly be detected by the panel, 
such as the YT*B and CO*B alleles. However, some of the attempts to investigate the 
GYPA*M allele failed and this may be due to the non-specific primers for the 
homologous genes of the MNS blood group system [Table 4.4].  
The HPAs were also included in the panel and they were assessed easily. All the 
genotyping results of the 16 HPAs are demonstrated in [Table 4.5]. Along the high 
clinically significant platelet alleles, HPA-1a was found in nine heterozygous and 19 
homozygous samples. The HPA-5b was detected in three samples in a heterozygous 
form.  
4.4.2 Missed regions in the designed panel  
One of the disadvantages of the HEA and HPA Panel was the issue of missed regions in 
the initial design by the Ampliseq™ Designer of non-covered targets. The missed areas 
in the initial design include 30 bp in the ABO gene, 45 bp in exon 18 in SLC4A1 of the 
Diego blood group system and 63 bp in exon 7 of the KEL gene. Fortunately, the missed 
regions of the Kell and Diego blood group systems did not belong to any predefined 
antigens, although it might be risky for any novel alleles that could be discovered in the 
future.  
Among the missed regions within the ABO blood group system, two missed regions 
were found in exon 7, which shows a high level of polymorphism. Such an issue was an 
obstacle to genotype the variants in the ABO blood group system, although the 
genotyping data was obtained. Fichou et al. (2014) designed a customised panel using 
the Ion Ampliseq™ Custom Panel and found that the missing regions were not amplified 
in the ABO gene although the initial design had full coverage of those areas. The 
authors stated that the consecutive stretches of homopolymers within numerous exons 
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and flanking introns were the reason for the complexity involved in amplifying the 
exons of the ABO gene (Yamamoto et al., 1990). However, in this study ABO 
genotyping was successfully performed, as listed in Table 4.2. 
4.4.3 Low depth of coverage  
One of the disadvantages of this study was that the depth of coverage in exon 8 of the 
RHD was very low which was around 16 repeated reads or fewer. In addition, the area 
of exon 8 of the RHD gene was poorly mapped [Figure 4.9]. This may affect the 
genotyping of RHD*DAU allele and make it unfeasible. The reason for this problem 
might be because of the unspecific primers and the mapping of the homologous genes 
RHD and RHCE.  
Regarding the MNS blood group system, some samples that observed the GYPA*M 
allele had a lower depth of coverage of around five sequencing reads. Furthermore, 
some samples observed missed regions between amino acid positions (23-31) [Figure 
4.10]. The only clear explanation for such an issue is the non-specificity of the primer 
design regarding homologous genes GYPA and GYPB.  
4.4.4 The issue of unspecific primers  
The missed regions and the poor mapping quality in the GYPA gene as well as the 
mistyping of the novel allele on the RHD gene instead of the RHCE gene are due to the 
unspecific primers provided by the Ion Ampliseq™ Designer. Fichou et al. (2014) 
designed a panel for blood group antigens based on the Ion Ampliseq™ Custom Panel to 
detect 15 blood group systems. The panel was for ABO, MNS, Rh, Lutheran, Kell, 
Duffy, Kidd, Diego, Yt, Scianna, Dombrock, Colton, Landsteiner-Wiener, Cromer and 
Knops. A similar issue with non-specific primers was found regarding homologous 
genes RHD, RHCE, GYPA and GYPB by Fichou and co-workers as an allelic 
imbalanced ratio of (80:20) instead of (50:50) for the heterozygous SNP.  
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To overcome this issue, Fichou et al. designed a set of specific primer pairs per sample 
for both exon 1 and exon 2 for RHD, RHCE, GYPA and GYPB. Stabentheiner et al. 
(2011) designed specific primers for the RHD gene and the amplification and ultimately 
the sequencing data were successfully obtained without any possible contamination to 
amplify the RHCE gene. By using our LR-PCR approach to amplify both RHD and 
RHCE genes, the sequencing data were aligned successfully for the gene of interest in 
consideration of masking the undesired gene [see Chapter 6]. The novel allele that was 
discovered in the RHCE gene by the HEA and HPA Panel was aligned incorrectly to the 
RHD gene. However, in consideration of using the specific primer of both genes in LR-
PCR approach, RHD and RHCE, the SNP was aligned properly to the RHCE gene.  
Weinzek-Lischka and co-workers designed a panel to genotype four HPAs and 10 
targets from the blood groups. The panel comprised HPA-1, HPA-3, HPA-5 and HPA-
15 alleles. The panel was mainly designed in order to avoid the risk of FNAIT in babies 
to HPA-1b/b mothers who developed anti-HPA-1a antibodies. Regarding the blood 
group antigens, the targets included exon 4 and 7 of the RHD gene and the SNP of the 
following antigens RHCE*C/c, RHCE*E/e, GYPA*M/N, GYPB*S/s, FY*A/FY*B, 
KEL*01/02, JK*A/B, FY*01N.01. To test the presence of foetal DNA, an internal 
control was used, including the SRY gene and eight anonymous SNPs from the Ion 
AmpliSeq™ Sample ID-Panel kit to prevent any false negative results. The authors 
stated that this method does not require paternal zygosity testing and provides non-
invasive prenatal testing for the HPAs and the blood groups (Wienzek-Lischka et al., 
2015). The advantage of the Ion Ampliseq™ Custom Panel is that it uses short 
amplicons ranging from 100 to 250 bp. However, the designed panel has limited 
numbers of SNPs which needs to be expanded to obtain more genotyping analysis, as 
the primer pool of Ampliseq only requires 10 ng of genomic DNA. Moreover, by using 
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a small number of SNPs the price of the NGS will be high and the benefit of the NGS 
will not be invested.  
4.4.5 Population screened  
Such a panel can be used as required by a laboratory and this gives the flexibility to 
determine the blood group antigens and the HPAs of interest. The choosing of this panel 
was similar to the Bloodgen project, which is more suitable for the European population 
(Avent, 2009). However, the Vel blood group system was added because of its clinical 
significance and the fact that it is encoded by SMIM1 gene which is 4187 bp. 
Furthermore, the custom panel can be adjusted to screen certain populations that need 
specific genotyping such as the Asian population. McBean et al. (2014) stated that 
different populations’ need for specific genotyping could vary because the ethnicity and 
the microarray platforms are not the right choice for the Australian population. The 
author stated that BeadChip™ was based in the United States and depends on African-
American ethnicity, while BLOODchip® was designed for the European population 
(McBean et al., 2014). 
4.4.6 Scalability of the number of samples  
The HEA and HPA Panel were based on NGS and can be used for sequencing on Ion 
PGM™ or Ion Proton™. Therefore, scalability can be managed according to the number 
of screened samples in consideration of using the barcoded adaptors. The size of the 
used panel in this project was 31.18 Kb. The number of samples can be scaled 
depending on the type of platform used and the type of chip used.  
Table 4.7 demonstrates the number of samples that can be analysed with the different 
chips with a depth of coverage of 100× on the Ion PGM™ platform, as well as the cost 
of the sequencing run. The size of the panel can be scaled depending on the sample 
number that needs to be screened. In other words, for a small number of donors, the Ion 
314™ chip Version 2 can be used to analyse 16 samples. For a large cohort, 160 samples 
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and 320 samples can be tested with the Ion 316™ Chip Version 2 and Ion 318™ Chip 
Version 2, respectively. The throughput can be increased to 3,207 samples if the Ion 
Proton™ platform using Ion PI™ Chip Version 2. However, there remains an issue of 
having a sufficient number of barcoded adaptors because there are still only 96 adaptors 
commercially available.  
This number of samples can be achieved with a 100× depth of coverage. This means the 
same target was sequenced at least a 100 times. There is an argument regarding which 
depth of coverage needs to be used. Bentley et al. (2008) published the first paper on 
sequencing the human genome using short read sequences with Illumina technology 
(Bentley et al., 2008). He stated that a coverage depth of 15× and 33× is suitable 
regarding accuracy, for homozygous and heterozygous SNPs, respectively. 
Consequently, these numbers of depth of coverage were applied on both HEA and HPA 
Panel and LR-PCR approach.  
WGS was performed for an Asian individual and obtained high accuracy sequencing 
reads with an average 36× depth of coverage (Wang et al., 2008). Ajay et al. (2011) 
concluded that using a depth of coverage of 50× sequencing reads is required for higher 
accuracy for WGS. Then, the author found that the same level of accuracy can be 
achieved by using a 35× depth of coverage when new software and new improved 
sequencing chemistry were used in order to reduce GC bias (Ajay et al., 2011). Thermo 
Fisher Scientific has released a new sequencing polymerase called Ion Hi-Q™ 
chemistry, which can be used for both Ion PGM™ and Ion Proton™. The improvements 
in this new sequencing chemistry include a development in variant detection and a 
reduction of false positives in indels for microbial de novo assembly (Thermo Fisher 
Scientific, 2015b).  
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                                                                                          Table 4.7 Number of samples can be performed on the HEA and HPA  
                                                                                          Panel using different chips with a depth of coverage of 100X on the Ion PGM. 
 
 
 
 
 
 
 
Chip type Capacity Number of samples Cost per run 
Ion 314™ 30-50 Mb 16 £271.55 
Ion 316™ 300-500 Mb 160 £444.80 
Ion 318™ 600 Mb – 1Gb 320 £619.67 
 141 
4.4.7 The cost of HEA and HPA  
The price per sample of the HEA and HPA Panel is around £118 for the sample 
preparation and the sequencing on the Ion PGM™ costs £3.22 per sample using the Ion 
318™ Chip. The price per SNP might be difficult to calculate. This is due to the 
sequencing which captures many targets within the gene and it is indeed a sequence-
based typing and requires an amplification process prior to the sequencing procedure. 
Therefore, many targets can be taken into consideration, including entire genes rather 
than a single SNP. In comparison, the BLOODchip® service mainly tests specific 
targets, mainly SNPs, for 10 blood group systems including ABO, Rh, Kell, Kidd, 
Duffy, MNS, Diego, Dombrock, Colton and Lutheran as well as the HPA1-11 and 
HPA-15. The cost is £150 per sample (Redfern, L., Personal Communication, 17th July 
2015). The price per sample for the HEA and HPA Panel is lower and the information 
received from the sequencing more comprehensive as it includes 11 blood group 
systems and the HPAs 1-16. Interestingly, the panel assay captures the entire exons of 
the blood group genes and targets the SNPs associated with HPAs.  
Overall, the HEA and HPA Panel provided a rapid protocol for genotyping of the blood 
group antigens and HPAs. The approach was based on deep sequencing using 
semiconductor technology. One of the advantages was that the scalability of the chip 
would provide high-throughput screening of many samples as long as the barcoded 
adaptors are used. Furthermore, this method of genotyping was able to identify novel 
alleles easily, as four alleles were identified in this study. Finally, the price per sample 
is extremely affordable in contrast to the microarray technology. Although some issues 
were faced in relation to the specificity of the primer sequences, the future of this assay 
will supplant the microarray technique and the conventional serology. This will assist to 
reduce the risk of alloimmunisation by screening many antigens, especially low 
prevalence ones. Therefore, this will help multiply transfused patients such as SCD 
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individuals. Moreover, using a combination of this assay to include HPA, the risk of 
MPR, PTP and FNAIT will be diminished. Interestingly, BGG using NGS technology 
will pave the way to genotype both the blood group antigens and the HPAs.  
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Chapter 5 : Genotyping the Kell Blood Group by Next-
generation Sequencing 
5.1 Introduction  
The Kell blood group system (ISBT 006) is a highly polymorphic blood group system 
[see section 1.6]. Most of the Kell blood group antigens have been associated with 
single nucleotide changes that give rise to amino acid substitutions, apart from KEL20, 
which require the presence of the Xk protein (Lee et al., 1997; Daniels, 2013a). 
Numerous genetic mechanisms may lead to the lack of all Kell antigens, which is 
designated as Knull (K0). These mechanisms include amino acid substitutions, premature 
stop codons, and a 5’ splicing-site mutation in exons and introns of the KEL gene (Lee 
et al., 2001). Different missense mutations result in the weak expression of Kell 
antigens, which is known as Kmod (Lee et al., 2003b).  
Anti-K is the most clinically significant antibody, which can cause HTR and HDFN. 
BGG paves the way to genotype the blood group antigens and to overcome 
conventional typing by serology (Avent et al., 2007). NGS is an emerging technique 
that enables to capture many targets in the genome and to sequence them repeatedly 
(Mardis, 2008).  
5.2 Aims 
The aim of this project was to investigate whether NGS is a suitable platform for 
genotyping the Kell blood group system. This design worked as a model for the Rh 
blood group genes to sequence the entire gene and to genotype its alleles using NGS in 
order to investigate the mutations within the gene. 
The entire KEL gene of the Kell blood group system was amplified by designing two 
primer pairs and was then sequenced by NGS using Ion PGM™. Using the LR-PCR 
approach assisted to obtain extensive genotyping of all the alleles of the Kell blood 
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group system, in particular the high prevalence ones. Intronic SNPs can be investigated, 
especially for those areas that might be accompanied by the alleles responsible for Knull 
and Kmod phenotypes due to giving rise to several molecular mechanisms including 
intronic polymorphisms. This approach was used as a model to assess whether such a 
procedure can be applicable to the Rh blood group system, which possesses two highly 
homologous genes.  
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5.3 Results 
5.3.1 Long range PCR for KEL gene  
Twenty samples with known serology were chosen for this experiment. Table 5.1 shows 
the serology information for the Kell blood group system. Two primer pairs, about 12 
Kb of each amplicon, were designed per sample to amplify the whole KEL gene [Figure 
5.1]. Figure 5.2 shows the PCR results of the KEL gene on 0.7% agarose gel, which 
runs on gel electrophoresis at 80V for 1 hour and 40 minutes.  
The PCR mastermix used was LongAmp Hot Start Taq 2X Master Mix (New England 
Biolabs, United Kingdom). This mastermix possesses a fidelity of two times in 
comparison to the standard Taq polymerase according to the manufacturer’s 
instructions. This polymerase has the capability to amplify up to 20 Kb from human and 
40 Kb from bacterial DNA.  
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            Table 5.1 Serology information for the 20 samples regarding the Kell phenotypes. 
No. Sample ID K k Kpa Kpb 
1 5686 −    
2 7268 −    
3 469X −    
4 3857 −    
5 9139 −    
6 736G −   + 
7 616Z −    
8 8387 −   + 
9 566L −    
10 799W −    
11 431S −    
12 004B −  − + 
13 227P +    
14 905N + +   
15 1516 −    
16 330C −    
17 619U −    
18 486Y −    
19 7496 −    
20 733M −    
            These samples were used in the amplification of the entire KEL gene and that had been 
             sequenced by NGS. 
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Figure 5.1 Two LR-PCR products covered the whole KEL gene. 
The KEL gene is approximately 21.3 Kb possessing 19 exons. Each PCR product is around 12 Kb with an overlap of 652 bp. The boxes show the exons 
(coding area), while the lines are the introns (non-coding area). The numbering of the exons is in reverse direction because the KEL gene is an anti-sense 
gene. The major antigens (K/k, Kpa/Kpb and Jsa/Jsb) are indicated in red.  
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Figure 5.2 Amplification of the entire KEL gene by two products of LR-PCR. 
Each sample had two products (A and B), about 12 Kb each. The PCR products were purified using 0.7% 
agarose which runs on gel electrophoresis at 80V for 1 hour and 40 minutes. The sample used in this example 
was identified by serology as kk antigen. The two samples of the Kk antigen had identical results. 
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5.3.2 Sequencing Libraries  
5.3.2.1 Fragmentation  
The sequencing libraries of the NGS were constructed following the purification of the 
amplicons. Then, the fragmentation was performed using the Ion Xpress™ Plus 
Fragment Library Kit. The shearing enzyme was utilised for 15 minutes. After the 
fragmentation had taken place, the purification was carried out using Agencourt® 
AMPure® XP reagent. The results were assessed using the high sensitivity DNA Kit 
which was run on Agilent® 2100 Bioanalyzer. A peak of fragmented DNA was 
achieved by the shearing enzyme and was around 50 to 500 bp. Figure 5.3 shows the 
fragmentation result for one of the KEL sequencing libraries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
 
 
 
 
 
Figure 5.3 An electropherogram of the fragmented KEL sequencing library (a pool of two KEL amplicons). 
The method was carried out using the Ion Xpress™ Plus Fragment Library Kit for 15 minutes. The assay was assessed using Agilent® 2100 
Bioanalyzer instrument. The green and purple numbers show the lower marker and upper marker in bp, respectively. 
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5.3.2.2 Ligation  
Figure 5.4 demonstrates the ligation result of one of the KEL sequencing libraries. The 
process of ligation was carried out using the Ion Xpress™ Plus Fragment Library Kit. 
Both adaptors, P1 and the barcode adaptor, were ligated using the ligase enzyme with 
the purified fragmented DNA.  
5.2.2.3 Size selection using SPRIselect magnetic beads  
Following the purified ligated products, the sequencing libraries underwent size 
selection. This procedure was performed using SPRIselect® magnetic beads. A peak of 
around 200 bp was achieved for the size selected sequencing libraries. This was in order 
to run it on a 200 bp reading length. Figure 5.5 demonstrates the size selection of one 
sample of the KEL sequencing libraries.  
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Figure 5.4 An electropherogram of the ligated products of the KEL sequencing library. 
The ligation was performed using the Ion Xpress™ Plus Fragment Library Kit. The assay was assessed by the Agilent® 
2100 Bioanalyzer instrument. The green and purple numbers show the lower marker and upper marker in bp, 
respectively. 
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 Figure 5.5 An electrophergram of the size selected KEL sequencing library. 
A peak of 200 bp was achieved for a 200 bp reading length. This procedure of size selection was performed using 
SPRIselect® magnetic beads. The assay was assessed by the Agilent® 2100 Bioanalyzer instrument. The green and 
purple numbers show the lower marker and upper marker in bp, respectively.  
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5.3.3 Analysis of NGS sequencing data  
Following the library construction for the KEL gene and sequencing them on the Ion 
PGM™, the sequencing data were generated in the first instance by Torrent Suite 
Version 4.4. Adaptors were trimmed by default by the Torrent Server software. The 
total reads for the 20 samples of the KEL gene were about 2.92 million reads with a 
mean coverage depth of around 840 sequencing reads. Figure 5.6 shows the sequencing 
report for the sequencing run on the Ion PGM™. The loading on Ion 316™ chip was 70% 
in which the wells of the chip were addressed by ISPs. This was in comparison to a 
percentage of 30% of the empty wells. The percentage of usable reads was 67% to be 
used for further downstream analysis. Two sets of software were used; the first was well 
classification and the other was responsible for filtering and trimming. The well 
classification considered the addressable wells in contrast to the empty wells and was 
reported as bead loading density. Regarding the filtering and trimming software, the 
filter removed the polyclonal reads with more than one template that attached to the 
beads, reads with low quality or less than 4 bp and a primer dimer of less than 8 bp.  
The percentage of the templates enriched with sequencing libraries was 100%. The 
clonal reads comprised 83%, while the percentage of polyclonal reads was 17%. The 
percentage of clonal templates demonstrates that the template had a single sequencing 
library attached to the ISP prior to starting the emulsion PCR. This is in comparison 
with the polyclonal templates, which had more than one sequencing library attached to 
the ISP. The final library was 79% and the mean and median of the read length were 
both 118 bp. 
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Figure 5.6 An overview of a report on the sequencing run of the KEL gene. 
(a) Loading density of ISP that was addressed by the chip wells, which was 70%.  
(b) Total of 2,926,424 reads after filtering and trimming. 
(c) A histogram of the read length of the sequencing libraries with a mean of 118 bp, on which the y-axis demonstrates 
the read count, while the x-axis shows the read length in the bp. 
 
(a) (b) (c) 
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5.3.4 Quality Control 
5.3.4.1 Per base sequence quality 
A plugin on the Torrent Suite called FastQC was run to assess the quality of the 
generated sequencing according to the Phred score. Figure 5.7 demonstrates the Phred 
score on the y-axis across the position in reads per base pair. In this study, the 
sequencing quality obtained a Phred score of around 29-30. Accordingly, this means 
accuracy of about 99.9% and the probability of the base being called incorrect was 1 in 
1000. This outcome enabled the user to carry out further analysis including the 
genotyping.  
The background of the graph splits the y-axis into three different regions with different 
colours; green for the best quality reads, orange for the reasonable reads and red for the 
poor quality reads. Box and Whisker plots were drawn on every position per base pair. 
The inter-quartile range (25-75%) was represented by yellow boxes. The upper and 
lower whiskers demonstrate 10% and 90% points.  
The blue line shows the mean Phred score across the reads in bp, while the central red 
line demonstrates the median. The mean for the sequencing results is around 29 on the 
Phred score, which gives accuracy more than 99%. The yellow boxes stopped after 
reaching the maximum range of the sequencing read length.  
5.3.4.2 Per Sequence Quality Scores  
Figure 5.8 demonstrates average quality using Phred score per reads. The FastQC tool 
was utilised to assess if a subset of the sequences has poor quality reads. The results 
here demonstrate that the quality of most of the reads was 30 according to the Phred 
score, which indicates high quality reads with an accuracy of 99.9%. This means the 
probability of the base called to be incorrect was 1 in 1000. 
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Figure 5.7 Phred quality scores across all the bases for a single sample of the KEL gene. 
The background of the y-axis demonstrates the Phred score, while the x-axis shows the position in reads per bp. The 
background of the graph splits the y-axis into three different regions with different colours; green for the best 
quality reads, orange for the reasonable reads and red for the poor quality reads. Box and Whisker plots were drawn 
on every position per bp. The inter-quartile range (25-75%) was represented by yellow boxes. The upper and lower 
whiskers demonstrate 10% and 90% points. The blue line represents the mean of the quality according to the Phred 
score across the reads in position. All the analysed sample has the same Phred scores.   
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Figure 5.8 Quality scores per sequencing count for a single sample of the KEL gene. 
The mean sequence quality according to the Phred score is demonstrated across the read counts. This tool assesses if a subset of 
the sequencing reads is of poor quality. The results here demonstrate that the quality of most of the reads was 30 according to the 
Phred score, which indicates high quality reads with an accuracy of 99.9%. This means the probability of the base called to be 
incorrect was 1 in 1000. All the analysed sample has the same Phred scores.    
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5.3.5 Sequencing visualisation 
The generated sequencing data were visualised using IGV Version 2.3.46. The IGV 
software aligns the sequencing data against a reference gene showing the chromosomal 
locations of nucleotides and assesses the genomic variations such as SNP changes 
including zygosity determination, insertion or deletions and the coverage depth of the 
sequencing. BAM files were utilised in order to visualise the sequencing data. Figure 
5.9 shows the heterozygous SNP for KEL*01.01/02 allele at a chromosomal position of 
chr7:142,655,008 with a coverage depth of 817. This confirmed the phenotyping by 
serology in which the sample types for both K and k phenotypes. The KEL gene is an 
anti-sense strand, therefore the SNP was shown as G>A instead of C>T at nucleotide 
position 578. Consequently, this missense mutation gives an amino acid substitution of 
Thr193Met.  
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Figure 5.9 A heterozygous SNP in the KEL gene for the KEL*01.01/02 genotype. 
This SNP was in chromosomal position chr7:142,655,008 with a coverage depth of 817. The KEL is an anti-sense strand, therefore the SNP was 
shown as G>A on the reference gene instead of 578C>T, which encoded an amino acid substitution to Thr193Met. Output from IGV software 
demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom. 
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5.3.6 Variant analysis 
The VariantCaller plugin in the Torrent Suite Software was used to annotate the SNPs 
against the reference gene and to produce the VCF files. Then, those files were 
uploaded for annotation using the SeattleSeq Annotation 141 website to annotate the 
SNPs (SeattleSeq Annotation Tool 141, 2014). Figure 5.10 illustrates the table that 
resulted from the website for the annotated SNP. 
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Figure 5.10 The genotyping results of the annotated SNP for the KEL*01.01/02 allele using SeattleSeq Annotation 141 website. 
The results show the chromosomal location of the SNP, the reference base, the sample alleles, the cDNA position, the type of mutation and the amino 
acid change. The reference nucleotide shown in this example was (G) and it was substituted by (A). This change in deed was C>T rather than G>A. 
This was because the KEL gene is an anti-sense strand, therefore the analysis was carried out on the sense strand by default. 
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5.3.7 Genotyping of the KEL 
Twenty samples with known serology were sequenced by the Ion PGM™ platform. Two 
of these samples were phenotyped by serology as K. The NGS data confirmed the 
serology for these two samples. A heterozygous SNP was detected at 578C>T in exon 6 
which gives rise to the amino acid substitution Thr193Met. An interesting finding was 
that the KEL*02.03 allele encoding the Kpa antigen was genotyped in a sample as 
841C>T in exon 8 (Arg281Trp) which was not identified by serology. Table 5.2 
demonstrates the main alleles of the Kell blood group system that were genotyped by 
NGS. One silent mutation was found in two samples A>C at 1680 in exon 15 with no 
change to the amino acid Pro560. The following high prevalence antigens k, Kpb, Jsb, 
KEL11, KEL12, KEL13, KEL14, KEL18, KEL19, KEL22, KEL26, KEL27, KEL29, 
KEL30, KEL32, KEL33, KEL34, KEL35, KEL36, KEL37 and KEL38 were predicted 
in all samples. Table 5.3 lists 57 Intronic SNPs and six new intronic SNPs were found 
in a number of samples.  
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               Table 5.2 Genotyping of the main alleles of the Kell blood group system by NGS. 
Allele Antigen Necletide Exon Amino acid Zygosity Allelic frequency (Caucasians) No. of Samples Serological matching 
KEL*01.01 K 578C>T 6 Thr193Met 
Heterozygous 54.3% 
Heterozygous 48% 
9.02% 2 Yes 
KEL*02.03 Kpa 841C>T 8 Arg281Trp Heterozygous 50% 2.28% 1 Not identified 
KEL*02.04 Kpb 
C at 841 
G at 842 
8 Arg281 Homozygous 100% 19 Yes 
 
 
 
 165 
 
Table 5.3 A list of intronic SNPs with the KEL gene. 
These SNPs were found in a number of samples. The rsID number is the number of the identified SNP 
 in the NCBI database. The non-applicable (N/A) were not yet included in the NCBI database.  
 
 
# rsID Zygosity Base change Intron position Distance to Splice Samples found 
1 N/A Heterozygous G>A 4 142657245 768 1 
2 N/A Heterozygous G>T 4 142656011 494 1 
3 8175963 Heterozygous G>A 4 142657775 238 2 
4 8175962 Heterozygous A>G 4 142657915 98 2 
5 8175972 Heterozygous A>G 4 142655717 200 1 
6 8175978 Heterozygous C>T 5 142655078 16 1 
7 8175977 Heterozygous G>A 5 142655097 35 1 
8 8175976 Heterozygous G>C 5 142655113 51 1 
9 N/A Heterozygous T>A 6 142652941 1325 1 
10 71545388 Heterozygous C>T 6 142654335 577 4 
11 7799481 Heterozygous C>T 6 142651868 252 3 
12 6954192 Heterozygous T>G 6 142652378 762 1 
13 6958998 Heterozygous A>G 6 142652850 1234 1 
14 8175984 Heterozygous G>A 6 142653478 1434 1 
15 8175985 Heterozygous T>C 6 142653424 1488 2 
16 N/A Heterozygous G>C 6 142653070 1454 1 
17 N/A Heterozygous G>A 6 142653514 1398 1 
18 3757853 
6 Heterozygous & 
6 Homozygous 
G>C 9 142650475 418 12 
19 8176003 Heterozygous G>A 10 142647564 2030 2 
20 145755643 Heterozygous A>G 10 142646888 2706 1 
21 8176063 Heterozygous G>A 10 142643870 464 5 
22 150938699 Heterozygous G>A 10 142649218 376 1 
23 8176061 Heterozygous T>C 10 142646386 2980 2 
24 79243129 Heterozygous C>T 10 142644474 1068 1 
25 11980340 Heterozygous G>A 10 142644521 1115 1 
26 8176008 Heterozygous A>G 10 142645944 2538 1 
27 73464414 Heterozygous A>G 10 142646081 2675 1 
28 8176006 Heterozygous T>C 10 142646995 2599 1 
29 8176005 Heterozygous G>A 10 142647428 2166 1 
30 7806742 Heterozygous G>A 10 142647720 1874 3 
31 6974425 Heterozygous A>G 10 142648273 1321 1 
32 8176001 Heterozygous T>C 10 142649292 302 1 
33 8175999 Heterozygous T>C 10 142649564 30 1 
34 10261078 Heterozygous G>A 10 142643676 270 2 
35 8176018 Heterozygous C>T 10 142643774 368 2 
36 8176012 Heterozygous C>A 10 142644900 1494 2 
37 8176010 Heterozygous G>A 10 142645614 2208 2 
38 N/A Heterozygous G>A 10 142649435 159 1 
39 7781817 Heterozygous A>G 11 142642940 352 1 
40 7780729 Heterozygous C>A 11 142642985 307 1 
41 7807823 Heterozygous A>G 11 142643099 193 3 
42 8176027 Heterozygous C>G 11 142641917 87 2 
43 8176026 Heterozygous T>C 11 142642098 268 2 
44 8176023 Heterozygous T>C 11 142642596 696 3 
45 7784417 Heterozygous C>T 11 142643092 200 2 
46 187074728 Heterozygous T>A 13 142641174 202 1 
47 8176031 Heterozygous T>C 13 142641382 26 3 
48 7810229 Heterozygous C>T 13 142641087 115 1 
49 7797896 Heterozygous A>G 13 142641189 217 2 
50 7797908 Heterozygous A>G 13 142641207 201 2 
51 187074728 Heterozygous C>T 13 142641174 202 1 
52 8176037 Heterozygous A>G 16 142640277 84 1 
53 8176044 
12 Heterozygous & 
3 Homozygous 
A>G 18 142639321 198 15 
54 N/A Heterozygous G>A 18 142639472 47 1 
55 143804816 Heterozygous G>C 18 142639446 73 1 
56 6949788 Heterozygous A>G 18 142638697 195 1 
57 7787760 Heterozygous A>G 18 142639155 364 3 
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5.3.8 Validation of the Kell Antigens 
Following the analysis of the NGS data, Sanger sequencing was carried out to validate 
the SNP of the KEL*01.01 allele encoding the K antigen. The primers used for this 
validation are shown in [section 2.5.6]. Figure 5.11 displays the validated SNP for the 
KEL*01.01 allele. The sample was heterozygous for that SNP (578 C>T) and 
considered to be a missense mutation, which gives an amino acid substitution, 
Thr193Met.  
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Heterozygous 578C>T 
Figure 5.11 Validation of the SNP for the KEL*01.01 allele encoding the K antigen. 
A heterozygous SNP (578 C>T) was confirmed using Sanger sequencing in order to validate the NGS data [see Figure 5.9]. The serology provided with this sample was 
typed for K and k antigens. The electropherogram was generated using MacVector Version 12.7. 
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5.4 Discussion  
5.4.1 Quality control of the NGS 
Quality control is the first step which should be taken to analyse any sequencing run 
from the high-throughput platforms. FastQC is a tool used to perform the test to 
evaluate if the sequencing possesses good or poor reads. It is available as standalone 
free software or as a plug-in with Torrent Suite software (Andrews, 2010).  
5.4.2 NGS data visualisation  
IGV software was used to visualise the sequencing reads against the reference gene of 
interest in order to facilitate the analysis. The software is free and easy to use and does 
not require any previous knowledge. It can be used for assessing the data to demonstrate 
the mutation with distinctive colours, to determine the zygosity as well as find out the 
count of the depth of coverage of the sequencing reads (Robinson et al., 2011). The 
challenging issue in this project was that the KEL gene is an anti-sense strand in 
comparison to the sequencing data and reference gene which are all assigned in the 
sense direction. This issue needs to be noticed, otherwise a false identification of new 
alleles will be possible.  
5.4.3 Genotyping of the Kell antigens 
Out of 20 samples, two samples were predefined by serology as K phenotype. The NGS 
results confirmed the serological data and genotyped both samples to have a 
heterozygous SNP C>T578 (Thr193Met) in exon 6. This antigen was reported to be 
involved in causing of HTR and HDFN by both haemolysis and suppression of 
erythropoiesis (Vaughan et al., 1998). The first sample of K phenotype did not observe 
any of the intronic SNPs, while the second one had three heterozygous SNPs. These 
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three intronic SNPs were in intron 9 G>C (chr7: 142650475), in intron 10 G>A (chr7: 
142647564) and in intron 18 A>G (chr7: 142639321).  
KEL*02.03 allele, encoding the Kpa antigen, was genotyped in a single sample as 
heterozygous SNP 841C>T (Arg281Trp) in exon 8. This antigen was not detected by 
standard serology. Although the Kpa antigen very rarely causes HDFN, it has the 
possibility to cause a severe type of HDFN that requires a blood transfusion 
(Costamagna et al., 1997). A case of hydrops fetalis was reported by Smoleniec et al. 
(1994) that was caused by anti-Kpa. The mother was typed by serology as RhD-positive 
and Kp(a−b+), while the father was typed as RhD-positive Kp(a+b+) which gave a 50% 
chance of the baby being heterozygous Kpa positive. The authors stressed that the low 
frequency antigens need to be serologically screened in a reference laboratory prior to a 
diagnosis of non-immune hydrops (Smoleniec et al., 1994). This shows the requirement 
for NGS platforms to involve as many antigens as possible. For example, the HEA and 
HPA Panel [see Chapter 4], which include 11 blood group systems and 16 HPAs.  
Furthermore, another case has been reported by Koshy et al. (2009) of a Caucasian 
woman suffering from delayed haemolytic transfusion reactions attributed to anti-Kpa 
after receiving multiple transfusion units. The DAT and the antibody screening were 
negative. One of the units was incompatible with antihuman globulin for Kpa 
phenotype. The authors suggested to include the crossmatch testing for all the 
transfusion units with consideration of which antigen should be included in the antibody 
screening cells (Koshy et al., 2009). It should be noted that the implication of BGG will 
get rid of such an issue caused by the standard serology.  
Another case of severe HDFN was reported by Rossi et al. (2013) which was caused by 
anti-Kpa. Rossi and co-workers recommended that extended phenotyping is required for 
low prevalence antigens in particular when a DAT is positive for the foetal or neonatal 
cells. They indicated that even if there is other etiology causing the foetal anaemia, a 
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DAT is recommended before intrauterine transfusion (Rossi et al., 2013). Furthermore, 
an interesting case was reported by Tuson et al. (2011) of a mother pregnant with twins 
and her serum contained anti-Kpa. The first child was anemic whose phenotyped (Kpa+) 
and the other twin (Kpa−) was not (Tuson et al., 2011). The constant decrease in 
bilirubin levels was coincident with the falling of the hemoglobin level in addition to a 
decrease in absolute reticulocyte count. These laboratory outcomes and clinical course 
of the affected twin were consistent with the suppression of erythropoiesis as well as 
immune RBCs destruction. Although anti-K is the antigen that is associated with 
erythropoiesis suppression, this case may confirm that the other antigens of the Kell 
blood group system can be involved in addition to K antigen (Tuson et al., 2011). The 
results may approve the interpretation of the Kell antigens that suppress the 
erythropoiesis due to the early representation of its protein in the red blood cells 
(Southcott et al., 1999; Daniels and Green, 2000). Consequently, the absence of 
hyperbilirubinemia in the patient stressed that the erythroid progenitor cells do not 
contain haemoglobin in the early phase of erythropoiesis (Tuson et al., 2011).  
5.4.4 Genotyping of the KEL  
The issue of having a test to detect the low prevalence antigens can be overcome by 
high-throughput sequencing. To our knowledge this is the first work that has utilised 
LR-PCR to amplify the entire KEL gene. The method helps to examine the KEL gene in 
high resolution by deep sequencing. This technique provides comprehensive genotyping 
for all the SNPs which can be found within the gene, and in particular the high 
prevalence antigens. In addition, all intronic SNPs can be examined, which will aid the 
detection of all the polymorphic mechanisms in rare cases that are associated with Kmod 
and Knull. The benefits of the intronic SNPs also include identification the area should 
be avoided when designing the primer and preventing any allelic dropout. The 
advantages of this approach can be invested in typing the low prevalence and rare Kell 
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antigens, which can be found in different ethnic backgrounds and used by different 
laboratories. Overall, it will facilitate the discovery of new alleles of the Kell system. 
This is due to its principle of genotyping by sequencing in comparison with the other 
limited molecular techniques such as microarray platforms, which requires previous 
knowledge of the alleles (Hurd and Nelson, 2009).  
Rieneck and co-workers (2013) used NGS to genotyping the KEL*01.01/02 encoding 
K/k phenotypes to predict the foetal phenotype. The method is based on the primer 
fusion to the barcoded adaptors to distinguish between the different samples and to 
amplify the PCR products. The products were run on agarose gel electrophoresis to 
assess the required size and a further restriction enzyme experiment was implemented 
that used BsmI to digest the K product (Rieneck et al., 2013). After that, the samples 
were sequenced on Illumina GAIIx which is no longer available. The drawback of this 
procedure was in observation of unexpected base calls, less than 3000 unpredicted base 
calls along the primer sequences and approximately 20000 in a number of positions.  
This outcome can lead to obtaining false-positive or false-negative results for the 
genotyping although the genotyping for KEL*01.01 was precise. In the LR-PCR study, 
no such issue was reported.  
The advantage of using NGS to screen many individuals in a single assay is due to the 
high capacity of the chip [see Table 5.4]. Furthermore, the sequencing chip can be 
scaled depending on the number of individuals required. On the other hand, the big 
target in our case to amplify the entire gene will reduce the number of individuals on the 
sequencing run. Such an issue can be resolved by the scalability of the chip in case the 
sequencing is run on Ion Torrent™ platforms.  
The run cost for the prenatal analysis of the K/k experiment by Rieneck and co-workers 
(2013) was around $1500 (£971). On the other hand, the cost of the sequencing run on 
the Ion PGM™ on the medium size chip, Ion 316™ Chip, costs around £444.80. This 
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enormous difference in price allows the Ion PGM™ platform to do more sequencing 
runs because it is more affordable in comparison to the Illumina GAIIx.  
The cost per sample preparation and library construction to test the entire KEL is 
approximately £48. This cost involved the two reactions of PCR per sample, the library 
construction using the Ion Xpress™ Fragment Kit including the barcoded adaptor and 
two runs of the assessment of the constructed library on the Bioanalyzer using the high 
sensitivity DNA kit.  
The capacity of the Ion chips varies according to the scalability. Table 5.4 demonstrates 
the three Ion chips, the number of samples that can be obtained by a chip as well as the 
sequencing cost of each chip. By using a depth of coverage of 100×, 20 samples of 
sequencing for the entire KEL gene can be sequenced on Ion 314™ Chip. In order to 
increase the number of samples, 204 and 408 samples can be scaled and sequenced 
using Ion 316™ Chip and Ion 318™ Chip, respectively. 
The cost of the run ranges from around £271.55 to £619.67 depending on the chip used. 
The sequencing cost is around £2.12 per sample. NGS using the Ion Torrent PGM™ 
offers scalability to examine as many individuals as is necessary. The cost of the 
sequencing run included the template preparation using the Ion OneTouch™ 2 system as 
well as the sequencing cost of the Ion PGM™ platform.  
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                                                                                        Table 5.4 Number of NGS samples can be achieved for KEL gene 
                                                                                        using different chips. 
Chip type Capacity Number of samples Cost per run 
Ion 314™ 30-50 Mb 20 £271.55 
Ion 316™ 300 Mb-500 Mb 204 £444.80 
Ion 318™ 600 Mb – 1Gb 408 £619.67 
 
 
 
 
 
 
A list of the three types of Ion chip, their capacities and the number of 
samples can be obtained with a depth of coverage of 100× in addition 
to the cost of the sequencing run. 
 174 
 
In summary, NGS using the approach of LR-PCR was capable of genotyping all the 
Kell blood group alleles among all the exons of the KEL gene, especially the high 
prevalence ones. Therefore, any low prevalence alleles of the Kell blood group system 
can be detected with this technique. Moreover, the intronic polymorphisms are easy to 
investigate and any possible mutations that may be associated with Knull or Kmod alleles 
can be detected. The finding of the heterozygous SNP for the KEL*02.03 allele 
encoding Kpa phenotype showed the power of this approach in overcoming the standard 
phenotyping by serology. Proof of principle of the LR-PCR approach for Kell blood 
group genotyping makes the application of this technique more feasible in complicated 
blood groups such as the Rh blood group system, which will be discussed in the next 
chapter.  
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Chapter 6 : Genotyping the Rh Blood Group by Next-
generation Sequencing  
6.1 Introduction 
The Rh blood group system is the most complex blood group due to the high number of 
polymorphisms. These polymorphisms are in fact because this system is encoded by 
two highly homologous genes, RHD and RHCE, which share of identity 92% (Cartron, 
1994). There are different mechanisms involved in the expression of the Rh antigens. 
For example, the presence of the entire RHD gene gives rise to the RhD-positive 
phenotype. On the other hand, in Caucasians, the deletion of the whole RHD gene leads 
to the RhD-negative phenotype (Avent et al., 2006). Genetic mechanisms such as point 
mutation, gene conversion and gene rearrangement leads to weak D and partial D, 
hybrid genes and RHCE variants including CX and CW antigens (Avent et al., 2006). 
Such variants lead to alloimmunisation in patients with SCD [see section 1.5 for further 
detail].  
BGG has aided in recent years to provide more compatible blood units in comparison to 
the conventional serology. There are numerous techniques have been developed 
following the cloning of most the blood group genes. SSP-PCR is a simple technique 
and is robust, but in some ambiguous cases it is not sufficient to type the variants and 
requires sequencing (Prager, 2007). Therefore, the sequencing-based typing may be the 
optimal solution to genotype the Rh blood group system. Array-based methods have 
been developed to facilitate the genotyping work for both donors and patients (Hashmi 
et al., 2005; Avent et al., 2007). The obstacles of these array-based platforms are that 
they cannot identify new alleles and they need to be updated for the newly discovered 
alleles (Avent et al., 2015).   
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6.2 Aims 
Here, the Rh blood group genes were entirely amplified and sequenced in high 
resolution on the Ion PGM™ platform. In the first instance, the KEL gene worked as a 
model and was amplified by two products and was fully sequenced on Ion PGM™ [see 
Chapter 5]. Such an approach gave a high resolution to genotype all the Kell antigens in 
addition to the high prevalence ones [see Chapter 5]. The same approach was applied to 
the RHD and RHCE genes in order to resolve the complicated variants of the Rh blood 
group system. Furthermore, NGS with LR-PCR is able to identify new alleles and 
works in ‘a discovery mode’ in contrast to array-based technology (Avent et al., 2015).  
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6.3 Results 
6.3.1 Long range PCR for Rh genes  
10 samples were chosen for this experiment according to serology typing, five RhD-
positive samples and five weak D samples. Table 6.1 shows the Rh status of these 
samples by conventional serology. A total of seven primer pairs were used to amplify 
the entire genes of the Rh blood group system which ranged from 11,215 bp to 24,387 
bp. Three primer pairs were used for the RHD gene and four for the RHCE gene. The 
primer pairs are listed in Table 2.3 and Table 2.4. Figure 6.1 illustrates a schematic 
diagram for the primer pairs used to amplify both genes. LR-PCR was performed using 
PrimeSTAR GXL Polymerase (Takara, Japan) as explained in [section 2.5.2.3]. Figure 
6.2 shows the results of the PCR products for the Rh blood group system run on 0.5% 
agarose gel electrophoresis. The figure demonstrates the negative control for the RHD 
gene, which was RhD-negative sample and shows no bands [Figure 6.2 a]. The three 
bands to amplify the entire of the RHD gene are shown in [Figure 6.2 b]. The products 
of the RHCE gene are displayed in [Figure 6.2 c].   
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                        Table 6.1 Serology information provided by NHSBT Filton for the Rh status. 
# D status Rh D C E c e Cw Defined zygosity§ 
1 D+ R0r + − − + + − Hemizygous 
2 D+ R1R1 + + − − + − Homozygous 
3 D+ R1R1 + + − − + − Homozygous 
4 D+ R2R2 + − + + − − Homozygous 
5 D+ R2R2 + − + + − − Homozygous 
6 Weak D R0r + − − + + − Hemizygous 
7 Weak D R1R2* + + + + + − Hemizygous 
8 Weak D R2r + − + + + − Hemizygous 
9 Weak D R1R2* + + − + + − Hemizygous 
10 Weak D R1r + + − + + − Hemizygous 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ = The defined zygosity for these samples were performed by Ms. Kelly Sillence. Samples 7 and 9 were typed as weak D by serology and it is known 
that weak D samples have only one copy of the RHD gene. The zygosity testing confirmed that samples 7 and 9 have a single copy of the RHD gene.  
The phenotype of sample 7 and 9 may be R2r’, R1r’’, Rzr or R0ry.  
* Weak D samples should never be described as RHD homozygous as they are by definition hemizygous, unless in very rare instances two variants 
RHD alleles are co-inherited.  
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Figure 6.1 Seven LR-PCR products covered the entire of the RHD and RHCE genes. 
The boxes show the exons (coding areas) of the genes, in which each gene has 10 exons, while the lines attached to the boxes are the introns  
(non-coding areas). TMEM50A is a gene flanked by the RHD and RHCE genes. It was previously called SMP1.  
URB= upstream rhesus box. 
DRB= downstream rhesus box.  
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Figure 6.2 LR-PCR products for the Rh blood group system.  
(a) The negative control for the RHD gene, which is the RhD-negative sample shows no bands in the three lanes 1, 2 and 3. 
(b) Three long-range amplicons (1, 2, and 3) were designed to amplify the entire of the RHD gene. The figure shows three products were amplified from the 
RhD-positive samples in which each product was about 22 Kb.  
(c) Four long-range amplicons (1, 2, 3, and 4) were amplified the entire RHCE gene from a single sample. The products range as following; 1= 19 Kb,  
2= 11.2 Kb, 3= 17.8 Kb and 4= 24.3 Kb.  
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6.3.2 Sequencing Libraries  
6.3.2.1 Fragmentation  
Following the purification of the seven LR-PCR products of the Rh blood group system 
[section 2.5.2.4], the products of each gene were pooled separately from the other gene. 
In other words, the three products of the RHD gene were pooled in a single tube and the 
four products of the RHCE gene were pooled in another one [section 2.5.2.5].  Then, the 
sequencing libraries were constructed using the Ion Xpress™ Plus Fragment Library Kit. 
The shearing enzyme was used for 15 minutes regarding the 200 bp sequencing reading 
length on the Ion PGM™ [section 2.5.2.6].  
Following the fragmentation procedure, the purification was performed utilising the 
Agencourt® AMPure® XP reagent. The high sensitivity DNA Kit was used in order to 
evaluate the fragmented DNA which was run on the Agilent® 2100 Bioanalyzer [section 
2.5.2.7]. Figure 6.3 and Figure 6.4 demonstrate the results of the fragmented DNA for 
the RHD and RHCE genes, respectively.  
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 Figure 6.3 An electropherogram of the fragmented RHD LR-PCR products. 
These fragments range (82-511 bp) using the Ion Xpress™ Plus Fragment Library Kit. The shearing enzyme of the kit was used for 15 minutes. The 
assay was assessed using the high sensitivity DNA Kit which was run on the Agilent® 2100 Bioanalyzer instrument. The green and purple numbers 
show the lower and upper markers in bp, respectively.  
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Figure 6.4 An electropherogram of the fragmented RHCE LR-PCR products. 
The fragments range (50-522 bp) using the Ion Xpress™ Plus Fragment Library Kit. The shearing enzyme of the kit was used for 15 minutes. 
The assay was assessed using the high sensitivity DNA Kit which was run on the Agilent® 2100 Bioanalyzer instrument. The green and purple 
numbers show the lower and upper markers in bp, respectively.  
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6.3.2.2 Ligation  
Following the purification of the fragmented DNA of both genes, the products were 
ligated to P1 and barcoded adaptors as discussed in [section 2.5.2.8]. After that, the 
ligated products were purified using the Agencourt® AMPure® XP reagent. Figure 6.5 
and Figure 6.6 demonstrate the assessment runs on the Agilent® 2100 Bioanalyzer 
instrument of the purified ligated products for both the RHD and RHCE genes using the 
high sensitivity DNA Kit. 
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Figure 6.5 An electropherogram of the ligation of the RHD sequencing library 
A peak of approximately 208 bp can be seen in this figure. The ligation was performed using the Ion Xpress™ Plus Fragment Library Kit. The assay 
was assessed using the high sensitivity DNA Kit that runs on the Agilent® 2100 Bioanalyzer instrument. The green and purple numbers show the 
lower marker and upper marker in bp, respectively. 
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Figure 6.6 An electropherogram of the ligation of the RHCE sequencing library.  
A peak of approximately 207 bp can be seen in this figure. The ligation was performed using the Ion Xpress™ Plus Fragment Library Kit. The assay 
was assessed using the high sensitivity DNA Kit that runs on the Agilent® 2100 Bioanalyzer instrument. The green and purple numbers show the 
lower marker and upper marker in bp, respectively.  
  
 187 
6.3.2.3 Size selection using SPRIselect® magnetic beads  
The size selection of the sequencing libraries was carried out for both the RHD and 
RHCE genes using SPRIselect® beads [section 2.5.2.8]. Figure 6.7 and Figure 6.8 show 
the results of the size selection for RHD and RHCE samples, respectively. The targets of 
the size selection ranged from 100 to 300 bp regarding 200 bp sequencing read lengths.  
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Figure 6.7 An electropherogram of the size-selected RHD sequencing library. 
A peak of 207 bp was achieved for a 200 bp reading length. This procedure of size selection was carried out using SPRIselect® magnetic beads. The 
assay was assessed using the high sensitivity DNA Kit that runs on the Agilent® 2100 Bioanalyzer instrument. The green and purple numbers show 
the lower marker and upper marker in bp, respectively.  
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Figure 6.8 An electropherogram of the size-selected RHCE sequencing library. 
A peak of 201 bp was achieved for a 200 bp reading length. This procedure of size selection was performed using SPRIselect® magnetic beads. The 
assay was assessed using the high sensitivity DNA Kit that runs on the Agilent® 2100 Bioanalyzer instrument. The green and purple numbers show the 
lower marker and upper marker in bp, respectively. 
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6.3.3 Analysis of NGS sequencing data  
Ten samples in total were sequenced for both the RHD and RHCE genes in a single 
sequencing run on the Ion PGM™. Figure 6.9 demonstrates a summary of the 
sequencing report. The loading density was 88% in which the ISPs was addressed by 
the chip wells in comparison to 12% of the empty wells. The total reads were 3,635,959, 
of which the usable reads were 65%. The enrichment of the clonal templates was 
successfully achieved a high percentage of 100%. The clonal amplification achieved 
69% in comparison to polyclonal amplification, which was 31%. The percentage of the 
final library was 95% of which 5% was a low quality library. Finally, the median of the 
read length was 112 bp [Figure 6.9]. 
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Figure 6.9 An overview of a report on the sequencing run of the genes of the Rh blood group system. 
(a) The loading density of the ISP that was addressed by the chip wells was 88%.  
(b) Total of 3,635,959 reads after filtering and trimming.  
(c) A histogram of the read length of the sequencing libraries with a median of 112 bp, in which the y-axis demonstrates the read count, while 
the x-axis shows the read length in the base pair. 
(a) (b) (c) 
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6.3.4 Quality Control 
6.3.4.1 Per base sequence quality 
The quality control of the generated sequences of the RHD and RHCE genes was 
assessed using FastQC software. Figure 6.10 shows the Phred score across the RHD 
sequences position in bp.  The quality of RHD sequencing started at a Phred score of 32 
and decreased gradually until it reached 24 at the end of the sequencing.  
Regarding the RHCE gene, the Phred score of the quality started at a score of 32 and 
then decreased gradually to reach a score of 22 by the end of the sequencing. Figure 
6.11 demonstrates the Phred score across the sequences of RHCE in bp.  
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Figure 6.10 Phred quality scores across all the bases for a single sample of the RHD gene.  
The x-axis represents the position of the reads in the bp, while the y-axis represents the Phred score of quality. The 
background of the y-axis is divided into three colour areas: green for the best reads, orange for the reasonable reads and red 
for the low quality reads. Box and Whisker plots were drawn on every position per bp. The inter-quartile range (25-75%) was 
represented by yellow boxes. The upper and lower whiskers demonstrate 10% and 90% points. The blue line shows the mean 
of the Phred quality score across the sequencing reads in the bp starting at a high quality of 32 and it was decreased gradually 
until it reached a score of around 24. The central red line demonstrates the median of the quality score. All the analysed 
samples had the same Phred score. 
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Figure 6.11 Phred quality scores across all the bases for a single sample of the RHCE gene.  
The x-axis represents the position of the reads in the bp, while the y-axis represents the Phred score of quality. The background of 
the y-axis is divided into three colour areas: green for the best reads, orange for the reasonable reads and red for the low quality 
reads. Box and Whisker plots were drawn on every position per bp. The inter-quartile range (25-75%) was represented by yellow 
boxes. The upper and lower whiskers demonstrate 10% and 90% points. The blue line shows the mean of the Phred quality score 
across the sequencing reads in the bp starting at a high quality of 32 and it was decreased gradually until it reached a score of 
around 22. The central red line demonstrates the median of the quality score. All the analysed samples had the same Phred score.  
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6.3.4.2 Per Sequence Quality Scores  
Another tool within the FastQC software called per sequence quality scores was used to 
analyse whether a subset of one of the sequencing reads represents poor quality reads. 
Figure 6.12 and Figure 6.13 illustrate the mean of the Phred quality sequence per reads 
across the count of the reads for the RHD and RHCE genes, respectively. The results of 
both the RHD and RHCE genes show that the quality of most reads was 30 according to 
the Phred score. Therefore, this indicates high quality reads were achieved with an 
accuracy of 99.9%. 
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Figure 6.12 Quality scores per sequencing count for a single sample of the RHD 
gene. 
The figure illustrates the mean sequence quality according to the Phred score across the 
read counts. It was used to assess if a subset of the sequencing reads is of poor quality. 
The results show that the quality of most reads was 30 according to the Phred score, 
which indicates high quality reads with an accuracy of 99.9%. All the analysed samples 
had the same quality scores. 
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Figure 6.13 Quality scores per sequencing count for a single sample of the RHCE 
gene.  
The figure shows the mean sequence quality according to the Phred score across the read 
counts. It was used to assess if a subset of the sequencing reads is of poor quality. The 
results show the quality of most reads was 30 according to the Phred score, which 
indicates high quality reads with an accuracy of 99.9%. All the analysed samples had the 
same quality scores. 
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6.3.5 Sequencing visualisation 
Due to the extremely high homology between the RHD and RHCE genes, when the 
NGS data were visualised and analysed for one gene, the other needed to be masked. 
This procedure was kindly performed by Dr. Xinzhong Li at Plymouth University using 
maskfasta utility from the bedtools website as explained in [section 2.5.5.1] (Bedtools, 
2015).  
IGV software was utilised to visualise the sequencing data of the RHD and RHCE 
genes. The reference of the human genome (hg19) was used to analyse the sequencing 
data. The software was used to assess the whole coverage of both genes, missed regions 
if found, visualisation of the variants, the depth of coverage of the sequencing data and 
the zygosity of the SNP.  
Figure 6.14 demonstrates an overview image for the entire RHD gene. An extremely 
low depth of coverage in exon 1 and intron 1 can be seen as well as some missed 
regions. The depth of coverage for those regions ranged between one to seven 
sequencing reads. In the remaining areas of the gene the depth of coverage varied from 
around 16 to 35 sequencing reads.  
Regarding the RHCE gene, the area between exon 1 and exon 3 expressed a very low 
depth of coverage of around 8-10 sequencing reads as well as some missed regions in 
the areas. Figure 6.15 shows a screenshot of the IGV software for sequencing reads for 
the regions that covered exon 1, intron 1, exon 2 and intron 2 of the RHCE gene.  
The regions that covered exon 3 and exon 4 show full coverage with no missed regions 
and high depth of coverage. The sequencing reads for those areas ranged from around 
130 to 191. Figure 6.16 demonstrates a screenshot of the IGV software for the regions 
of exon 3 and exon 4 of the RHCE gene.  
The depth of coverage became low again after exon 4 of the RHCE gene. Around 4-21 
sequencing reads were obtained in the regions that covered exon 5 to exon 7. The depth 
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of coverage was decreased again to around four to eight sequencing reads in exons 8-10. 
Figure 6.17 illustrates the low depth of coverage from the regions that covered from 
exon 5 to exon 10 in the RHCE gene. 
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Figure 6.14 An overview image of the coverage by sequencing for the entire RHD gene.  
The ten exons of the RHD gene are shown in number. There is a very low depth of coverage in exon 1 and intron 1, which was 
amplified by the first amplicon. This sample is the RhD-positive (R2R2) phenotype. Schematic diagram for the amplicons that covered 
both RHD and RHCE genes is demonstrated in Figure 6.1. Output from IGV software demonstrates the visualisation of the sequencing 
data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom.  
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 Figure 6.15 Regions with low depth of coverage for the first amplicon of the RHCE gene.  
The covered area include (exon 1, intron 1, exon 2 and intron 2). The sequencing reads express a very low depth of coverage of 
around 8-10 sequencing reads as well as some missed regions in that area. This sample is a weak D sample with R1r phenotype. 
Schematic diagram for the amplicons that covered both RHD and RHCE genes is demonstrated in Figure 6.1. Output from IGV 
software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and the reference 
gene in blue at the bottom.  
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Figure 6.16 High depth of coverage for the regions that covered exon 3 and exon 4 of the RHCE region by the second 
amplicon.  
This sample is a weak D sample with R1r phenotype. Schematic diagram for the amplicons that covered both RHD and RHCE 
genes is demonstrated in Figure 6.1. Output from IGV software demonstrates the visualisation of the sequencing data. 
Chromosomal locations are shown on the top and the reference gene in blue at the bottom.  
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Figure 6.17 Very low depth of coverage in the RHCE gene in the regions between exon 5 and exon 10.  
These regions were amplified by the third and fourth amplicons. This sample is a weak D sample with R1r phenotype. Schematic diagram for the 
amplicons that covered both RHD and RHCE genes is demonstrated in Figure 6.1. Output from IGV software demonstrates the visualisation of the 
sequencing data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom.  
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6.3.5.1 Obstacles of the visualisation  
RhD-positive samples should observe no mutations in any of the exons of the RHD 
gene. Interestingly, all the samples were found to have the mutation of RHD*DAU 
allele in exon 8 1136C>T (Thr379Met). In fact, the reference gene used by the IGV 
software was the transcript variant 2 [NCI Reference Sequence: NM_001127691]. This 
reference gene shows the 1136C>T (Thr379Met) instead of 1136T>C (Met397Thr). 
Figure 6.17 shows the misalignment of the RHD*DAU mutation in exon 8 of the RHD 
gene due to the different reference allele used by the IGV software. Therefore, all the 
RhD-positive samples did not observe any mutation in any of the exons of the RHD 
gene.  
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Figure 6.18 A misalignment in data visualisation of exon 8 of the RHD gene due to the different reference allele used by the IGV software.  
The reference gene used by the IGV software was the transcript variant 2 in the human genome (hg19) [NCI Reference Sequence: NM_001127691]. 
This reference gene shows the 1136C>T (Thr379Met) which is the RHD*DAU allele instead of 1136T>C (Met397Thr). This sample is the R1R2 
phenotype. Output from IGV software demonstrates the visualisation of the sequencing data. Chromosomal locations are shown on the top and the 
reference gene in blue at the bottom. 
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6.3.6 Variant analysis 
VCF files were produced to annotate the sequencing data against the reference gene 
using the VariantCaller plugin in the Torrent Suite Software. Then, the VCF files were 
uploaded for annotation using the SeattleSeq Annotation 141 website (SeattleSeq 
Annotation Tool 141, 2014). The results of the genotyping are presented in the next 
section.   
6.3.7 Genotyping of the Rh blood group system  
6.3.7.1 Genotyping of the RHD gene 
Ten samples were fully sequenced on the Ion PGM™ following amplification by LR-
PCR. Five samples were typed by serology as RhD-positive samples, while the other 
five were typed as weak D samples. Regarding the RhD-positive samples, there were no 
mutations detected in any of the 10 exons of the RHD gene.  
With respect to the weak D samples, two samples were observed to be weak D type 1 
(RHD*01W.01) 809T>G Val270Gly. Furthermore, two samples were detected to be 
weak D type 2 (RHD*01W.02) 1154G>C at exon 9 (Gly385Ala). Figure 6.19 shows the 
SNP of the weak D type 2 on the IGV software. The last sample was shown to be 
DAR3.1 weak partial D 4.0 (RHD*DAR3.01). The last sample had three altered 
nucleotides: 602C>G (Thr201Arg) in exon 4, 667T>G (Phe223Val) in exon 5 and 
819G>A (silent) in exon 6. Table 6.2 lists the genotyping results of the weak D samples 
found by NGS.  
Sixty-four intronic SNPs in the 10 samples were found in the RHD gene. The 
hemizygous SNPs were associated with weak D samples. On the other hand, 
homozygous and heterozygous SNPs were found in the RhD-positive samples. Table 
6.3 demonstrates the intronic SNPs found in the RHD gene with different phenotypes.  
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6.3.7.2 Genotyping of the RHCE gene  
Table 6.4 lists the genotyping results of the RHCE gene. The reference gene used in the 
human genome assembly (hg19) is RHCE*ce allele. The alleles of RHCE*c and 
RHCE*e matched the reference gene while the variants of the other alleles, RHCE*C 
and RHCE*E, were called. Two samples of R1R1 were found to be homozygous for 
307C>T (Pro103Ser) in exon 2 of the RHCE gene. This confirmed the serology and was 
genotyped as RHCE*C allele. The samples were predefined by serology as R2R2 and 
were found to be homozygous for the RHCE*E allele and had a homozygous SNP 
676G>C (Ala226Pro) in exon 5 of the RHCE gene. Two samples of R1R2 were 
identified by conventional serology. The first sample was found to be heterozygous for 
307C>T (Pro103Ser) in exon 2 and had a heterozygous SNP for 676G>C (Ala226Pro). 
The second sample had three SNPs for the RHCE*C allele. These include 178C>A 
(Leu60Ile), 203A>G (Asn68Ser) and 307C>T (Pro103Ser) and all were in exon 2 of the 
RHCE gene. In addition, it was found to have a heterozygous SNP for 676G>C 
(Ala226Pro). 
Regarding the R0r sample, it had four heterozygous SNPs. The first SNP was in exon 1 
48G>C (Trp16Cys). The second SNP was a heterozygous 733C>G (Leu245Val) in 
exon 5. The third SNP was a heterozygous 1025C>T (Thr342Ile) in exon 7. The 
outcome of the three SNPs gives RHCE*ceVS.04 allele, which encodes partial e V+ 
VS+ antigens. The fourth SNP was in exon 5 as heterozygous 744T>C and was found to 
be a silent mutation. 
The R1r sample was identified by serology. It shows the three heterozygous SNPs of the 
RHCE*C allele 178C>A (Leu60Ile), 203A>G (Asn68Ser) and 307C>T (Pro103Ser) and 
all were in exon 2 of the RHCE gene. In addition, there was a silent mutation found 
201A>G (Serine at amino acid 67) in exon 2. Furthermore, the novel allele that was 
identified by the HEA and HPA Panel [Chapter 4] was found and aligned properly to 
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the RHCE gene instead of the RHD gene. The SNP is in exon 2 of the RHCE and it was 
heterozygous 208C>T (Arg70Trp). Figure 6.20 shows all five SNPs found in the R1r 
sample.  
A sample was typed by serology as R0r and due to the low depth of coverage of two 
sequencing reads, only RHCE*e could be identified by the NGS by matching the 
nucleotide of the reference gene. Figure 6.21 demonstrates the low depth of coverage of 
this sample with two sequencing reads around amino acid position 226. The last sample 
was identified by serology as R2r and has been confirmed by NGS by finding the 
heterozygous SNP 676G>S (Ala226Pro) in exon 5. Due to the low depth of coverage, 
not all the intronic SNPs of the RHCE gene could not be identified. Introns 3-6 with 
high depth of coverage were identified [Table 6.5].  
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Figure 6.19 A hemizygous SNP in exon 9 of the RHD gene indicating a weak D type 2 sample.  
The sample R2r shows a SNP in exon 9 1154G>C (Gly385Ala) of the RHD gene. Output from IGV software demonstrates the visualisation of the 
sequencing data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom. 
  
 210 
 
 
 
             
 
 
                                              Table 6.2 The genotyping results of five weak D samples using LR-PCR amplification followed by  
                                              sequencing on the Ion PGM™. 
Samples Quantity Exon Nucleotides Amino acid Prediction from NGS Genotyping 
6 1 
4 
5 
6 
602C>G 
667T>G 
819G>A 
 
Thr201Arg 
Phe223Val 
Silent 
 
DAR3.1 weak partial D 4.0 (RHD*DAR3.01) 
 
9 and 10 2 6 809T>G Val270Gly Weak D type 1 (RHD*01W.01) 
7 and 8 2 9 1154G>C Gly385Ala Weak D type 2 (RHD*01W.02) 
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              Table 6.3 Intronic SNPs found in the RHD gene by NGS. 
# Intronic SNPs Zygosity Intron Phenotype Sample number 
1 25,611,035 G>C Homozygous 1 R1R1, R1r, R0r, R1R2 1, 2, 3, 6, 9, 10 
2 25,611,580 G>A Homozygous 2 R2R2, R2r, R1R2 4, 5, 7, 8 
3 25,611,635 T>C Homozygous 2 R1r 10 
4 25,614,235 C>T 
Homozygous in R1r 
Heterozygous 
& Homozygous in R1R1 
2 R1R1, R1r 2, 3, 6 
5 25,614,400 C>G Homozygous 2 R2R2, R2r, R1R2 4, 5, 7, 8 
6 25,618,869 T>G Homozygous 3 R0r 6 
7 25,619,444 G>A Homozygous 3 R1R1, R1r, R0r, R1R2 1, 2, 3, 6, 9, 10 
8 25,621,489 T>C Homozygous 3 R0r 6 
9 25,621,894 G>A Homozygous 3 R0r 6 
10 25,621,980 C>T Homozygous 3 R2R2, R2r, R1R2 4, 5, 7, 8 
11 25,622,244 A>G Homozygous 3 R2R2 4 
12 25,622,288 T>A Homozygous 3 R1R1, R1r, R0r 1, 2, 3, 6, 9, 10 
13 25,622,291 G>A Homozygous 3 R1R1, R1r, R0r, R1R2 1, 2, 3, 6, 9, 10 
14 25,622,341 A>G Homozygous 3 R1R1, R0r, R2r 1, 2, 3, 6, 8, 9 
15 25,623,105 C>A Heterozygous 3 R1R1 3 
16 25,623,118 T>G Homozygous 3 R0r 6 
17 25,623,620 A>G Homozygous 3 R0r 6 
18 25,623,622 C>T Homozygous 3 R0r 6 
19 25,623,750 T>A Homozygous 3 R0r 6 
20 25,623,967 A>G Homozygous 3 R1R1, R1r, R0r, R1R2 1, 2, 3, 9, 10 
21 25,624,252 G>C Homozygous 3 R0r 6 
22 25,625,318 G>A Homozygous 3 R0r 6 
23 25,625,471 T>C Homozygous 3 R2R2, R2r, R1R2 4, 5, 7, 8 
24 25,626,327 G>A Homozygous 3 R0r 6 
25 25,627,023 A>G Homozygous 3 R0r 6 
26 25,627,066 C>G Homozygous 3 R2R2, R2r, R1R2 4, 5, 7, 8 
27 25,627,121 T>G Homozygous 3 R0r 6 
28 25,627,323 A>G Heterozygous 3 R2R2 5 
29 25,628,396 T>G 
Homozygous 
Heterozygous in R2R2 
5 
R1R1, R2R2, R1r, R0r, 
R1R2, 
1, 2, 3, 4, 6, 9, 
10 
30 25,628,572 G>A Homozygous 5 R0r 6 
31 25,628,814 A>C Homozygous 5 R0r 6 
32 25,629,797 C>T Homozygous 5 R0r 6 
33 25,630,950 A>G Homozygous 5 R0r 6 
34 25,631,188 A>C Homozygous 5 R0r 6 
35 25,631,436 A>T Homozygous 5 R1R1, R1r, R0r, R1R2, 1, 2, 3, 9, 10 
36 25,631,534 C>T Homozygous 5 R0r 6 
37 25,631,730 T>G Homozygous 5 R0r 6 
38 25,631,983 G>A Homozygous 5 R0r 6 
39 25,632,068 A>G Homozygous 5 R0r 6 
40 25,632,389 A>G Homozygous 5 R2R2, R2r, R0r 4, 5, 6, 7, 8 
41 25,632,639 T>G Homozygous 5 R0r 6 
42 25,632,654 C>T Homozygous 5 R2R2 4 
43 25,632,738 A>G Homozygous 5 R0r 6 
44 25,633,531 G>C Homozygous 7 R1R1, R1r, R0r, R1R2 1, 2, 3, 6, 9, 10 
45 25,633,982 A>G Homozygous 7 R0r 6 
46 25,634,205 G>A Homozygous 7 R2R2, R1r R2r, R1R2 4, 5, 6, 10 
47 25,635,134 A>C Heterozygous 7 R1R1 3 
48 25,635,336 G>C Homozygous 7 R2R2, R0r 4, 5, 6, 7, 8 
49 25,637,536 G>A Homozygous 7 R0r 6 
50 25,638,011 G>A Homozygous 7 R1R1, R1r, R0r, R1R2 1, 2, 3, 9, 10 
51 25,638920 G>A Homozygous 7 R0r 1 
52 25,642,132 C>T Homozygous 7 R0r 6 
53 25,644,654 A>G 
Heterozygous in R1R1 
Homozygous in R1R2 
8 R1R1, R1R2 3, 9 
54 25,645,175 C>T Heterozygous 8 R1R1 3 
55 25,654,529 C>T Homozygous 8 R0r 6 
56 25,646,258 C>A Homozygous 8 R0r 6 
57 25,646,634 C>A Homozygous 8 R0r 6 
58 25,646,748 A>C Homozygous 8 R1R1, R1r, R0r, R1R2 1, 2, 3, 9, 10 
59 25,646,763 A>G Homozygous 8 R0r 6 
60 25,646,933 T>G Homozygous 8 R2R2, R2r, R1R2 4, 5, 7, 8 
61 25,648,349 T>C Homozygous 8 R2R2, R2r, R1R2 4, 5, 7, 8 
62 25,648,782 C>G Homozygous 9 R0r 6 
63 25,648,885 T>C Homozygous 9 R0r 6 
64 25,651,301 G>A Homozygous 9 R1R1, R1r, R1R2 3, 9, 10 
The serology of the samples is listed in Table 6.1. The depth of coverage used for 
homozygous SNP was 15, while 33 for heterozygous SNPs, respectively (if 
applicable). The areas with low depth of coverage could not be analysed. The 
highlighted SNPs with green shows are R1R2 phenotypes sharing some of the SNPs of 
the R2 allele. Zygosity as defined by Ms. Kelly Sillence. Note all R1R2 samples 
defined by serology are in fact hemizygous for RHD gene.  
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             Table 6.4 The genotyping results of the RHCE alleles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
 
 
 
 
 
Sample Serology Quantity Exon Nucleotides Amino acid NGS Genotyping 
1 R0r 1 5 676C>G Homozygous 
Pro226Ala 
 
RHCE*e 
2 and 3 R1R1 2 2 307C>T Homozygous Pro103Ser RHCE*C 
4 and 5 R2R2 2 5 
676G>C Homozygous 
 
Ala226Pro 
 
RHCE*E 
6 R0r 1 
1 
2 
5 
5 
5 
7 
48G>C Heterozygous 
307T>C Homozygous 
733C>G Heterozygous 
744T>C Heterozygous 
676C>G Homozygous 
1025C>T Heterozygous 
Trp16Cys 
Ser103Pro 
Leu245Val 
Silent 
Pro226Ala 
Thr342Ile 
 
RHCE*ceVS.04 
RHCE*c 
RHCE*e 
7 R1R2 1 
2 
 
5 
307C>T Heterozygous 
676G>C Heterozygous 
Pro103Ser 
 
Ala226Pro 
 
RHCE*C/RHCE*c 
 
RHCE*E/RHCE*e 
8 R2r 1 5 
676G>C Heterozygous 
 
Ala226Pro 
 
RHCE*E/RHCE*e 
9 R1R2 1 
1 
2 
2 
2 
 
 
5 
48G>C 
177C>A§ 
202A>G§ 
307C>T§ 
All Heterozygous 
 
676G>C Heterozygous 
Trp16Cys 
Leu60Ile 
Asn68Ser 
Pro103Ser 
 
 
Ala226Pro 
 
RHCE*C/RHCE*c 
 
 
 
 
RHCE*E/RHCE*e 
10 R1r 1 
1 
2 
2 
2 
2 
 
 
2 
48G>C§ 
177C>A§ 
202A>G§ 
307C>T§ 
200A>G 
All Heterozygous 
 
208C>T Heterozygous 
Trp16Cys 
Leu60Ile 
Asn68Ser 
Pro103Ser 
Silent 
 
 
Arg70Trp 
RHCE*C 
 
 
 
 
 
 
Novel 
§= These SNPs are corresponding to the RHCE*C allele are not observed in sample 
7. These were matching the reference gene in which G at 48, C at 177, A at 202 and 
C at 307.  
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Table 6.5: Intronic SNPs found in the RHCE gene by NGS.  
# Intronic SNPs Zygosity Intron Phenotype Sample number 
1 25,728,930C>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R0r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
2 25,728,612 Gdel Heterozygous 3 R1R1, R2R2, R2r, R1R2, 
R1r 
2, 3, 8, 9, 10 
3 25,728,396 A>G Heterozygous 3 R1r, R1R2 9, 10 
4 25,727,968 G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R0r, R1R2 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
5 25,727,486 A>G Heterozygous in R1r, R0r, R1R2 
Homozygous R2R2, R2r, R0r, R1R2, 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
6 25,727,438G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R0r, R1R2 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
7 25,727,386G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2 R2r, R0r, R1R2 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
8 25,726,916 Cdel Heterozygous 3 R1R1, R2R2, R1r, R0r, 
R1R2 
2, 3, 4, 6, 7, 8, 9, 10 
9 25,626,836 G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
10 25,724,783A>G Homozygous in R2R2, R2r, R1R2 
Heterozygous in R1r, R0r, R1R2 
3 R2R2, R1r, R2r, R0r, R1R2 
 
4, 5, 6, 7, 8, 9, 10 
11 25,724,524C>A Heterozygous 3 R0r 6 
12 25,724,501T>C Heterozygous 3 R1R1, R1r, R1R2 3, 9, 10 
13 25,724,366C>T Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R1R2 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
14 25,724,306G>T Heterozygous 3 R0r 8 
15 25,724,234C>T Heterozygous 3 R1R1 3 
16 25,724,146A>G Heterozygous in R1r, R0r, R1R2, 
Homozygous in R2R2, R2r, R0r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
17 25,724,005G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R0r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
18 25,722,334A>G Heterozygous 3 R1R1 2 
19 25,722,206A>G Heterozygous in R0r, R1r, R1R2 
Homozygous in R2R2, R2r, R0r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
20 25,722,090T>C Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r, R0r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
21 25,721,457C>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R0r, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
22 25,721,154T>C Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
23 25,720,404G>A Heterozygous 3 R0r 6 
24 25,720,370T>C Homozygous in R2R2, R2r, R0r, R1R2 
Heterozygous in R1R2, R1r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
4, 5, 6, 7, 8, 9, 10 
25 25,720,301G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
26 25,720,248C>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
27 25,720,204C>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
28 25,720,101C>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
3 R1R1, R2R2, R1r, R2r, R0r, 
R1R2 
 
1, 2, 4, 5, 6, 7, 8, 9, 10 
29 25,720,088C>T Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
3 R1R1, R2R2, R1r, R2r, R0r, 
R1R2 
1, 2, 4, 5, 6, 7, 8, 9, 10 
30 25,720,045C>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
31 25,719,677A>G Heterozygous 3 R0r 6 
32 25,719,599A>T Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
33 25,719,677A>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
34 25,719,235T>G Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
3 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
35 25,717,841C>T Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
4 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
36 25,717,139G>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R1R1, R2R2, R2r 
5 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
37 25,715,885G>T Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
5 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
38 25,714,249A>C Heterozygous 6 R1R2 9 
39 25,713,234T>A Heterozygous in R1r, R0r, R1R2 
Homozygous in R2R2, R2r 
6 R2R2, R1r, R2r, R0r, R1R2 
 
1, 4, 5, 6, 7, 8, 9, 10 
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Figure 6.20 Five SNPs in the R1r sample.  
All five SNPs are located in exon 2 of the RHCE gene and listed below in order as annotated in the figure: 
1. 307C>T (Pro103Ser). 
2. The novel SNP is 208C>T (Arg70Trp). 
3. 202A>G (Asn68Ser). 
4. Unreported silent mutation found 200A>G (Serine at amino acid 67). 
5. 177C>A (Leu60Ile). 
SNP numbers 1, 3 and 5 are associated with the RHCE*C allele. Output from IGV software demonstrates the visualisation of the 
sequencing data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom. 
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Figure 6.21 Low depth of coverage for RHCE*e allele.  
The sample serotyped with R0r phenotype. The photo only shows two sequencing reads in amino acid position 226 to genotype in exon 5 of the 
RHCE gene. The depth of coverage was insufficient for genotyping. Output from IGV software demonstrates the visualisation of the sequencing 
data. Chromosomal locations are shown on the top and the reference gene in blue at the bottom. 
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6.4 Discussion  
6.4.1 Primer design  
In this project, both genes of the Rh blood group system were amplified by LR-PCR 
and were fully sequenced based on NGS using the Ion PGM™ platform. The first step in 
designing a specific primer was to find the differences in sequencing nucleotides 
between the RHD and RHCE genes.  
The primer design then took place to obtain products for both genes with consideration 
of the specificity according to the human reference genome (hg19). The primer pairs 
were substituted numerous times and in various combinations and different primer pairs 
were performed in order to obtain the required and specific amplicons (data not shown).  
There were no co-amplification issues observed in the RHD and RHCE data regarding 
the specificity of the primer sequences of the LR-PCR approach in comparison with the 
HEA and HPA Panel [see Chapter 4]. Fichou and co-workers (2014) observed the same 
issue, in which those two genes were co-amplified using Ion Ampliseq™ Custom Panel. 
The primers of the LR-PCR were designed bearing in mind the homologous genes of 
the Rh blood group system. Interestingly, the RHCE*C allele successfully and its 
related SNPs on exon 2 was genotyped by the LR-PCR method. Moreover, the novel 
allele that was discovered by the HEA and HPA Panel and misaligned to the RHD gene 
was genotyped and perfectly aligned to the RHCE gene using the LR-PCR approach 
[Figure 6.20]. Furthermore, the three SNPs of the RHCE*C allele were identified in that 
sample containing the novel allele [Table 6.4]. These SNPs had not been identified by 
the HEA and HPA Panel. It can be summarised that co-amplification of exon 2 of RHD 
and RHCE took place by the HEA and HPA Panel. Obviously, this is due to the non-
specific primers that were provided for that panel which did not take into consideration 
the homologous genes of the Rh blood group system.  
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Stabentheiner and co-workers (2011) successfully achieved sequencing of the 10 exons 
of the RHD by taking into consideration the designing of specific primers. Here, in this 
study the LR-PCR approach was used, not only for the 10 exons of the RHD, but also 
for both entire genes including exons and introns. Therefore, this method may provide 
high resolution and increase the depth of knowledge regarding the Rh blood group 
genes.  
6.4.2 LR-PCR Polymerase 
Many versions of long-range polymerase kits were used, starting by using the 
LongAmp Hot Start Taq 2X Master Mix and then changed using the PrimeSTAR GXL 
Polymerase with the requirement of little optimisation. Jia and co-workers (2014) found 
that the PrimeSTAR GXL Polymerase successfully achieved the best amplification of 
the BRCA1 and BRCA2 genes among a total of different six polymerases used without 
alteration of the PCR conditions, although the difference in melting temperatures 
between the primer sequences (Jia et al., 2014). The same results were obtained in the 
LR-PCR experiment in which all the amplicons of the RHD and RHCE genes were 
amplified using the same condition although there were differences between the Tm of 
the primers. Finally, the last PCR products obtained, three products for the RHD gene 
and four for the RHCE gene [Figure 6.2], were sequenced due to the time factor 
although they were not as good PCR bands as for sequencing.  
Another extraction kit Gentra® Puregene® Blood kit was used to purify the genomic 
DNA [section 2.2.2]. This kit was designed to obtain extremely high molecular weight 
templates from the human genomic DNA, which approximately 100-200 Kb. 
Unfortunately, the same outcomes were obtained regarding the PCR products. This is 
suggested that the design primer sequences with smaller range may overcome the 
sequencing issues related to the depth of coverage. Moreover, it is highly recommended 
that to design the new primer sequences according to the new release of human genome 
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assembly (GRCh38/hg38). This new release could not be used because it has been 
allowed for the public in December 2013, which following the finishing the design of 
the current primer sequences in this study (Rosenbloom et al., 2015).  
6.4.3 The depth of coverage 
According to Bentley et al. (2008), they stated that a depth of coverage of 15× and 33× 
could be achievable for the homozygous and heterozygous SNPs, respectively. The 
sequencing on the Ion PGM™ platform was achieved but with low depth of coverage. 
The depth of coverage for the RHD gene ranged from around 16 to 35 sequencing reads. 
Although these numbers were sufficient for the hemizygous SNPs represented in the 
weak D samples (Bentley et al., 2008), the first amplicon of the RHD gene expressed 
the lowest level of depth of coverage, which ranged from one to seven sequencing reads 
and some missed regions were not covered [Figure 6.14]. All the RHD amplicons were 
around 22 Kb.  
Regarding the RHCE gene, the depth of coverage of the first amplicon was very low 
which was around 8-10 sequencing reads and showed missed regions [Figure 6.15]. The 
size of the first product was 19,426 bp and covered the regions of exons 1-3. The 
second amplicon was 11,215 bp, covered exons 3 and 4 and had an extremely high 
depth of coverage. The depth of coverage for that region was around 130-191 
sequencing reads and no missed regions were observed [Figure 6.16].  
The depth of coverage was then decreased again in the areas covered by exons 5-7 to 
around 4-21 sequencing reads. The third amplicon was designed to cover the region of 
exon 5 to exon 7, which was 17,856 bp. The fourth amplicon covered from exon 7 to 
exon 10 expressed an extremely low depth of coverage, which was about four to eight 
sequencing reads [Figure 6.17].  
Obviously, the high depth of coverage was achieved with the smallest product of the 
LR-PCR as can be seen in the second product of the RHCE gene. That product of 
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11,215 bp obtained more than a sufficient depth of coverage and is adequate for the 
genotyping analysis. Moreover, the two products of the KEL gene were around 12 Kb 
and achieved a high depth of coverage [see Chapter 5]. Consequently, smaller products 
for both the RHD and RHCE genes are required with a re-design of the primers’ 
sequences. It is highly recommended that the primer sequences of the RHD and RHCE 
genes should be redesigned in order to obtain shorter amplicons ranging between 10-12 
Kb. This is in order to accomplish a proper amplification and to obtain a high depth of 
coverage.  
The method used to quantify the sequencing library was based on Agilent® 2100 
Bioanalyzer. Fichou et al. (2014) found that using of Ion Library Equalizer™ Kit 
observed 10-folds of higher depth of coverage in comparison to Ion Library 
Quantitation Kit (Fichou et al., 2014). The Ion Library Equalizer™ Kit is based on 
library amplification using unique primers, capturing the sequencing library using 
special beads and heat elution to normalise the library to 100 pM to prevent dilution of 
the library. This might be used in the future if the low depth of coverage obtained 
although this kit can be prone to polymerase error because the amplification procedure.  
6.4.4 Genotyping results of the Rh blood group system  
6.4.4.1 Genotyping results of the RHD gene 
Ten RhD-positive samples were genotyped by NGS. Out of the five normal RhD-
positive samples, no mutations were observed in the entire 10 exons of the RHD gene. 
This confirmed the predefined phenotypes by conventional serology. All the weak D 
samples observed homozygous SNPs (i.e. hemizygous) and there were two samples of 
weak D type 1 (RHD*01W.01), two samples of weak D type 2 (RHD*01W.02) and the 
fifth sample was DAR3.1 weak partial D 4.0 (RHD*DAR3.01) [Table 6.2].  
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6.4.4.2 Genotyping results of the RHCE gene 
With respect to the RHCE gene, the alleles of RHCE*C, RHCE*c, RHCE*E and 
RHCE*e were genotyped easily by NGS in both forms of zygosity, i.e. heterozygous or 
homozygous. The reference gene used in the human genome assembly (hg19) is 
RHCE*ce allele. The alleles of RHCE*c and RHCE*e matched the reference gene while 
the variants of the other alleles, RHCE*C and RHCE*E, were called. The genotyping of 
the RHCE alleles regarding to the C, c, E, and e antigens were achieved.  
The allele RHCE*ceVS.04, was genotyped successfully by the LR-PCR in the R0r 
sample. This allele observed a silent mutation which it did not previously report and it 
might be considered as a new allele of RHCE*ceVS. The individual was mentioned in 
the serology sheet as having an ‘other White’ background. The genotyping of the novel 
RHCE allele 208C>T (Arg70Trp), identified by HEA and HPA Panel, was achieved 
despite the issue of low depth of coverage. This novel allele, which was misaligned to 
the RHD gene instead of the RHCE gene by the HEA and HPA Panel, was properly 
genotyped in the RHCE gene by the LR-PCR approach.  
6.4.4.3 Genotyping results of the intronic SNPs  
There were numerous intronic SNPs observed in the RHD and RHCE genes whether 
they were hemizygous in the case of the weak D, homozygous, or heterozygous. 
However, because of the low depth of coverage, Only 64 and 39 intronic SNPs could be 
identified in the RHD and RHCE, respectively. 
In this experiment, because a low depth of coverage was observed, most of the SNPs 
detected regarding the RHD gene were homozygous or hemizygous [see Table 6.3]. The 
depth of coverage for the RHCE gene was high especially in intron 3 and 4. Therefore, 
the heterozygous SNPs in the RHCE gene were detected easily [see Table 6.5].  
The locations of the intronic SNPs need to be avoided when designing new primers. 
These reported SNPs here should be taken into consideration when the new primer pairs 
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would be designed. This is in order to prevent the allele dropout during the annealing of 
the primers pairs to the target of interest due to the mismatching nucleotide of that SNP. 
Consequently, no amplification will be achieved as some of experiments could not 
achieve any amplification (data not shown). Mullins and co-workers (2007) stated that 
12 primer pairs were changed in order to prevent allele dropout when amplify the 
cadherin 1 (CDH1) gene. They recommend assessing the primer-binding site whether 
having any intronic SNPs that have been reported in the databases (Mullins et al., 2007). 
The databases were used by Mullins and co-workers (2007) include University of 
California Santa Cruz genomic bioinformatics browser (UCSC Genome Bioinformatics, 
2015), the Ensembl Genome browser (Ensembl Genome Browser, 2015)  and the Single 
Nucleotide Polymorphism Database [dbSNP] (Single Nucleotide Polymorphisms 
Database, 2014). Therefore, the assessment of the reported intronic SNPs needs to be 
taken into account when the new sets of primers are designed for the RHD and RHCE 
genes.  
6.4.5 Zygosity results  
Samples 7 and 9 were typed by serology as weak D but presumed serotype was given as 
R1R2. Regarding weak D samples, these types of samples are always hemizygous in 
which one copy of the RHD gene observed in such samples. Zygosity testing, which 
was performed by Ms. Kelly Sillence, confirmed that it was only a single copy of the 
RHD gene was found in those two samples (unpublished data). Accordingly, this is 
suggested that, along with the results of the zygosity test, the phenotypes of samples 7 
and 9 may be one of the following phenotypes (R1r’’, R2r’, Rzr or R0ry). 
Regarding sample 7, it carries the intronic SNPs that are associated with R2R2 and R2r 
phenotypes. These intronic SNPs include 2, 5, 10, 23, 26, 60 and 61 [see the highlighted 
SNPs in Table 6.3]. R0r
y is extremely rare in English population approximately <0.01%, 
therefore sample 7 is extremely unlikely to be this phenotype (Daniels, 2013a). The 
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percentage of these phenotypes R1r’’, R2r’, Rzr in English population is as follows; 1%, 
0.28% and 0.19%. Therefore, sample 7 is possibly R2r’ phenotype. 
Sample 9 and 10 (R1r) observed four SNPs in exon 2 of the RHCE gene, which are 
corresponding to RHCE*C allele. These SNPs were 48G>C (Trp16Cys), 177C>A 
(Leu60Ile), 202A>G (Asn68Ser) and 307C>T (Pro103Ser). This data suggested that 
sample 9 is probably R1r’’ phenotype. 
6.4.6 The cost of the NGS for the Rh blood group system 
The cost of the NGS library preparation for one sample is around £100.79 for both the 
RHD and RHCE genes. The number of samples can be scaled depending on the required 
load of the sequencing. For example, the Ion 314™ chip can be used for up to three 
samples with a 100× depth of coverage. The number can be raised to match the 
requirement of the laboratory to 35 samples and 70 samples for Ion 316™ chip and Ion 
318™ chip, respectively. Table 6.5 lists the different types of chips, their capacities, the 
number of samples that can be obtained and the cost per run.  
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Chip type Capacity Number of samples Cost per run 
Ion 314™ 30-50 Mb 3 £271.55 
Ion 316™ 300-500 Mb 35 £444.80 
Ion 318™ 600 Mb – 1 Gb 70 £619.67 
                                                                                      The price per sequencing run on the Ion PGM™ is given.    
 
 
Table 6.5 The number of samples of the RHD and RHCE genes that 
can be obtained with a depth of coverage of 100× in addition to the 
cost of the sequencing run.  
  
 224 
In conclusion, the LR-PCR approach for the Rh blood group system contributes a high-
resolution genotyping based on NGS. The different alleles especially the weak and rare 
variants of both the RHD and RHCE genes can be easily identified. This approach 
provides a crucial method to identify new alleles as well as to facilitate the investigation 
of the hybrid alleles. This can be performed better if the issues of the small products are 
designed to obtain as high a depth of coverage as possible.  
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Chapter 7 : General Discussion and Conclusion  
Alloimmunisation occurs following transfusion of mismatched serotyped units to the 
patients. These transfusion reactions have been increased in patients requiring multiple 
units, such as those with SCD (Chou and Westhoff, 2011). Accordingly, the demand of 
the serological reagents has become higher in cost in some of special cases [see section 
7.6]. Moreover, conventional serology cannot identify the phenotype in recently 
transfused patients. Using BGG can preclude these issues. Currently, many techniques 
and platforms of BGG are available. However, none of these platforms, including the 
microarray platforms, are able to define the new alleles. The array-based platforms have 
issues including the requirement of updating for new alleles as well as inability to 
investigate the weakening and silencing alleles. Furthermore, an issue of non-valid 
samples was reported [Chapter 3]. This is may be due to allelic droput in which the 
amplification did not take place or due to a presence of novel allele in the primer-
binding sites. In addition, it could be the hybridisation of the microarray beads to the 
sample did not occur.   
Interestingly, NGS offers the high-throughput upon these platforms as well as in 
identification of the new variants, whilst simultaneously describing all known alleles 
(Avent et al., 2015). In this PhD project, two approaches were used to assess whether 
NGS is capable of genotyping the blood groups. This will be discussed in the next 
sections.  
7.1 The HEA and HPA Panel 
The first approach was amplicon-based target selection using Ion Ampliseq™ Custom 
Panel for capturing the exons of the blood group genes and the SNPs encoding the 
HPAs (HEA and HPA Panel) [see Chapter 4]. The HEA and HPA Panel is a rapid 
technique in comparison to other sequencing library construction methods in which no 
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fragmentation, size selection or multiple steps of purification are required. The 
sequencing library takes up to 5 hours to prepare and the clonal amplification as well as 
the sequencing can be carried out in the same day. Therefore, the results can be obtained 
by the next day. It is more comprehensive to genotype the blood groups and HPAs in a 
single assay. Therefore, there may avoid using multiple kits for various genes for blood 
groups or a separate kit for HPAs.  
Indeed, out of 28 samples four novel alleles were investigated [see Chapter 4]. The first 
novel allele was investigated in the RHCE gene (208C>T Arg70Trp). The location of 
the amino acid 70 is extracellular to the RHCE protein and this is suggested that such a 
SNP may be weakening the expression of the antigen on the RhCE membrane. This 
SNP was misaligned to RHD gene instead of the RHCE gene. This issue was resolved 
by LR-PCR approach for the Rh blood group genes, which have the specific primer 
sequences [see Chapter 6]. The misalignment was due to the primer sequences provided 
by the panel not being specific and did not take the homologous genes into account. 
Consequently, co-amplification of homologous genes occurred. Fichou et al. (2014) 
reported this issue when they used Ampliseq™ Custom Panel for BGG. The remaining 
three alleles were investigated in the KEL gene. The first SNP was in exon 4 331G>A 
(Ala111Thr). The second SNP was in exon 17 1907C>T (Ala636Val) and the third SNP 
was in exon 19 2165T>C (Leu722Pro). All these amino acid substitutions occur on the 
external domain of the Kell glycoprotein. Accordingly, this might change the protein 
conformation and therefore it might affect the antigenicity of the Kell glycoprotein.  
Apart from the co-amplification issue, all the advantages mentioned above give the 
HEA and HPA Panel to be the method of choice in the near future if the issue of co-
amplification of homologous genes is resolved. Liu et al (2014) stressed that it is 
impossible to genotype all the blood group antigens by the previous molecular 
techniques, such as the microarray, in a single assay. Therefore, this can be feasible 
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using a broad panel encompassing all of the genes encoding the blood groups (Liu et al., 
2014).  
Because the Ion Ampliseq™ Custom Panel has the capacity to amplify 6144 amplicons 
per pool, the panel can be enlarged to encompass many targets. In fact, this gives the 
advantage to Ion Ampliseq™ Custom Panel over the microarray, which can have the 
multiplex up to 500 targets.  In the United States, it has been recommended that using 
17 blood group systems for genotyping as a molecular reference standard by the 
American Association of Blood Banks (Denomme et al., 2010). The other blood groups 
to be included in the HEA and HPA Panel are Lutheran, Scianna, Landsteiner-Wiener, 
Knops, Cromer, Indian, Ok. Regarding the HEA and HPA Panel, more blood group 
genes can be added for an extremely comprehensive assay. In addition, human 
leukocyte antigens (HLA) and human neutrophil antigens could be added in order to 
provide matching units to preclude complications regarding stem cell transplantation 
and transfusion related acute lung injury.  
Moreover, the designed panel can be expanded more to obtain all the human blood 
group genes. The total human genome contains 3.2 × 109 bp while the exome, the exons 
exclusive only to the coding areas, comprises 1-2%. The customised panel reduces the 
undesired DNA sequences. All the blood group genes comprise an approximate of 150 
Kb (Tilley and Grimsley, 2014).  
7.2 LR-PCR approach  
The second approach was the LR-PCR for the KEL, RHD and RHCE genes. LR-PCR 
followed by deep sequencing on the Ion PGM™ approach provides a higher resolution 
analysis. Kell blood group system along with the LR-PCR approach was used as a 
model for the Rh blood group system. The sequencing of the entire KEL gene helped to 
genotype all the alleles and predict the related antigens in particular the high prevalence 
ones. Moreover, the approach will help to resolve the discrepancies obtained by 
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serology. An interesting finding was that genotyping of a sample showed it to be 
heterozygous for the SNP 841C>T (Arg281Trp) in exon 8 indicating the KEL*02.03 
allele encoding Kpa antigen. This sample was not typed by serology and some cases 
were reported involvement of the Kpa antigen causing HDFN (Smoleniec et al., 1994; 
Costamagna et al., 1997). Some rare Kell samples, such as Knull or Kmod, can be 
investigated to assess whether any intronic mutations can be involved in the genetic 
backgrounds of such cases.  
Following the Kell NGS sequencing, the approach of LR-PCR has been applied on 
RHD and RHCE genes. The outcomes of the sequencing reactions were satisfactory 
especially in differentiating between RhD-positive samples and the weak D apart from 
the missing regions found during the analysis. The Rh LR-PCR approach perfectly 
distinguished between RhD-positive, weak D and partial D samples. In five samples 
that serotyped as weak D, two samples were weak D type 1, two samples weak D type 2 
and one DAR3.1 weak partial D 4.0. Furthermore, the RHCE*ceVS.04 allele was 
observed in the RHCE gene in one of the samples. Moreover, this may be able to 
resolve the complex situations in particular to the hybrid genes of the Rh blood group 
system. Unquestionably, this gives the advantage to NGS in identification of the 
unprecedented alleles. 
In fact, the LR-PCR for the RHD and RHCE genes resolved the misalignment, which 
occurred using the HEA and HPA Panel for the novel allele of the RHCE (208C>T 
Arg70Trp) when it incorrectly mapped to the RHD gene. This SNP was reported 
recently in French Guiana case with weak E antigen phenotype and with further cloning 
the allele revealed to be RHCE*cE (Vrignaud et al., 2014). In contrast, in our study the 
serotyping of this sample was (C+c+e+) and genotyped as RHCE*Ce/RHCE*ce. 
Further cloning needs to be carried out to determine in which the novel allele belong 
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either to RHCE*Ce or RHCE*ce. This could not be performed due to the time 
remaining for PhD completion.  
7.3 Intronic SNPs 
Intronic SNPs may help to distinguish the allele of interest. In other words, it can be 
stated that each phenotype has a pattern of its own intronic SNPs. For instance, the R0r 
phenotypes had many unique intronic SNPs in comparison to the other sequenced 
phenotypes [Table 6.3]. Moreover, regarding the RHD gene the intronic SNPs may help 
to determine the specific allele with the assistance of zygosity testing [see Chapter 6]. 
Two samples were investigated by the zygosity test to be having a single copy of the 
RHD gene, while they were typed by serology as R1R2. One sample shared intronic 
SNPs with samples of R2R2 and R2r phenotypes. Consequently, it might be possible for 
this sample to be R2r’ phenotype. The second sample observed the four SNPs associated 
with the RHCE*C allele in exon 2 of the RHCE gene, therefore this suggests that this 
sample may be R1r’’ phenotype.     
Non-amplification of some of the Rh amplicons was observed (data not shown). This 
may be due to intronic SNPs, which may hamper amplification and cause allelic 
dropout. Hence, the knowledge regarding the intronic SNPs is crucial to preclude any 
SNPs located within the primer-binding sites, as many of the intronic SNPs are 
available in the public databases.  
At least seven patterns have been found during the analysis of the intronic SNPs of the 
Kidd blood group system (Avent et al., 2015). Avent et al. (2015) stated that it might be 
worthwhile to establish and confirm the genetic background of certain weakening or 
silencing for Kidd blood group alleles. In fact, this will assess the genetic background 
for all the blood groups especially the hybrid genes of the Rh. In a thorough study of the 
BRCA1 gene for the breast cancer, Ratanaphan et al. (2011) found novel intronic 
variants related to the Thai families with inherited breast cancer. Out of five breast 
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cancer patients, a single sample observed an unprecedented intronic mutation, which 
was a deletion of 14 nucleotides in intron 7 of the BRCA1 gene (Ratanaphan et al., 
2011). This deletion shows the importance of the analysis of the intronic SNPs and how 
it may help in clinical investigations of patients.  
Furthermore, the intronic SNPs are useful to determine the zygosity. For example, the 
father can be genotyped to the RHD introns when the fetus at risk of HDFN. The 
intronic SNPs will appear as hemizygous or heterozygous depending on how many 
RHD copies the father has. 
Currently, the limitations of this technique include the low depth of coverage and some 
missed regions. Indeed, the smallest product of 11,215 bp among the seven amplicons 
for the entire Rh blood group system observed the highest depth of coverage. This may 
be because the product was small in comparison to other amplicons. In addition, the 
products of the KEL gene were approximately 12 Kb and achieved a high depth of 
coverage. Ozcelik et al. (2012) used amplicons ranging from approximately 5 Kb to 14 
Kb to amplify the entire genes of BRCA1 and BRCA2 for breast cancer. The same 
finding of successfully sequencing products for HLA genes using LR-PCR was 
obtained when PCR amplicon size ranged approximately from 4 Kb to 11 Kb. It should 
be noted that they were using the same polymerase kit used for the Rh blood group 
genes and the Ion PGM™ was used for sequencing (Shiina et al., 2012). Consequently, 
redesigning of new primers to give amplicons not exceeding 14 Kb is highly 
recommended to obtain a proper coverage in sequencing. By then, numerous samples at 
least 100 serotyped blood donors can be investigated. The LR-PCR approach will easily 
sequence the null alleles and hybrid genes and resolve the complicated cases in Rh and 
Kell blood group systems.  
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7.4 Small read length and cloning 
Due to small reads of the NGS platforms, in the Ion PGM™ platform 200-400 bp, it is 
unfeasible to determine whether the SNPs of a particular allele are located in cis or 
trans arrangement. It might be possible to perform cloning following by the sequencing 
on the Ion PGM™. In fact, single molecule sequencing offers long read length of 
approximately 98 Kb using a MiniION platform from Oxford Nanopore technologies 
(Laver et al., 2015). This number exceeds the size of most of the blood group genes if is 
not all. It might help to demonstrate if the SNPs are inherited together or separately. 
7.5 Data analysis and storage  
The genotyping process does not require a deep knowledge of bioinformatics to analyse 
the data, as many tools are easy to use. The user needs to be aware about the knowledge 
regarding the different alleles encoding the blood group antigens. Most importantly, 
special software was required to convert the VCF files and digitalise that to predicted 
phenotypes in order to facilitate these approaches and to be adopted for the blood bank. 
Therefore, software is needed to automatically score blood group alleles, but none are as 
yet commercially available.  
Screening of donors and patients at blood bank on a routine basis by the NGS has 
challenges of keeping record of the sequencing information. This is due to the amount 
of the generated sequences from NGS platforms are extremely huge, therefore sufficient 
storage is needed. Cloud storage could resolve the issue of the extreme data generated 
from the NGS (Shanker, 2012).  
7.6 The cost   
NGS will replace the current array-based platforms due to the cost factor. The price of 
the HEA and HPA Panel for genotyping 11 blood group systems and 16 HPAs is 
approximately £121.22 per sample. Regarding the high-resolution sequencing of the 
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LR-PCR products of the KEL gene costs around £50.12 and regarding the RHD and 
RHCE genes £115.54 per sample. On the other hand, the serology has become 
extremely expensive in particular some cases such as autoimmune haemolytic anaemia 
can be reached to $1490 [around £1048.20] (Mazonson et al., 2014). In future, WGS or 
WES may apply for every individual when they are born, thus no further cost will be 
required for the BGG.  
7.7 The future of the NGS technology 
As the technology of NGS is rapidly evolving, lots of optimization occurs nowadays to 
develop and speed up library construction, clonal amplification and the bioinformatics 
tools. For example, Ion Chef™ system from Thermo Fisher Scientific has been released 
recently to generate sequencing template and perform loading onto the chip rapidly and 
automation of the procedure. The future of NGS may be will develop WGS by using the 
single molecule sequencing for every individual when they are born and can get all the 
information needed. Therefore, no additional cost will be added to burden the blood 
bank. Moreover, this will increase the knowledge regarding the genetic basis of the 
blood groups. Interestingly, the genetic basis of the Vel blood group system was 
performed by whole exome sequencing of five individuals of Vel negative (Cvejic et al., 
2013). This is shown the importance of NGS, which will pave the way to resolve the 
genetic basis of orphan antigens and those not currently allocated to blood group 
systems.  
7.8 Future work 
Future work can be carried out including an extensive customised panel of blood groups 
and HPAs for BGG and non-invasive foetal genotyping from maternal plasma to 
prevent HDFN. Optimisation of Sanger sequencing is required to validate the SNPs in 
particular the novel ones. High resolution genotyping using LR-PCR approach followed 
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by sequencing can resolve complicated cases in particular the samples with hybrid 
genes. This approach can be performed for other blood group systems such as MNS, 
Diego, Colton and Dombrock as some serological reagents are not available such as 
Dombrock blood group (Reid, 2009). MNS blood group system has hybrid genes 
because it has three genes with high homology. The amplification of the entire genes of 
the MNS blood group, and other blood groups, will broaden our knowledge about the 
variants causes and intronic SNPs. 
Regarding the high resolution sequencing for Rh, redesigning of the primers is essential 
to obtain a satisfactory level of sequencing. Short PCR products should be considered in 
order to obtain a better depth of coverage of sequencing. This type of sequencing would 
allow studying the Rh variants in depth. 
The knowledge of intronic SNPs regarding those variants can be expanded and illustrate 
how such samples could behave and may assist to determine the specific haplotype. 
Furthermore, chromosomal locations of the defined intronic SNPs must be avoided 
when redesign the Rh primers to preclude any allelic dropout. Interestingly, intronic 
SNPs may assist to determine the Rh zygosity.  
It is highly recommended to establish an integrated system based on laboratory 
information management system (LIMS) for NGS for the BGG. The system should 
include tracking for different projects or studies, sample information registry, tracking 
form for NGS library preparation including sample input quality and barcoded 
submission form, workflow for NGS data analysis, data reporting system with high 
accessibility and storage of the sequencing data (Scholtalbers et al., 2013). In addition, 
comprehensive traceability must be ensured for the accomplished analysis (Bianchi et 
al., 2016). This may provide a suitable and reliable laboratory automation environment 
to save time and reduce errors.  
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In conclusion, two approaches have been developed in this project. The first one is a 
comprehensive assay for blood groups and HPAs. Such an approach may help the 
community to investigate both donors and patients. Furthermore, it will definitely assist 
regarding the identification of novel alleles. The second approach of LR-PCR can be 
used to resolve complicated cases as well as to broaden our knowledge about the blood 
groups in particular to the intronic SNPs and primer design. Although of some issues 
aligned with the both approaches, NGS will likely replace conventional serology in the 
near future.  
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Appendix A  
 
Margaret Kenwright Young Scientist Award 2014 from British Blood Transfusion 
Society (BBTS) for the following work:  
Halawani, A. J., Altayar, M. A., Kiernan, M., Reynolds, A. J., Madgett, T. E. & Avent, 
N. D. 2014. Human Erythrocyte Antigens and Human Platelet Antigens Panel: A 
Genotyping Protocol Based on Next-Generation Sequencing. Transfusion Medicine, 24, 
suppl. 2, 1-32. 
 
Alloimmunisation occurs when there is disparity between the antigens of donor red cells 
and the patient during blood transfusion. Therefore it is important to have 
comprehensive information regarding the antigens on the donor and patient red cells. 
Previous platforms of genotyping techniques have several limitations such as cost, 
requirement of previous knowledge of single nucleotide polymorphisms (SNPs) and 
identification of hybrid genes. Next-generation sequencing (NGS) is able to provide 
high-throughput sequencing and capture many targets within the human genome. A 
protocol has been designed to genotype human erythrocyte antigens (HEA) and human 
platelet antigens (HPA) based on NGS. The protocol is for 11 blood group systems 
(ABO, RH, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Yt, Colton and Vel) and HPA 
(1–16). The method is based on Ion Ampliseq
TM Custom Panel provided by Life 
Technologies. Four weak D donor blood samples were amplified using ultra- high 
multiplex PCR. The primers were then partially digested and ligated to barcoded 
adaptors. After that, the sequencing libraries were added to the beads for clonal 
amplification and enrichment. The sequencing templates were finally loaded onto a 314 
Chip and have been sequenced on an Ion Torrent Personal Genome Machine
TM
. The data 
were analysed using CLC Genomic Workbench Version 7.0. The output results 
generated more than 400 K sequencing reads with an average coverage depth of 700. 
Out of the four samples the following variants were found: Weak D Type 1 
(RHD*01W.01), Weak D Type 2 (RHD*01W.02), Weak D Type 4.0 (RHD*DAR3.01), 
GYPB*S, DO*A, JK*B, FY*A, FY*B, JK*01W.01, HPA-1a/HPA-1b, HPA-3a/HPA-3b, 
HPA-5a/HPA-5b and HPA-15b/ HPA-15b. The weak D sample genotyped as (809T>G, 
Val270Gly), which is a Weak D Type 1, also had a novel SNP on exon 2 (208C>T, 
Arg70Trp). Confirmation of this SNP will be done by long-range PCR of both RHD and 
RHCE genes. We have described here a rapid approach to sequence all clinically 
significant blood group and HPA alleles. The method would be readily applicable to 
blood donors and alloimmunised patients. Ultimately, NGS will pave the way to 
genotype blood group variants in the near future.  
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Conference proceedings  
 
Halawani, A. J., Altayar, M. A., Kiernan, M., Kaushik, N., Reynolds, A. J., Madgett, 
T. E. & Avent, N. D. 2013. Comprehensive Genotyping for Kell and Rh Blood Group 
Systems by Next-generation DNA Sequencing. Transfusion Medicine, 23, suppl. 2, 30-
71. 
  
Blood group genotyping (BGG) has emerged as a core technique in transfusion 
medicine and has impacted on the clinical management of multi-transfused patients. 
The vast majority of these technical platforms require previous knowledge of the blood 
group polymorphisms under investigation. Next-generation sequencing (NGS) has 
emerged as a powerful replacement technology to genotyping single nucleotide 
polymorphisms (SNP), insertion/deletion (indels) and gene rearrangements. We have 
used NGS to define Rh and Kell alleles by amplification of the entire genes (KEL RHD, 
and RHCE). DNA was extracted from 14 random blood donor samples. Two primer 
pairs were designed to amplify the entire KEL gene using long-range polymerase chain 
reaction (LR-PCR). The sequencing library was constructed by fragmenting the DNA, 
ligating into barcoded adaptors and size selected using SPRIselect magnetic beads. The 
sequencing template was then immobilised to sphere particles that clonally amplified 
using emulsion PCR, emulsion breaking and enrichment for positive sphere particles. 
Finally, the sequencing reaction was loaded into a chip and sequenced on the Ion 
Torrent Personal Genome Machine (PGM) that generating 2·6 million reads. Data was 
analysed using CLC Genomics workbench Version 6·0.4. Data from the serological 
testing was confirmed by NGS. Two samples were typed serologically as K antigen and 
four as Kpb and this was confirmed by NGS as an initial genotype as [K antigen, 
Thr193Met (578C>T), heterozygous SNP 53·4% and 46·3%, respectively] and Kpb 
(Arg281, 841C and 842G). Moreover, one sample was found to be Kpa Arg281Trp 
(841C>T). Genotyping will be performed for all the antigens of Kell blood group 
system that encode the following antigens: (K/k, Kpa/Kpb/Kpc, Jsa/Jsb, K11/K17, K12, 
K13, K14/K24, VLAN/VONG, K18, K19, Km, K22, TOU, RAZ, KALT, KTIM, 
KYO/KYOR, KUCI, KANT, KASH, KELP, KETI and KHUL). NGS using LR-PCR 
approach offers a powerful technique enabling users to investigate comprehensive 
screening of all the Kell and Rh antigens. Similar approaches are in progress to define 
Rh alleles and that will reveal their variants in respect of the hybrid genes.  
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Altayar, M. A., Halawani, A. J., Kiernan, M., Kaushik, N., Reynolds, A. J., Madgett, 
T. E. & Avent, N. D. 2013. Next Generation Sequencing of ABO, Duffy and Kidd 
Blood Group Genotyping. Transfusion Medicine, 23, suppl. 2, 30-71. 
 
Blood group Genotyping (BGG) has become well established in transfusion medicine. 
However, all current technologies are based on pre-existing knowledge of known 
polymorphisms. Next generation sequencing circumvents this requirement and adopts a 
discovery mode, which is important, as almost every new BGG project reveals new 
alleles. NGS has become high-throughput, rapid and accurate. Also, costs have 
significantly reduced in the past five years. In this pilot study, Ion Torrent Personal 
Genome Machine (PGM) sequencer was used to optimise and develop a reliable 
protocol for sequencing the entire Duffy, ABO and Kidd blood group genes including 
flanking regions. A DNA library was prepared from randomly selected DNA samples. 
Duffy, ABO and Kidd genes were targeted by long-range PCR, enzymatic amplicon 
fragmentation before ligation with barcoded adapters and size selection. Templates were 
immobilised on beads, then clonally amplified using emulsion PCR. Sequencing 
revealed millions of reads that were then aligned to the reference gene sequences. 
Variants were visualised with two software packages, CLC workbench and Integrative 
Genomics Viewer (IGV). Initial Bioinformatics analysis of Duffy gene samples 
revealed all genotypes matched phenotype, however a number of SNPs (single 
nucleotide polymorphisms) were identified in exons 1,2 and intron1 and under 
investigation. We also identified that a significant number of the FY genes sequenced 
(5/12) encoded the previously described Ala100Thr mutation. The samples concerned 
were FY (a-b+) (3 of 4) (1 homozygous and 2 heterozygous), FY (a+b-) (0 of 1) and FY 
(a+b+) (2/7) both heterozygous). We therefore conclude that the Ala100Thr mutation is 
much more frequent than previously described. We suggest that NGS will supplant 
other genotyping platforms in the near future and will potentially become the 
methodology of choice for genotyping patients and donors.  
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Halawani, A. J., Altayar, M. A., Kiernan, M., Reynolds, A. J., Kaushik, N., Madgett, 
T. E. & Avent, N. D. 2014. Can Next-generation DNA Sequencing Solve the RH 
Complexity for Genotyping? Vox Sang, 107, suppl. 1, 57-248. 
 
The Rh blood group system is considered as the most polymorphic blood group system 
and contains many variants. These variants may cause severe complications to patients, 
due to alloimmunisation from mismatching products of blood transfusion. Next-
generation sequencing (NGS) is an intensely powerful technique capable of sequencing 
huge regions of the human genome. Here we sequenced the entire RHD and RHCE 
genes to genotype for the RhD and RhCE antigens, in order to provide a safer 
transfusion practice. DNA was extracted from random blood donors with known 
serology. By using long-range PCR (LR-PCR), four and three primer pairs were 
designed (giving PCR products in the range from 8 to 24 Kb) for RHD and RHCE, 
respectively. The sequencing libraries were then made by fragmenting the amplicons 
and ligating to adaptors using Ion XpressTM Plus Fragment Library Kit. Size selection 
was performed by SPRIselect magnetic beads. After that, the sequencing template was 
immobilised to beads, which possess a complementary strand to the adaptors, for clonal 
amplification using emulsion PCR. Finally, the sequencing template was loaded onto a 
316 chip and sequenced on the Ion Torrent Personal Genome MachineTM Sequencer. 
Millions of reads were generated and the data were analysed with CLC Genomics 
Workbench (Version 6.5). Sanger sequencing will be utilised in order to validate any 
variants from the sequencing data. NGS using the LR-PCR approach offers a crucial 
method assisting users to genotype many samples in a single run for detecting the Rh 
variants in depth. This will be extremely worthwhile to genotype the difficult alleles of 
Rh, especially hybrid genes, and will pave the way for the discovery of novel alleles. 
NGS for blood group alleles may represent a viable alternative to array and bead based 
platforms, and it is no more expensive and technically challenging on a per sample 
basis. 
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Altayar, M. A., Halawani, A. J., Kiernan, M., Reynolds, A. J., Kaushik, N., Madgett, 
T. E. & Avent, N. D. 2014 Extensive Genotyping of Blood Groups Duffy, Kidd and 
ABO by Next-generation Sequencing Vox Sang, 107, suppl. 1, 57-248. 
 
The determination of the blood groups present in an individual attains a great clinical 
importance for the purposes of blood transfusion and transplantation. Blood group 
genotyping (BGG) has become well established in transfusion medicine. However, all 
current technologies are based on predefined knowledge of known polymorphisms. The 
approach of Next Generation Sequencing (NGS) circumvents this requirement and 
adopts a discovery mode, which is important, as almost every new BGG project 
discovers new alleles. NGS is capable of producing high-throughput, rapid and accurate 
data that results in extensive and detailed genotyping. Also, costs have considerably 
reduced in the past years. In this pilot study, Ion Torrent Personal Genome Machine 
(PGMTM) sequencer was used to optimise and develop a reliable protocol for sequencing 
the entire Duffy (DARC), Kidd (SLC14A1) and ABO blood group genes including 
flanking regions. First, a DNA library was prepared from 12 randomly selected DNA 
samples. DARC, SLC14A1 and ABO genes were targeted by long-range PCR, 
enzymatic amplicon fragmentation before ligation with barcoded adapters and size 
selection. Templates were immobilised on beads, then clonally amplified using 
emulsion PCR. Then, up to 20 samples from FY and JK samples were selected with 
certain serology for sequencing. The reason for this is to seek the possibility that those 
serologically typed as negative for a particular blood group are actually genotypically 
weak positive. Sequencing revealed millions of reads with great coverage depth that 
were then aligned to the reference gene sequences. Variants were analysed and 
visualised with software packages, Ion Torrent SuiteTM plugins, CLC Genomic 
Workbench, Integrative Genomics Viewer (IGV) and SeattleSeq Annotation 138 
website. Initial bioinformatics analysis of samples for the DARC and SLC14A1 genes 
revealed various single nucleotide polymorphisms (SNPs) in exons encoding for amino 
acid changes, such as (Gly42Asp and Ala100Thr in DARC) and (Asp280Asn, 
Ala270Ala and Glu44Lys in SLC14A1). In the FY samples sequenced, a significant 
number (5/12) encoded the Ala100Thr mutation. In addition, the Allele JK ⃰ 01W.01 
(associated with Jka+w) was found with a frequency of 8%. A great number of 
polymorphisms (SNPs and Indel) were found in introns in JK samples (ranging from 52 
to122) and in FY samples (ranging from 2 to 4). An example of one of these SNPs is 
chromosomal position 43319274 in the SLC14A1 gene, close to the splice site region of 
exon 8. Interestingly, sets of intronic polymorphisms present differently among samples 
with same phenotype. Therefore, the intronic polymorphisms are possibly unique to 
individuals or families. The ABO sequencing is in progress. We suggest that NGS 
shows the capability of the comprehensive sequencing of blood group genes and will 
supplant other genotyping platforms in the near future, becoming the potential 
methodology of choice for genotyping patients and donors. 
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Avent, N. D., Madgett, T. E., Halawani, A. J., Altayar, M. A., Kiernan, M. & 
Reynolds, A. J. 2014. Next Generation Sequencing: Academic Overkill or High-
resolution Blood Group Genotyping? . Vox Sang, 107, supple. 1, 1-56. 
 
Background: Next generation sequencing (NGS) has emerged as a high throughput 
method to rapidly determine the genotype of an individual without prior knowledge of 
single nucleotide polymorphism sequences that govern the probe or primer sequences 
associated with many conventional genotyping systems. For blood group genotyping 
(BGG) array or bead based platforms have emerged as commercially available high 
resolution systems that are in routine use. However, they do not operate in discovery 
mode, and still many BGG studies are revealing new (and unknown) alleles. NGS may 
have greater capacity to deal with complex hybrid genes that are associated with ABO, 
RH and MNS polymorphic variation.  
Aims: We aimed to develop a cheap viable alternative to bead/array based genotyping 
with much higher resolution being based on a commercially available NGS plat- form, 
the Ion Torrent PGM. 
Methods: Using long-range PCR we have amplified the complete genomic sequences of 
ABO, RHCE, RHD, KEL, FY and JK with many other blood group genes also under 
development. These PCR products are fragmented, ligated to barcoded adaptors and 
sequenced on the Ion Torrent PGM machine using an appropriate chip.  
Results: A high resolution (500–20009 coverage) NGS approach to blood group 
genotyping has been developed and complete sequences of blood group active genes 
can be rapidly sequenced and known and unknown blood group alleles have been 
defined quickly and cheaply. Bioinformatic approaches to filter data for known alleles 
have been done, but a considerable level of complexity has emerged especially in the 
intronic regions of KEL, RH and JK genes. We have defined the allele frequency of 
some JK*A (weak) is much higher than previously published and we are currently 
sequencing an extended cohort of phenotyped blood samples to assess the frequency of 
a number of these observed blood group alleles.  
Summary/Conclusions: Next generation sequencing based blood group genotyping has 
significant value in the academic environment for unravelling the complex evolution of 
human blood group alleles. A level of complexity observed with intronic SNPs will 
make zygosity assignment (e.g. for RHD) extremely simple, and will help confirm the 
presence of rare mutations in many samples. NGS based genotyping is rapidly reducing 
in costs and the procedures and data interpretation is relatively simple for any 
competent molecular diagnostics laboratory. Whilst undoubtedly NGS is of great 
academic interest (as is true in our laboratory) the evolution into a system of complete 
utility where all data regarding a blood donor is stored as DNA sequence will 
undoubtedly replace current array based BGG systems. Bioinformatic assessment of 
NGS data can be simplified to extraction of data on a ‘as required’ basis. Key 
information regarding clinically significant blood group alleles are easy to process, and 
this is coupled with the added benefit of having the complete sequence of donor or 
patient available which can be interrogated on the discovery of a new blood group 
allele.  
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Halawani, A. J., Altayar, M. A., Kiernan, M., Li, X., Madgett, T. E. & Avent, N. D. 
2015. High Resolution Genotyping of the Rh Blood Group System by Next-generation 
Sequencing Vox Sang, 109, suppl. 1, 1-379.  
 
The RH blood group system is the most complicated blood group system due to 
encoding by two highly homologous genes, RHD and RHCE. Typing the antigens of 
this system by conventional serology is not very appropriate to distinguish between D 
positive, weak D and partial D. It is only possible to assign weak D and partial D alleles 
accurately using blood group genotyping (BGG). Here, 10 samples of the RH system 
were genotyped, 5 D positive and 5 weak D samples using a long-range PCR (LR-PCR) 
approach coupled with next generation sequencing (NGS). For every sample, both 
genes, RHD and RHCE, were amplified by LR-PCR, with three amplicons for RHD and 
four amplicons for RHCE. Then the PCR products were fragmented, ligated to barcoded 
adaptors and sequenced using NGS on an Ion Torrent PGMTM platform. We showed 
that LR-PCR for RHD and RHCE completely correlated with their corresponding 
genomic sequence. For the D positive samples, there were no obvious SNPs on the 
RHD exons. The 5 weak D samples have been identified as following; two weak D 
Type 1 (exon 6 809T>G Val270Gly), two weak D Type 2 (exon 9 1154G>C 
Gly385Ala) and one weak partial D 4.1 with [exon 1 48G>C (Trp16Cys), exon 4 
602C>G (Thr201Arg), exon 5 667T>G (Phe223Val), exon 6 819G>A (silent)]. The LR-
PCR method has confirmed that a novel heterozygous SNP, 208 C>T (Arg70Trp) in 
exon 2 is derived from the RHCE gene, although it had previously been identified by a 
Human Erythrocyte Antigen and Human Platelet Antigen panel as belonging to the 
RHD gene. More samples are currently being sequenced. Our approach, we believe, 
will facilitate the comprehensive genotyping of the antigens of the RH system, 
especially those with hybrid genes or insertions/deletions. Our method is able to 
demonstrate novel alleles by direct sequence analysis, a major drawback of current 
array-based BGG platforms.  
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Altayar, M. A., Halawani, A. J., Kiernan, M., Madgett, T. E. & Avent, N. D. 2015. 
Complete Gene Sequencing of ABO Blood Group by Next-generation Sequencing Vox 
Sang, 109, suppl. 1, 1-379. 
 
The ABO blood group system is the most clinical significant in blood transfusion and 
transplantation medicine. Due to naturally occurring antibodies, mismatched transfusion 
of blood can cause rapid transfusion reactions. ABO is one of the most complex and 
polymorphic blood group genes, with an ever-increasing number of variant alleles. 
These variant alleles not only affect the specificity of the enzymes but also the activity 
of the enzymes, which might result in a weak phenotype. Therefore the determination of 
ABO alleles is important for the safety of blood transfusion and transplantation 
medicine. Although high-throughput platforms have revolutionised the approach 
towards blood group genotyping (BGG), they are based on pre-defined polymorphisms, 
which are not suitable for the discovery of new alleles. Next Generation Sequencing 
(NGS) circumvents this requirement and operates in discovery mode, which is critical 
for emerging alleles. NGS is capable of producing comprehensive, high-throughput, 
rapid and accurate data resulting in extensive genotyping. ABO genotyping has 
frequently only focused on exons 6 and 7, neglecting the rest of the gene. Following our 
successful NGS-genotyping of blood group genes Duffy (DARC) and Kidd (SLC14A1), 
here we have used the Ion Torrent Personal Genome MachineTM (PGMTM) sequencer to 
optimise and develop a reliable protocol for sequencing the entire ABO blood group 
gene including flanking regions. In this pilot study, four long-range polymerase chain 
reactions (LR-PCR) were used to target the entire ABO gene plus over 5 kb upstream, 
regulatory regions (Promoter and CBF/NF-Y), and downstream in 16 randomly selected 
genomic DNA samples. DNA libraries were prepared by enzymatic fragmentation, 
ligation of barcoded adapters and size selection, before clonal amplification of 
templates was achieved using emulsion PCR and then the samples were loaded onto a 
316 chip for sequencing. Millions of reads with great coverage depth (100–1800x) were 
generated, which were then aligned to the reference gene sequence (NG_006669.1). 
These data were analysed and visualised with multiple software packages, such as CLC 
Genomic Work- bench version 6.5. The serological phenotype data matched that of 
ABO genotyping. Bioinformatics analysis revealed a number of polymorphisms 
including single nucleotide polymorphisms (SNPs) and insertion/deletions (indels) 
distributed throughout exons, introns and the regulatory regions at around 4 kb 
upstream. Examples of amino acid changes due to the SNPs found in exons are those 
causing the differences between A and B alleles, previously described in exon 7 
(Arg176Gly, Gly235Ser, Leu266Met and Gly268Ala), whilst other SNPs found in 
exons 3, 4 and 5 have been found to be of higher frequency in our samples than 
previously reported, including Arg63His (13/16 samples) and Ser74Pro (14/16 samples) 
and found in all ABO phenotypes. In addition, in two samples (of A and O phenotype), 
we showed the Trp181stop mutation, previously described only for the rare ABO*O.06 
(O6) allele. We suggest that NGS can provide a reliable approach to genotype ABO due 
to its powerful capabilities of comprehensive analysis and revealing novel alleles. NGS 
will supplant other genotyping platforms in the near future, becoming the potential 
methodology of choice for genotyping patients and donors for safe transfusion/ 
transplantation practice.  
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Appendix B 
 
DNA concentrations and purity  
 
 
 
Cohort A: Samples for Microarray assay (Chapter 3) 
 
Sample ID NanoVue Purity Qubit 
1 93.6 1.95 111 
2 239.6 1.95 256 
3 11 1.94 50 
4 540.9 1.90 230 
5 289.8 1.92 233 
6 252.2 1.93 301 
7 146.8 1.93 356 
8 103.7 1.92 504 
9 84.2 1.94 200 
10 55 1.95 140 
11 26.4 1.95 90 
12 87.4 1.95 80.5 
13 232.5 1.87 233 
14 116.8 1.92 103.6 
15 147.8 1.92 344 
16 96.2 1.90 423 
17 107.1 1.96 256 
18 75.6 1.90 226 
19 78.6 1.97 202 
20 122.6 1.88 235 
21 111.7 1.90 322 
22 60.1 1.88 109 
23 136.4 1.94 190 
24 88.9 1.90 112 
25 260.6 1.94 270 
26 175.7 1.89 118 
27 207.4 1.95 119.4 
28 322.2 1.94 510 
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Cohort B: Samples for HEA and HPA Panel (Chapter 4) 
 
Sample ID NanoVue Purity Qubit 
1 83.5 1.95 102 
2 104.6 1.95 99 
3 4.7 1.75 50 
4 129 1.95 90.4 
5 81.9 1.93 112 
6 122.9 1.94 234 
7 77.1 1.94 224 
8 160.5 1.92 340 
9 147.4 1.94 120 
10 303 1.95 543 
11 212.5 1.91 433 
12 28 1.87 67 
13 45.5 1.70 88 
14 45.5 1.72 91 
15 89.5 1.83 88 
16 35 1.51 55 
17 142 1.82 241 
18 56 1.75 40 
19 297 1.84 441 
20 44.5 1.78 98 
21 506 1.82 236 
22 239 1.87 340 
23 231 1.99 356 
24 281 1.92 200 
25 181.5 1.85 180 
26 140.5 1.82 340 
27 79 1.71 101 
28 120.5 1.84 140 
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Cohort C: Samples for Kell LR-PCR (Chapter 5)  
 
Sample ID NanoVue Purity Qubit 
1 555 1.70 301 
2 340 1.95 139 
3 544 1.73 209 
4 270 1.70 261 
5 240 1.94 233 
6 80 1.80 174 
7 340 1.84 251 
8 300 1.85 378 
9 540 1.82 399 
10 560 1.89 272 
11 798 1.92 329 
12 270 1.95 235 
13 450 1.95 268 
14 270 1.70 269 
15 290 1.90 305 
16 260 1.90 289 
17 230 1.94 129 
18 430 1.95 311 
19 340 1.70 179 
20 220 1.70 280 
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Cohort D: Samples for Rh LR-PCR (Chapter 6)  
 
Sample ID NanoVue Purity Qubit 
1 301 1.95 340 
2 230 1.95 115 
3 222 1.89 138 
4 332 1.87 267 
5 240 1.88 121 
6 255 1.89 209 
7 111 1.95 68.5 
8 229 1.70 123 
9 232 1.89 89.9 
10 243 1.77 108 
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Appendix C  
 
Optimisation of the size selection for NGS libraries  
 
(a) Different SPRIselect beads ratio  
 
 
 
       Bioruptor mix was the sample, which had fragmentation by the physical sonication                      
using Bioruptor™ UCD-200.  
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       (b) 0.8X-0.7X ratio of SPRIselect 
 
 
 
  Sample 9,10 and 11 were just controls, which had no DNA.  
